[{"title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","googleId":"E-vjoGcBuowJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/424/36196","googleCitationCount":2400,"googleAuthor":"H Döhner","doi":"10.1182/blood-2016-08-733196","elsevierAuthor":"Döhner H.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"1657"},{"title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","googleId":"e71laQw6V68J","googleLink":"https://ashpublications.org/blood/article-abstract/130/6/722/36814","googleCitationCount":751,"googleAuthor":"AT Fathi","doi":"10.1182/blood-2017-04-779405","elsevierAuthor":"Stein E.M.","publicationName":"Blood","elsevierCoverDate":"2017-08-10","elsevierCoverDisplayDate":"10 August 2017","elsevierCitationCount":"527"},{"title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","googleId":"rkKJHiGs1AEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/25/2745/37141","googleCitationCount":520,"googleAuthor":"M Hallek","doi":"10.1182/blood-2017-09-806398","elsevierAuthor":"Schuh A.H.","publicationName":"British Journal of Haematology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"8"},{"title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","googleId":"NCGG1DGmVzcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/16/1800/36474","googleCitationCount":503,"googleAuthor":"SS Neelapu","doi":"10.1182/blood-2017-03-769620","elsevierAuthor":"Snider J.T.","publicationName":"American Journal of Managed Care","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"5"},{"title":"Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","googleId":"z589FarS5lMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/12/1275/36625","googleCitationCount":432,"googleAuthor":"","doi":"10.1182/blood-2017-09-801498","elsevierAuthor":"Schuurhuis G.J.","publicationName":"Blood","elsevierCoverDate":"2018-03-22","elsevierCoverDisplayDate":"22 March 2018","elsevierCitationCount":"278"},{"title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy","googleId":"AEpV1U7zoPIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2295/36661","googleCitationCount":417,"googleAuthor":"LA Hanafi","doi":"10.1182/blood-2017-06-793141","elsevierAuthor":"Hay K.A.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"310"},{"title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","googleId":"E8aMl3vI9MwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3322/107614","googleCitationCount":459,"googleAuthor":"RA Gardner","doi":"10.1182/blood-2017-02-769208","elsevierAuthor":"Gardner R.A.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"346"},{"title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","googleId":"usyL4ZQfnBoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1365/105711","googleCitationCount":301,"googleAuthor":"V Pengo","doi":"10.1182/blood-2018-04-848333","elsevierAuthor":"Pengo V.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"223"},{"title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","googleId":"X4IYF3gmtwoJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1522/36655","googleCitationCount":302,"googleAuthor":"","doi":"10.1182/blood-2017-08-798322","elsevierAuthor":"Paul S.","publicationName":"Acta Haematologica","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"19"},{"title":"Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience","googleId":"7lP1ZQaRlWcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1910/36756","googleCitationCount":250,"googleAuthor":"JA Burger","doi":"10.1182/blood-2017-10-810044","elsevierAuthor":"O’Brien S.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"184"},{"title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","googleId":"jC3Vez8tg2IJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/6/742/36791","googleCitationCount":292,"googleAuthor":"GL Norddahl","doi":"10.1182/blood-2017-02-769869","elsevierAuthor":"Zink F.","publicationName":"Blood","elsevierCoverDate":"2017-08-10","elsevierCoverDisplayDate":"10 August 2017","elsevierCitationCount":"214"},{"title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma","googleId":"YWSx3sip4-MJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/8/974/36976","googleCitationCount":292,"googleAuthor":"","doi":"10.1182/blood-2017-05-785246","elsevierAuthor":"Chari A.","publicationName":"Blood","elsevierCoverDate":"2017-08-24","elsevierCoverDisplayDate":"24 August 2017","elsevierCitationCount":"217"},{"title":"Thrombotic thrombocytopenic purpura","googleId":"OPNZaP5j7l8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2836/36273","googleCitationCount":266,"googleAuthor":"P Coppo","doi":"10.1182/blood-2016-10-709857","elsevierAuthor":"Joly B.S.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"166"},{"title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","googleId":"MMaBdEJk_gcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/25/2728/36884","googleCitationCount":240,"googleAuthor":"AC Horne","doi":"10.1182/blood-2017-06-788349","elsevierAuthor":"Bergsten E.","publicationName":"Blood","elsevierCoverDate":"2017-12-21","elsevierCoverDisplayDate":"21 December 2017","elsevierCitationCount":"152"},{"title":"Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma","googleId":"OkC53CAA17oJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/22/2401/36573","googleCitationCount":243,"googleAuthor":"JL Kaufman","doi":"10.1182/blood-2017-06-788786","elsevierAuthor":"Kumar S.","publicationName":"Blood","elsevierCoverDate":"2017-11-30","elsevierCoverDisplayDate":"30 November 2017","elsevierCitationCount":"163"},{"title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase","googleId":"Hm6xthMzMPAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2437/35948","googleCitationCount":271,"googleAuthor":"SJ Kim","doi":"10.1182/blood-2016-12-756841","elsevierAuthor":"Kwong Y.L.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"188"},{"title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","googleId":"rL4zz46xOG8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/26/3419/36220","googleCitationCount":225,"googleAuthor":"W Ding","doi":"10.1182/blood-2017-02-765685","elsevierAuthor":"Ding W.","publicationName":"Blood","elsevierCoverDate":"2017-06-29","elsevierCoverDisplayDate":"29 June 2017","elsevierCitationCount":"158"},{"title":"PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma","googleId":"c25GBdmi0WQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/23/3071/36041","googleCitationCount":225,"googleAuthor":"","doi":"10.1182/blood-2017-01-764209","elsevierAuthor":"Nayak L.","publicationName":"Blood","elsevierCoverDate":"2017-06-08","elsevierCoverDisplayDate":"8 June 2017","elsevierCitationCount":"174"},{"title":"Clinical updates in adult immune thrombocytopenia","googleId":"cmdW4XGQ0CwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2829/36293","googleCitationCount":216,"googleAuthor":"MP Lambert","doi":"10.1182/blood-2017-03-754119","elsevierAuthor":"Lambert M.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"135"},{"title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL","googleId":"4X4ex8QcoFgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/23/2446/40003","googleCitationCount":137,"googleAuthor":"P Hillmen","doi":"10.1182/blood-2018-05-850461","elsevierAuthor":"Flinn I.W.","publicationName":"Blood","elsevierCoverDate":"2018-12-06","elsevierCoverDisplayDate":"6 December 2018","elsevierCitationCount":"91"},{"title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","googleId":"KXKLSsanZgsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/587/39419","googleCitationCount":157,"googleAuthor":"BA Walker","doi":"10.1182/blood-2018-03-840132","elsevierAuthor":"Manni S.","publicationName":"Frontiers in Oncology","elsevierCoverDate":"2020-05-15","elsevierCoverDisplayDate":"15 May 2020","elsevierCitationCount":"0"},{"title":"Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial","googleId":"ywR-oRml3z8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/393/103899","googleCitationCount":167,"googleAuthor":"PD le Coutre","doi":"10.1182/blood-2016-09-739086","elsevierAuthor":"Cortes J.E.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"113"},{"title":"Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma","googleId":"VTK0Z6bOqAMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/267/36926","googleCitationCount":203,"googleAuthor":"PL Zinzani","doi":"10.1182/blood-2016-12-758383","elsevierAuthor":"Zinzani P.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"163"},{"title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","googleId":"nC2fjARYPcgJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/11/1183/36457","googleCitationCount":181,"googleAuthor":"AF Herrera","doi":"10.1182/blood-2017-10-811224","elsevierAuthor":"Herrera A.","publicationName":"Blood","elsevierCoverDate":"2018-03-15","elsevierCoverDisplayDate":"15 March 2018","elsevierCitationCount":"130"},{"title":"Clinical significance of somatic mutation in unexplained blood cytopenia","googleId":"V19bNXJIurIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3371/107625","googleCitationCount":200,"googleAuthor":"L Malcovati","doi":"10.1182/blood-2017-01-763425","elsevierAuthor":"Malcovati L.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"156"},{"title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","googleId":"fN5I4Kls-a8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/23/2456/40023","googleCitationCount":137,"googleAuthor":"A Perrot","doi":"10.1182/blood-2018-06-858613","elsevierAuthor":"Perrot A.","publicationName":"Blood","elsevierCoverDate":"2018-12-06","elsevierCoverDisplayDate":"6 December 2018","elsevierCitationCount":"105"},{"title":"Role of RUNX1 in hematological malignancies","googleId":"6LNRwht3yigJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2070/36427","googleCitationCount":206,"googleAuthor":"","doi":"10.1182/blood-2016-10-687830","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"0"},{"title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","googleId":"Tg67Np0BHccJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/24/2661/37193","googleCitationCount":148,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood-2017-12-818948","elsevierAuthor":"Stein E.M.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"104"},{"title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","googleId":"Ttb1RV90FW0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2877/39185","googleCitationCount":129,"googleAuthor":"J Picarsic","doi":"10.1182/blood-2018-03-839753","elsevierAuthor":"Abla O.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"83"},{"title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","googleId":"3TZPe9H9QW0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2243/36673","googleCitationCount":174,"googleAuthor":"EK Waller","doi":"10.1182/blood-2017-07-793786","elsevierAuthor":"Miklos D.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"110"},{"title":"PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR","googleId":"eKl6IJHv59UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/1039/36337","googleCitationCount":252,"googleAuthor":"","doi":"10.1182/blood-2016-09-738245","elsevierAuthor":"Chong E.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"206"},{"title":"HUS and atypical HUS","googleId":"CgrA1AAW1ZQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2847/36275","googleCitationCount":172,"googleAuthor":"","doi":"10.1182/blood-2016-11-709865","elsevierAuthor":"Sakari Jokiranta T.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"99"},{"title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","googleId":"Phcv2JDVDXsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120325842","googleCitationCount":158,"googleAuthor":"C Chester","doi":"10.1182/blood-2017-06-741041","elsevierAuthor":"Chester C.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"129"},{"title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","googleId":"zvWVUyEev8MJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/23/2515/36958","googleCitationCount":139,"googleAuthor":"R Romee","doi":"10.1182/blood-2017-12-823757","elsevierAuthor":"Romee R.","publicationName":"Blood","elsevierCoverDate":"2018-06-07","elsevierCoverDisplayDate":"7 June 2018","elsevierCitationCount":"113"},{"title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion","googleId":"qo9QMXAxsPUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/677/36802","googleCitationCount":167,"googleAuthor":"F Locatelli","doi":"10.1182/blood-2017-04-779769","elsevierAuthor":"Locatelli F.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"135"},{"title":"Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B","googleId":"SlZWOYuoJ98J","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/1022/39176","googleCitationCount":151,"googleAuthor":"","doi":"10.1182/blood-2017-09-804419","elsevierAuthor":"Miesbach W.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"109"},{"title":"CD38 antibodies in multiple myeloma: back to the future","googleId":"555YzaDWP9QJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/1/13/107710","googleCitationCount":153,"googleAuthor":"NWCJ van de Donk","doi":"10.1182/blood-2017-06-740944","elsevierAuthor":"Van De Donk N.W.C.J.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"104"},{"title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","googleId":"vW4QgQEXtdAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2471/36258","googleCitationCount":170,"googleAuthor":"C Herbaux","doi":"10.1182/blood-2016-11-749556","elsevierAuthor":"Herbaux C.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"133"},{"title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","googleId":"qwi--Gwd3XsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1753/35813","googleCitationCount":166,"googleAuthor":"L Malcovati","doi":"10.1182/blood-2016-06-724500","elsevierAuthor":"De Witte T.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"115"},{"title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","googleId":"ZxyXPy_haXIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1703/39364","googleCitationCount":112,"googleAuthor":"R Gabdoulline","doi":"10.1182/blood-2018-02-829911","elsevierAuthor":"Thol F.","publicationName":"Blood","elsevierCoverDate":"2018-10-18","elsevierCoverDisplayDate":"18 October 2018","elsevierCitationCount":"76"},{"title":"Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy","googleId":"7v8VC-sQAN8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/1/121/107692","googleCitationCount":151,"googleAuthor":"JA Hill","doi":"10.1182/blood-2017-07-793760","elsevierAuthor":"Hill J.A.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"113"},{"title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","googleId":"1jcoMEnGQXgJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/301/38303","googleCitationCount":142,"googleAuthor":"MA Dimopoulos","doi":"10.1182/blood-2017-07-795047","elsevierAuthor":"Facon T.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"102"},{"title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","googleId":"Gz1xFg_lcMwJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/22/2420/36575","googleCitationCount":152,"googleAuthor":"CD Carey","doi":"10.1182/blood-2017-03-770719","elsevierAuthor":"Carey C.D.","publicationName":"Blood","elsevierCoverDate":"2017-11-30","elsevierCoverDisplayDate":"30 November 2017","elsevierCitationCount":"126"},{"title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","googleId":"AcBE25t2gEMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1955/36746","googleCitationCount":133,"googleAuthor":"MP Ledoux","doi":"10.1182/blood-2017-11-818286","elsevierAuthor":"Ghez D.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"115"},{"title":"International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease","googleId":"akXyCTf7xsYJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1646/36100","googleCitationCount":218,"googleAuthor":"DC Fajgenbaum","doi":"10.1182/blood-2016-10-746933","elsevierAuthor":"Fajgenbaum D.C.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"142"},{"title":"Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","googleId":"no-hAO6uBlcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2317/36672","googleCitationCount":141,"googleAuthor":"","doi":"10.1182/blood-2017-06-786129","elsevierAuthor":"Mueller K.T.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"105"},{"title":"Vitamin B12 deficiency from the perspective of a practicing hematologist","googleId":"Y-tNRDNbGfAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/19/2603/36140","googleCitationCount":152,"googleAuthor":"R Green","doi":"10.1182/blood-2016-10-569186","elsevierAuthor":"Green R.","publicationName":"Blood","elsevierCoverDate":"2017-05-11","elsevierCoverDisplayDate":"11 May 2017","elsevierCitationCount":"77"},{"title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","googleId":"uuhGcoLKU1sJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/7/900/36992","googleCitationCount":156,"googleAuthor":"GP Kaufman","doi":"10.1182/blood-2017-01-763599","elsevierAuthor":"Kaufman G.","publicationName":"Blood","elsevierCoverDate":"2017-08-17","elsevierCoverDisplayDate":"17 August 2017","elsevierCitationCount":"126"},{"title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","googleId":"LB_7YQffihsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2115/39506","googleCitationCount":98,"googleAuthor":"A Dispenzieri","doi":"10.1182/blood-2018-07-862334","elsevierAuthor":"Van Rhee F.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"63"},{"title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","googleId":"s5EYNz3JPOQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3352/107622","googleCitationCount":150,"googleAuthor":"","doi":"10.1182/blood-2016-12-758979","elsevierAuthor":"Reshmi S.C.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"109"},{"title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","googleId":"jlzvBJHyooMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/23/2463/36769","googleCitationCount":133,"googleAuthor":"","doi":"10.1182/blood-2017-08-801662","elsevierAuthor":"Lenting P.J.","publicationName":"Blood","elsevierCoverDate":"2017-12-07","elsevierCoverDisplayDate":"7 December 2017","elsevierCitationCount":"95"},{"title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","googleId":"STZGyrWRXk4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1548/35938","googleCitationCount":216,"googleAuthor":"E Gluckman","doi":"10.1182/blood-2016-10-745711","elsevierAuthor":"Gluckman E.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"166"},{"title":"Anemia at older age: etiologies, clinical implications, and management","googleId":"v6yqyf2nro8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/505/104393","googleCitationCount":130,"googleAuthor":"","doi":"10.1182/blood-2017-07-746446","elsevierAuthor":"Stauder R.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"76"},{"title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","googleId":"Y_Af8DU1rXgJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2111/36385","googleCitationCount":153,"googleAuthor":"E Muchtar","doi":"10.1182/blood-2016-11-751628","elsevierAuthor":"Muchtar E.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"132"},{"title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","googleId":"rGEf5YiIIasJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1442/36639","googleCitationCount":134,"googleAuthor":"","doi":"10.1182/blood-2017-12-820852","elsevierAuthor":"Weiss E.S.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"97"},{"title":"Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study","googleId":"ibG1-ZjD23YJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/23/2527/36754","googleCitationCount":133,"googleAuthor":"","doi":"10.1182/blood-2017-04-748707","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2018-02-08","elsevierCoverDisplayDate":"8 February 2018","elsevierCitationCount":"0"},{"title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","googleId":"oVQu7B3H2tQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/7/846/36207","googleCitationCount":196,"googleAuthor":"","doi":"10.1182/blood-2016-09-742205","elsevierAuthor":"Rea D.","publicationName":"Blood","elsevierCoverDate":"2017-02-16","elsevierCoverDisplayDate":"16 February 2017","elsevierCitationCount":"158"},{"title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma","googleId":"nq0x2Wsi6fkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1189/36356","googleCitationCount":140,"googleAuthor":"A Badros","doi":"10.1182/blood-2017-03-775122","elsevierAuthor":"Badros A.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"108"},{"title":"Age-related clonal hematopoiesis","googleId":"KLfSQtHm2rAJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/496/104398","googleCitationCount":121,"googleAuthor":"LI Shlush","doi":"10.1182/blood-2017-07-746453","elsevierAuthor":"Shlush L.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"95"},{"title":"A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in …","googleId":"zPEWyi_8HAMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/LBA-4/375111","googleCitationCount":96,"googleAuthor":"TD Shanafelt","doi":"10.1182/blood-2018-120779","elsevierCitationCount":0},{"title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","googleId":"cLUZkQ77jzYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2357/37110","googleCitationCount":112,"googleAuthor":"IE Ahn","doi":"10.1182/blood-2017-12-820910","elsevierAuthor":"Ahn I.E.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"83"},{"title":"The genetics and molecular biology of T-ALL","googleId":"h1yw4hIJD1oJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1113/36559","googleCitationCount":142,"googleAuthor":"J Cools","doi":"10.1182/blood-2016-10-706465","elsevierAuthor":"Girardi T.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"99"},{"title":"Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled …","googleId":"cmlnwS8dVUoJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/661/266168","googleCitationCount":89,"googleAuthor":"","doi":"10.1182/blood-2018-99-112614","elsevierCitationCount":0},{"title":"Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib","googleId":"S1tBohtid0AJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2307/36662","googleCitationCount":123,"googleAuthor":"","doi":"10.1182/blood-2017-08-801191","elsevierAuthor":"Rao V.K.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"101"},{"title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","googleId":"JqKLPCyyS1MJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/572/36151","googleCitationCount":184,"googleAuthor":"N Jain","doi":"10.1182/blood-2016-07-726588","elsevierAuthor":"Jain N.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"123"},{"title":"Erythroferrone inhibits the induction of hepcidin by BMP6","googleId":"yIDQiSybwBcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1473/39343","googleCitationCount":91,"googleAuthor":"J Arezes","doi":"10.1182/blood-2018-06-857995","elsevierAuthor":"Arezes J.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"67"},{"title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","googleId":"j7uubKxFYAMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1469/35906","googleCitationCount":180,"googleAuthor":"IE Ahn","doi":"10.1182/blood-2016-06-719294","elsevierAuthor":"Ahn I.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"124"},{"title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","googleId":"whNdaMenG1oJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/3/347/36021","googleCitationCount":179,"googleAuthor":"L Sedek","doi":"10.1182/blood-2016-07-726307","elsevierAuthor":"Theunissen P.","publicationName":"Blood","elsevierCoverDate":"2017-01-19","elsevierCoverDisplayDate":"19 January 2017","elsevierCitationCount":"131"},{"title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","googleId":"FT--ZHVolIIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/25/2709/36882","googleCitationCount":123,"googleAuthor":"B Pro","doi":"10.1182/blood-2017-05-780049","elsevierAuthor":"Pro B.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"0"},{"title":"Therapeutic targeting of acute myeloid leukemia stem cells","googleId":"B1mnwanW7S0J","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1627/36074","googleCitationCount":135,"googleAuthor":"CT Jordan","doi":"10.1182/blood-2016-10-696039","elsevierAuthor":"Pollyea D.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"100"},{"title":"Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience","googleId":"N3gMHvb-I6UJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/91/265997","googleCitationCount":91,"googleAuthor":"","doi":"10.1182/blood-2018-99-114152","elsevierAuthor":"Kharfan-Dabaja M.A.","publicationName":"American Journal of Hematology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"September 2019","elsevierCitationCount":"0"},{"title":"Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation","googleId":"Oz1kzOPKeuMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/16/1857/36493","googleCitationCount":124,"googleAuthor":"SO Ciurea","doi":"10.1182/blood-2017-05-785659","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2018-12-27","elsevierCoverDisplayDate":"27 December 2018","elsevierCitationCount":"0"},{"title":"How I treat disseminated intravascular coagulation","googleId":"TJc-EMAiLfUJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/8/845/104418","googleCitationCount":120,"googleAuthor":"M Levi","doi":"10.1182/blood-2017-10-804096","elsevierAuthor":"Levi M.","publicationName":"Blood","elsevierCoverDate":"2018-02-22","elsevierCoverDisplayDate":"22 February 2018","elsevierCitationCount":"62"},{"title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","googleId":"S1SSL8qPru4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/40/39282","googleCitationCount":101,"googleAuthor":"P Caimi","doi":"10.1182/blood-2017-11-815183","elsevierAuthor":"LaCasce A.S.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"67"},{"title":"How I treat acquired aplastic anemia","googleId":"9gEb9J72XzgJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1428/35931","googleCitationCount":173,"googleAuthor":"","doi":"10.1182/blood-2016-08-693481","elsevierAuthor":"Bacigalupo A.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"117"},{"title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","googleId":"tofRwts1eUEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/410/37114","googleCitationCount":125,"googleAuthor":"J Taylor","doi":"10.1182/blood-2017-02-734541","elsevierAuthor":"Taylor J.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"69"},{"title":"Aging of hematopoietic stem cells","googleId":"JXCbrFQT-U4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/479/104419","googleCitationCount":109,"googleAuthor":"SS Lazare","doi":"10.1182/blood-2017-06-746412","elsevierAuthor":"De Haan G.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"78"},{"title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma","googleId":"3_1VxXlRH4cJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1380/35994","googleCitationCount":170,"googleAuthor":"HT Kim","doi":"10.1182/blood-2016-09-738385","elsevierAuthor":"Merryman R.W.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"123"},{"title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","googleId":"TGBSZGYtHP4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2429/35954","googleCitationCount":127,"googleAuthor":"CJ Liu","doi":"10.1182/blood-2016-09-742296","elsevierAuthor":"Manier S.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"100"},{"title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","googleId":"xzuxe4YELQQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/24/2594/36866","googleCitationCount":113,"googleAuthor":"JN Kochenderfer","doi":"10.1182/blood-2017-06-793869","elsevierAuthor":"Mikkilineni L.","publicationName":"Blood","elsevierCoverDate":"2017-12-14","elsevierCoverDisplayDate":"14 December 2017","elsevierCitationCount":"87"},{"title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","googleId":"uQkRoWC0CPgJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2413/37097","googleCitationCount":100,"googleAuthor":"V Spina","doi":"10.1182/blood-2017-11-812073","elsevierAuthor":"Sollini M.","publicationName":"European Journal of Hybrid Imaging","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1"},{"title":"Philadelphia chromosome–like acute lymphoblastic leukemia","googleId":"D2ieljrH9VcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/19/2064/36686","googleCitationCount":107,"googleAuthor":"SK Tasian","doi":"10.1182/blood-2017-06-743252","elsevierAuthor":"Tasian S.K.","publicationName":"Blood","elsevierCoverDate":"2017-11-09","elsevierCoverDisplayDate":"9 November 2017","elsevierCitationCount":"63"},{"title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","googleId":"H_-Y8SuLmrEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1415/36624","googleCitationCount":98,"googleAuthor":"JF Zeidner","doi":"10.1182/blood-2017-09-805895","elsevierAuthor":"Swords R.T.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"78"},{"title":"The NCI Genomic Data Commons as an engine for precision medicine","googleId":"z0AFF__dd18J","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/453/37127","googleCitationCount":112,"googleAuthor":"RL Grossman","doi":"10.1182/blood-2017-03-735654","elsevierAuthor":"Jensen M.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"81"},{"title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","googleId":"g_KxC7BKdSEJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1595/36129","googleCitationCount":162,"googleAuthor":"TL Holyoake","doi":"10.1182/blood-2016-09-696013","elsevierAuthor":"Holyoake T.L.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"121"},{"title":"Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents","googleId":"wey0myfSgUoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120322941","googleCitationCount":92,"googleAuthor":"XR Xu","doi":"10.1182/blood-2017-05-743187","elsevierAuthor":"Xu X.R.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"72"},{"title":"Chimeric antigen receptor–modified T cells: CD19 and the road beyond","googleId":"JqIEvAwb2DEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/24/2621/37176","googleCitationCount":83,"googleAuthor":"AI Salter","doi":"10.1182/blood-2018-01-785840","elsevierAuthor":"Salter A.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"63"},{"title":"Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo","googleId":"BRpy8z3dbJ8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/14/1991/35879","googleCitationCount":119,"googleAuthor":"A Lin","doi":"10.1182/blood-2016-10-744441","elsevierAuthor":"Vono M.","publicationName":"Blood","elsevierCoverDate":"2017-04-06","elsevierCoverDisplayDate":"6 April 2017","elsevierCitationCount":"79"},{"title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","googleId":"eDH2rS16EckJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/16/2291/35922","googleCitationCount":114,"googleAuthor":"S Subramaniam","doi":"10.1182/blood-2016-11-749879","elsevierAuthor":"Subramaniam S.","publicationName":"Blood","elsevierCoverDate":"2017-04-20","elsevierCoverDisplayDate":"20 April 2017","elsevierCitationCount":"91"},{"title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma","googleId":"0WsfvX70FZwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3294/107599","googleCitationCount":111,"googleAuthor":"","doi":"10.1182/blood-2016-09-740787","elsevierAuthor":"Martin T.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"82"},{"title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","googleId":"r_gtEplH82gJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1478/39337","googleCitationCount":84,"googleAuthor":"A Dispenzieri","doi":"10.1182/blood-2018-04-839480","elsevierAuthor":"Fermand J.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"56"},{"title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","googleId":"fWVlNvs7JqcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1689/39360","googleCitationCount":89,"googleAuthor":"C Guillerey","doi":"10.1182/blood-2018-01-825265","elsevierAuthor":"Guillerey C.","publicationName":"Blood","elsevierCoverDate":"2018-10-18","elsevierCoverDisplayDate":"18 October 2018","elsevierCitationCount":"70"},{"title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","googleId":"6OfUu5YyiGwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/13/35804","googleCitationCount":154,"googleAuthor":"K MacDonald","doi":"10.1182/blood-2016-06-686618","elsevierAuthor":"MacDonald K.P.A.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"101"},{"title":"Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT","googleId":"eBA0UDxCufkJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2978/39137","googleCitationCount":88,"googleAuthor":"BW Haak","doi":"10.1182/blood-2018-01-828996","elsevierAuthor":"Haak B.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"64"},{"title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","googleId":"--M2DnFfnSYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/577/115519","googleCitationCount":113,"googleAuthor":"CS Tam","doi":"10.1182/blood.V130.Suppl_1.577.577","elsevierCitationCount":0},{"title":"LGL leukemia: from pathogenesis to treatment","googleId":"On35GMvKZRsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1082/36568","googleCitationCount":116,"googleAuthor":"","doi":"10.1182/blood-2016-08-692590","elsevierAuthor":"Lamy T.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"83"},{"title":"Integrin αIIbβ3 outside-in signaling","googleId":"k3rN58gEZuUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/14/1607/107662","googleCitationCount":102,"googleAuthor":"MT van den Bosch","doi":"10.1182/blood-2017-03-773614","elsevierAuthor":"Durrant T.N.","publicationName":"Blood","elsevierCoverDate":"2017-10-05","elsevierCoverDisplayDate":"5 October 2017","elsevierCitationCount":"68"},{"title":"Treating sickle cell disease by targeting HbS polymerization","googleId":"9cTF9rH9FnwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/20/2719/36133","googleCitationCount":106,"googleAuthor":"WA Eaton","doi":"10.1182/blood-2017-02-765891","elsevierAuthor":"Eaton W.","publicationName":"Blood","elsevierCoverDate":"2017-05-18","elsevierCoverDisplayDate":"18 May 2017","elsevierCitationCount":"79"},{"title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE)","googleId":"BvedO4ZYwksJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/957/266016","googleCitationCount":71,"googleAuthor":"S Mailankody","doi":"10.1182/blood-2018-99-113548","elsevierCitationCount":0},{"title":"The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia","googleId":"kCY-XSC7Mu8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1124/36596","googleCitationCount":106,"googleAuthor":"M Sanchez-Martin","doi":"10.1182/blood-2016-09-692582","elsevierAuthor":"Sanchez-Martin M.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"75"},{"title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","googleId":"AYdnzZFCR84J","googleLink":"https://ashpublications.org/blood/article-abstract/132/24/2546/39526","googleCitationCount":66,"googleAuthor":"NJ Bahlis","doi":"10.1182/blood-2018-06-858852","elsevierAuthor":"Bahlis N.","publicationName":"Blood","elsevierCoverDate":"2018-12-13","elsevierCoverDisplayDate":"13 December 2018","elsevierCitationCount":"46"},{"title":"Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus","googleId":"LzqpIAygEYkJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1960/36763","googleCitationCount":94,"googleAuthor":"A Lattanzi","doi":"10.1182/blood-2017-10-811505","elsevierAuthor":"Antoniani C.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"62"},{"title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","googleId":"Zb9xzJWGEzsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/26/2838/36597","googleCitationCount":92,"googleAuthor":"","doi":"10.1182/blood-2017-04-778423","elsevierAuthor":"Gogishvili T.","publicationName":"Blood","elsevierCoverDate":"2017-12-28","elsevierCoverDisplayDate":"28 December 2017","elsevierCitationCount":"65"},{"title":"Gemtuzumab ozogamicin for acute myeloid leukemia","googleId":"Vmdf4whq_7UJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/22/2373/36556","googleCitationCount":98,"googleAuthor":"FR Appelbaum","doi":"10.1182/blood-2017-09-797712","elsevierAuthor":"Appelbaum F.R.","publicationName":"Blood","elsevierCoverDate":"2017-11-30","elsevierCoverDisplayDate":"30 November 2017","elsevierCitationCount":"68"},{"title":"Classification systems for chronic graft-versus-host disease","googleId":"3ZGcqknCS6MJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/30/35839","googleCitationCount":140,"googleAuthor":"SJ Lee","doi":"10.1182/blood-2016-07-686642","elsevierAuthor":"Lee S.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"81"},{"title":"High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","googleId":"O7nL5Yhl7dAJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2060/36718","googleCitationCount":87,"googleAuthor":"RL King","doi":"10.1182/blood-2017-12-820605","elsevierAuthor":"Scott D.W.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"56"},{"title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","googleId":"O8T4qdxuI5AJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/311/38326","googleCitationCount":94,"googleAuthor":"AK Sewell","doi":"10.1182/blood-2017-05-787598","elsevierAuthor":"Legut M.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"72"},{"title":"Myeloid neoplasms with eosinophilia","googleId":"TG28vyrqYfIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/6/704/36333","googleCitationCount":138,"googleAuthor":"","doi":"10.1182/blood-2016-10-695973","elsevierAuthor":"Reiter A.","publicationName":"Blood","elsevierCoverDate":"2017-02-09","elsevierCoverDisplayDate":"9 February 2017","elsevierCitationCount":"95"},{"title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","googleId":"LaDodVtRNS4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/9/1104/36991","googleCitationCount":101,"googleAuthor":"M Pai","doi":"10.1182/blood-2017-04-778993","elsevierAuthor":"Warkentin T.E.","publicationName":"Blood","elsevierCoverDate":"2017-08-31","elsevierCoverDisplayDate":"31 August 2017","elsevierCitationCount":"58"},{"title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations","googleId":"I8vVW1leuNcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1225/39628","googleCitationCount":74,"googleAuthor":"E Sharma","doi":"10.1182/blood-2018-04-843771","elsevierAuthor":"Pellagatti A.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"55"},{"title":"Coagulation factor XII in thrombosis and inflammation","googleId":"VnujRBMUezYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1903/36747","googleCitationCount":78,"googleAuthor":"C Maas","doi":"10.1182/blood-2017-04-569111","elsevierAuthor":"Maas C.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"52"},{"title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","googleId":"9pXXCiHMCHgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/25/2639/39577","googleCitationCount":80,"googleAuthor":"","doi":"10.1182/blood-2018-07-861641","elsevierAuthor":"Moskowitz C.H.","publicationName":"Blood","elsevierCoverDate":"2018-12-20","elsevierCoverDisplayDate":"20 December 2018","elsevierCitationCount":"54"},{"title":"Genetic predisposition to hematologic malignancies: management and surveillance","googleId":"bCzxpgduvvAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/424/37108","googleCitationCount":97,"googleAuthor":"","doi":"10.1182/blood-2017-02-735290","elsevierAuthor":"Godley L.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"65"},{"title":"Immune regulatory cell infusion for graft-versus-host disease prevention and therapy","googleId":"gZnCmbwA9CYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/24/2651/37155","googleCitationCount":76,"googleAuthor":"BR Blazar","doi":"10.1182/blood-2017-11-785865","elsevierAuthor":"Blazar B.R.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"55"},{"title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML","googleId":"UUmN-mj-7WsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/598/39411","googleCitationCount":75,"googleAuthor":"","doi":"10.1182/blood-2018-01-821629","elsevierAuthor":"Cortes J.E.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"63"},{"title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","googleId":"Nr_yEjV6wVAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/19/2055/36693","googleCitationCount":95,"googleAuthor":"","doi":"10.1182/blood-2017-06-788026","elsevierAuthor":"Scully M.","publicationName":"Blood","elsevierCoverDate":"2017-11-09","elsevierCoverDisplayDate":"9 November 2017","elsevierCitationCount":"73"},{"title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","googleId":"beUCTvr3V5kJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/19/2702/36147","googleCitationCount":105,"googleAuthor":"O Al-Sawaf","doi":"10.1182/blood-2017-01-761973","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"0"},{"title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","googleId":"3mLEDeWxv7EJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/92/266121","googleCitationCount":64,"googleAuthor":"J Ritz","doi":"10.1182/blood-2018-99-117199","elsevierCitationCount":0},{"title":"Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML","googleId":"5kmc4FrHYb4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/23/2469/36739","googleCitationCount":91,"googleAuthor":"AH Wei","doi":"10.1182/blood-2017-08-784066","elsevierAuthor":"Wei A.H.","publicationName":"Blood","elsevierCoverDate":"2017-12-07","elsevierCoverDisplayDate":"7 December 2017","elsevierCitationCount":"77"},{"title":"Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type","googleId":"j4-S_OhYCI4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/23/2528/36945","googleCitationCount":81,"googleAuthor":"","doi":"10.1182/blood-2017-12-791418","elsevierAuthor":"Yamaguchi M.","publicationName":"Blood","elsevierCoverDate":"2018-06-07","elsevierCoverDisplayDate":"7 June 2018","elsevierCitationCount":"51"},{"title":"How I treat autoimmune hemolytic anemia","googleId":"8QZolMI1SqcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/22/2971/36045","googleCitationCount":98,"googleAuthor":"RS Go","doi":"10.1182/blood-2016-11-693689","elsevierAuthor":"Go R.","publicationName":"Blood","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"61"},{"title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","googleId":"PqfArGry4TYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/15/1568/39320","googleCitationCount":70,"googleAuthor":"FT Awan","doi":"10.1182/blood-2018-05-853564","elsevierAuthor":"Rogers K.","publicationName":"Blood","elsevierCoverDate":"2018-10-11","elsevierCoverDisplayDate":"11 October 2018","elsevierCitationCount":"65"},{"title":"Pathophysiology of thrombotic thrombocytopenic purpura","googleId":"5spDYvJOGEUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1181/36350","googleCitationCount":94,"googleAuthor":"","doi":"10.1182/blood-2017-04-636431","elsevierAuthor":"Sadler J.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"74"},{"title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","googleId":"cxA89f1TdOwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/11/1095/39390","googleCitationCount":75,"googleAuthor":"AJ Silver","doi":"10.1182/blood-2018-05-850339","elsevierAuthor":"Kahn J.D.","publicationName":"Blood","elsevierCoverDate":"2018-09-13","elsevierCoverDisplayDate":"13 September 2018","elsevierCitationCount":"56"},{"title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","googleId":"SPd0qc1gMBIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1275/36003","googleCitationCount":128,"googleAuthor":"Y Abaza","doi":"10.1182/blood-2016-09-736686","elsevierAuthor":"Abaza Y.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"100"},{"title":"Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","googleId":"k__LF6XF_4YJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/100/35801","googleCitationCount":127,"googleAuthor":"M Goebeler","doi":"10.1182/blood-2016-05-718395","elsevierAuthor":"Braig F.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"93"},{"title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells","googleId":"rfj6dbCsuUYJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1071/36572","googleCitationCount":97,"googleAuthor":"","doi":"10.1182/blood-2016-09-692574","elsevierAuthor":"Watanabe T.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"73"},{"title":"Biology and treatment of Richter syndrome","googleId":"n62INAq8hboJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/25/2761/37138","googleCitationCount":69,"googleAuthor":"D Rossi","doi":"10.1182/blood-2018-01-791376","elsevierAuthor":"Rossi D.","publicationName":"Blood","elsevierCoverDate":"2018-06-21","elsevierCoverDisplayDate":"21 June 2018","elsevierCitationCount":"49"},{"title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","googleId":"pcc3QziIM2UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2395/35979","googleCitationCount":96,"googleAuthor":"SK Tasian","doi":"10.1182/blood-2016-08-736041","elsevierAuthor":"Tasian S.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"80"},{"title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","googleId":"XQB7BY9H-m0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2454/37093","googleCitationCount":74,"googleAuthor":"E Ladewig","doi":"10.1182/blood-2017-11-814913","elsevierAuthor":"Tiacci E.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"51"},{"title":"Genetics of diffuse large B-cell lymphoma","googleId":"XCAQhp-8WZEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2307/37115","googleCitationCount":73,"googleAuthor":"L Pasqualucci","doi":"10.1182/blood-2017-11-764332","elsevierAuthor":"Pasqualucci L.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"53"},{"title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","googleId":"qRfWJj-a2Q8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/257/36083","googleCitationCount":126,"googleAuthor":"LY Lee","doi":"10.1182/blood-2016-10-745133","elsevierAuthor":"Lee L.","publicationName":"Blood","elsevierCoverDate":"2017-01-12","elsevierCoverDisplayDate":"12 January 2017","elsevierCitationCount":"91"},{"title":"Mechanisms of platelet clearance and translation to improve platelet storage","googleId":"tTXYey4l7NMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1512/36658","googleCitationCount":74,"googleAuthor":"ME Quach","doi":"10.1182/blood-2017-08-743229","elsevierAuthor":"Edward Quach M.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"56"},{"title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","googleId":"EgIMzMtOdogJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/17/1737/39507","googleCitationCount":68,"googleAuthor":"E Haddad","doi":"10.1182/blood-2018-03-840702","elsevierAuthor":"Haddad E.","publicationName":"Blood","elsevierCoverDate":"2018-10-25","elsevierCoverDisplayDate":"25 October 2018","elsevierCitationCount":"57"},{"title":"Hepcidin agonists as therapeutic tools","googleId":"1jxdJ4rHkEYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/16/1790/36820","googleCitationCount":69,"googleAuthor":"C Casu","doi":"10.1182/blood-2017-11-737411","elsevierAuthor":"Casu C.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"44"},{"title":"A MALT lymphoma prognostic index","googleId":"V-aS-JNbw9sJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/12/1409/36508","googleCitationCount":85,"googleAuthor":"C Thieblemont","doi":"10.1182/blood-2017-03-771915","elsevierAuthor":"Thieblemont C.","publicationName":"Blood","elsevierCoverDate":"2017-09-21","elsevierCoverDisplayDate":"21 September 2017","elsevierCitationCount":"58"},{"title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma","googleId":"D6Sw2tiUZp8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/8/777/39453","googleCitationCount":68,"googleAuthor":"","doi":"10.1182/blood-2018-04-839217","elsevierAuthor":"Chow V.A.","publicationName":"Blood","elsevierCoverDate":"2018-08-23","elsevierCoverDisplayDate":"23 August 2018","elsevierCitationCount":"53"},{"title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN","googleId":"coVaQ-RJTvIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/13/1514/36551","googleCitationCount":89,"googleAuthor":"NJ Short","doi":"10.1182/blood-2017-06-788497","elsevierAuthor":"Jabbour E.","publicationName":"Blood","elsevierCoverDate":"2017-09-28","elsevierCoverDisplayDate":"28 September 2017","elsevierCitationCount":"63"},{"title":"A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","googleId":"CPgNlcVH0e4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/597/36786","googleCitationCount":90,"googleAuthor":"","doi":"10.1182/blood-2017-03-771220","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2020-03-26","elsevierCoverDisplayDate":"26 March 2020","elsevierCitationCount":"0"},{"title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly …","googleId":"mvR9xDUoV18J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/LBA-2/375112","googleCitationCount":66,"googleAuthor":"T Plesner","doi":"10.1182/blood-2018-120737","elsevierAuthor":"Zanwar S.","publicationName":"Current Hematologic Malignancy Reports","elsevierCoverDate":"2019-04-15","elsevierCoverDisplayDate":"15 April 2019","elsevierCitationCount":"3"},{"title":"How I treat double-hit lymphoma","googleId":"HjVjTbx1xooJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/590/36799","googleCitationCount":84,"googleAuthor":"","doi":"10.1182/blood-2017-04-737320","elsevierAuthor":"Friedberg J.W.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"52"},{"title":"PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy","googleId":"f3pazvX_S8UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2186/36420","googleCitationCount":90,"googleAuthor":"","doi":"10.1182/blood-2016-09-741629","elsevierAuthor":"Asano T.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"75"},{"title":"The Medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or …","googleId":"jido8SlaCjoJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1/262479","googleCitationCount":62,"googleAuthor":"GJ Mufti","doi":"10.1182/blood-2018-99-110805","elsevierCitationCount":0},{"title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","googleId":"Mu5B_czUTfIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/17/1889/36509","googleCitationCount":85,"googleAuthor":"AJ Mead","doi":"10.1182/blood-2017-05-785790","elsevierAuthor":"Harrison C.N.","publicationName":"Blood","elsevierCoverDate":"2017-10-26","elsevierCoverDisplayDate":"26 October 2017","elsevierCitationCount":"62"},{"title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","googleId":"cW6MbPVcwSEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/995/39172","googleCitationCount":75,"googleAuthor":"R Aplenc","doi":"10.1182/blood-2017-07-794214","elsevierAuthor":"Bride K.L.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"58"},{"title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","googleId":"wivty1wFMcsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/6/699/36794","googleCitationCount":84,"googleAuthor":"","doi":"10.1182/blood-2017-02-763086","elsevierAuthor":"Prokocimer M.","publicationName":"Blood","elsevierCoverDate":"2017-08-10","elsevierCoverDisplayDate":"10 August 2017","elsevierCitationCount":"58"},{"title":"Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice","googleId":"TQZ-dpKfXagJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/405/36190","googleCitationCount":113,"googleAuthor":"S Canali","doi":"10.1182/blood-2016-06-721571","elsevierAuthor":"Canali S.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"91"},{"title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin …","googleId":"xzNNahH9jgUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1547/79746","googleCitationCount":79,"googleAuthor":"FL Locke","doi":"10.1182/blood.V130.Suppl_1.1547.1547","elsevierCitationCount":0},{"title":"GATA factor mutations in hematologic disease","googleId":"-DHU_4tFCjAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2103/36433","googleCitationCount":87,"googleAuthor":"","doi":"10.1182/blood-2016-09-687889","elsevierAuthor":"Crispino J.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"58"},{"title":"Splenectomy for immune thrombocytopenia: down but not out","googleId":"S3Cvy7ruGEMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/11/1172/36453","googleCitationCount":76,"googleAuthor":"S Chaturvedi","doi":"10.1182/blood-2017-09-742353","elsevierAuthor":"Chaturvedi S.","publicationName":"Blood","elsevierCoverDate":"2018-03-15","elsevierCoverDisplayDate":"15 March 2018","elsevierCitationCount":"46"},{"title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients","googleId":"rOPcNqhun6AJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/24/2610/36869","googleCitationCount":77,"googleAuthor":"NJ Bahlis","doi":"10.1182/blood-2017-06-791228","elsevierAuthor":"Avet-Loiseau H.","publicationName":"Blood","elsevierCoverDate":"2017-12-14","elsevierCoverDisplayDate":"14 December 2017","elsevierCitationCount":"51"},{"title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","googleId":"kZ6Byc6aM-gJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/25/2846/37158","googleCitationCount":70,"googleAuthor":"AS Renteria","doi":"10.1182/blood-2018-01-822957","elsevierAuthor":"Major-Monfried H.","publicationName":"Blood","elsevierCoverDate":"2018-06-21","elsevierCoverDisplayDate":"21 June 2018","elsevierCitationCount":"48"},{"title":"Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma …","googleId":"woSmchPMw4gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/740/83633","googleCitationCount":84,"googleAuthor":"D Siegel","doi":"10.1182/blood.V130.Suppl_1.740.740","elsevierCitationCount":0},{"title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","googleId":"jRbN5WW2f1gJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/89/39281","googleCitationCount":79,"googleAuthor":"OS Eckstein","doi":"10.1182/blood-2017-11-814244","elsevierAuthor":"Chinn I.K.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"57"},{"title":"Inflammation, von Willebrand factor, and ADAMTS13","googleId":"ommquQR-iZAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120320796","googleCitationCount":59,"googleAuthor":"","doi":"10.1182/blood-2018-02-769000","elsevierAuthor":"Chen J.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"47"},{"title":"The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease","googleId":"D-SdaI49pbMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/927/36334","googleCitationCount":111,"googleAuthor":"A Staffas","doi":"10.1182/blood-2016-09-691394","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"0"},{"title":"Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study","googleId":"A8jyJboyg2YJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/20/2183/6537","googleCitationCount":70,"googleAuthor":"EJ van Beers","doi":"10.1182/blood-2017-10-810796","elsevierAuthor":"Grace R.F.","publicationName":"Blood","elsevierCoverDate":"2018-05-17","elsevierCoverDisplayDate":"17 May 2018","elsevierCitationCount":"42"},{"title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a …","googleId":"5hpGuIy02UsJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/959/266042","googleCitationCount":56,"googleAuthor":"S Mailankody","doi":"10.1182/blood-2018-99-119717","elsevierCitationCount":0},{"title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","googleId":"IDTlT-s1iDMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2016/39480","googleCitationCount":55,"googleAuthor":"L Cerchietti","doi":"10.1182/blood-2018-07-859769","elsevierAuthor":"Ruan J.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"35"},{"title":"Safety and persistence of WT1-specific T-cell receptor gene− transduced lymphocytes in patients with AML and MDS","googleId":"WX6rhSoXBhMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/18/1985/36534","googleCitationCount":79,"googleAuthor":"","doi":"10.1182/blood-2017-06-791202","elsevierAuthor":"Tawara I.","publicationName":"Blood","elsevierCoverDate":"2017-11-02","elsevierCoverDisplayDate":"2 November 2017","elsevierCitationCount":"59"},{"title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","googleId":"arE2_PKMvkAJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/4/387/38494","googleCitationCount":72,"googleAuthor":"AT Fathi","doi":"10.1182/blood-2017-06-789800","elsevierAuthor":"Stein E.M.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"60"},{"title":"A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice","googleId":"wiGjepcqZqoJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/e1/37145","googleCitationCount":69,"googleAuthor":"JS Dahlin","doi":"10.1182/blood-2017-12-821413","elsevierAuthor":"Dahlin J.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"38"},{"title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","googleId":"TF80EpG6xzUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2143/39510","googleCitationCount":60,"googleAuthor":"","doi":"10.1182/blood-2018-04-840090","elsevierAuthor":"Jestin M.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"40"},{"title":"Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions","googleId":"ujbScnkP0nsJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2283/37126","googleCitationCount":58,"googleAuthor":"","doi":"10.1182/blood-2017-10-764373","elsevierAuthor":"Puente X.","publicationName":"Blood","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"2018","elsevierCitationCount":"36"},{"title":"Chronic immune response dysregulation in MDS pathogenesis","googleId":"XjiJpFqKXRoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/15/1553/39326","googleCitationCount":58,"googleAuthor":"L Barreyro","doi":"10.1182/blood-2018-03-784116","elsevierAuthor":"Barreyro L.","publicationName":"Blood","elsevierCoverDate":"2018-10-11","elsevierCoverDisplayDate":"11 October 2018","elsevierCitationCount":"40"},{"title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements","googleId":"mUOHwiYVBAcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/3/280/36006","googleCitationCount":103,"googleAuthor":"NA Johnson","doi":"10.1182/blood-2016-02-636316","elsevierAuthor":"Sesques P.","publicationName":"Blood","elsevierCoverDate":"2017-01-19","elsevierCoverDisplayDate":"19 January 2017","elsevierCitationCount":"77"},{"title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","googleId":"N5--ku4I-FcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/9/948/39426","googleCitationCount":56,"googleAuthor":"DT Yeung","doi":"10.1182/blood-2018-02-832253","elsevierAuthor":"Branford S.","publicationName":"Blood","elsevierCoverDate":"2018-08-30","elsevierCoverDisplayDate":"30 August 2018","elsevierCitationCount":"41"},{"title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","googleId":"7_me1GrDGL0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/328/38363","googleCitationCount":72,"googleAuthor":"S Kurtenbach","doi":"10.1182/blood-2017-06-789669","elsevierAuthor":"Yang H.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"60"},{"title":"BCL-2 inhibition in AML: an unexpected bonus?","googleId":"d-qm0buyEHAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/10/1007/39300","googleCitationCount":59,"googleAuthor":"A Letai","doi":"10.1182/blood-2018-03-828269","elsevierAuthor":"Konopleva M.","publicationName":"Blood","elsevierCoverDate":"2018-09-06","elsevierCoverDisplayDate":"6 September 2018","elsevierCitationCount":"39"},{"title":"The rise of apoptosis: targeting apoptosis in hematologic malignancies","googleId":"EmLsgQSGCDkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1248/39612","googleCitationCount":51,"googleAuthor":"","doi":"10.1182/blood-2018-02-791350","elsevierAuthor":"Valentin R.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"46"},{"title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","googleId":"iUpIXx1ajJcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/632/36808","googleCitationCount":78,"googleAuthor":"","doi":"10.1182/blood-2017-02-767475","elsevierAuthor":"Dittrich T.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"63"},{"title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","googleId":"5KiIvmIKHrIJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/7/746/39305","googleCitationCount":68,"googleAuthor":"","doi":"10.1182/blood-2017-05-781351","elsevierAuthor":"Lee L.","publicationName":"Blood","elsevierCoverDate":"2018-02-15","elsevierCoverDisplayDate":"15 February 2018","elsevierCitationCount":"53"},{"title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact","googleId":"r1EKb0TmoBIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/20/2760/36119","googleCitationCount":76,"googleAuthor":"","doi":"10.1182/blood-2016-11-747022","elsevierAuthor":"Ennishi D.","publicationName":"Blood","elsevierCoverDate":"2017-05-18","elsevierCoverDisplayDate":"18 May 2017","elsevierCitationCount":"59"},{"title":"Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation","googleId":"BvaC95LppWIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2083/36382","googleCitationCount":74,"googleAuthor":"R Avellino","doi":"10.1182/blood-2016-09-687822","elsevierAuthor":"Avellino R.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"50"},{"title":"Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non–transferrin-bound iron","googleId":"UYEKx8pgnDAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/245/36928","googleCitationCount":75,"googleAuthor":"J Arezes","doi":"10.1182/blood-2017-03-772715","elsevierAuthor":"Stefanova D.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"56"},{"title":"Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in …","googleId":"RswXyWqq4wsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/401/72564","googleCitationCount":71,"googleAuthor":"M Cavo","doi":"10.1182/blood.V130.Suppl_1.401.401","elsevierCitationCount":0},{"title":"In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps","googleId":"ZNsYhIwfj7QJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/1021/36344","googleCitationCount":96,"googleAuthor":"DF Noubouossie","doi":"10.1182/blood-2016-06-722298","elsevierAuthor":"Noubouossie D.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"75"},{"title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","googleId":"gIYucgIUGU8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/16/2316/35932","googleCitationCount":76,"googleAuthor":"JA Hill","doi":"10.1182/blood-2016-10-748426","elsevierAuthor":"Hill J.A.","publicationName":"Blood","elsevierCoverDate":"2017-04-20","elsevierCoverDisplayDate":"20 April 2017","elsevierCitationCount":"61"},{"title":"Efficacy and updated safety analysis of a safety Run-in cohort from Griffin, a phase 2 randomized study of Daratumumab (DarA), bortezomib (V), lenalidomide (R), and …","googleId":"ZH75Pkbn6WcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/151/272998","googleCitationCount":51,"googleAuthor":"","doi":"10.1182/blood-2018-151","elsevierCitationCount":0},{"title":"An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","googleId":"8tTrycBR22YJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/609/36176","googleCitationCount":102,"googleAuthor":"S Sukumaran","doi":"10.1182/blood-2016-08-735365","elsevierAuthor":"Leong S.R.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"73"},{"title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","googleId":"wrFUIUHlazMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/473/36199","googleCitationCount":100,"googleAuthor":"M Matlock","doi":"10.1182/blood-2016-07-729954","elsevierAuthor":"Krysiak K.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"68"},{"title":"Clinical and pathological characteristics of HIV-and HHV-8–negative Castleman disease","googleId":"xWFhSNGBXFUJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1658/36127","googleCitationCount":95,"googleAuthor":"","doi":"10.1182/blood-2016-11-748855","elsevierAuthor":"Yu L.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"62"},{"title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical …","googleId":"1NYmCEp70YsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/811/83447","googleCitationCount":68,"googleAuthor":"JY Song","doi":"10.1182/blood.V130.Suppl_1.811.811","elsevierCitationCount":0},{"title":"Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe …","googleId":"xO7cZs-egXkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/560/263325","googleCitationCount":52,"googleAuthor":"AT Fathi","doi":"10.1182/blood-2018-99-110449","elsevierAuthor":"Becker J.S.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"DNA damage responses and p53 in the aging process","googleId":"F6sZVUf9x_8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120325064","googleCitationCount":73,"googleAuthor":"B Schumacher","doi":"10.1182/blood-2017-07-746396","elsevierAuthor":"Ou H.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"41"},{"title":"How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions","googleId":"--i6pGVeK68J","googleLink":"https://ashpublications.org/blood/article-abstract/131/25/2773/37156","googleCitationCount":59,"googleAuthor":"K Yazdanbakhsh","doi":"10.1182/blood-2018-02-785964","elsevierAuthor":"Pirenne F.","publicationName":"Blood","elsevierCoverDate":"2018-06-21","elsevierCoverDisplayDate":"21 June 2018","elsevierCitationCount":"38"},{"title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","googleId":"02d2ndeRITEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2305/39525","googleCitationCount":55,"googleAuthor":"F Lemonnier","doi":"10.1182/blood-2018-04-840538","elsevierAuthor":"Lemonnier F.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"38"},{"title":"The MYC oncogene is a global regulator of the immune response","googleId":"oPV94PRqKt4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2007/36721","googleCitationCount":61,"googleAuthor":"V Baylot","doi":"10.1182/blood-2017-11-742577","elsevierAuthor":"Casey S.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"43"},{"title":"EPCR expression marks UM171-expanded CD34+ cord blood stem cells","googleId":"FbprXvQFpAMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3344/107629","googleCitationCount":72,"googleAuthor":"I Fares","doi":"10.1182/blood-2016-11-750729","elsevierAuthor":"Fares I.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"55"},{"title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","googleId":"qY3rs9fONO4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/8/855/104417","googleCitationCount":66,"googleAuthor":"D Siegel","doi":"10.1182/blood-2017-08-797886","elsevierAuthor":"Chen C.","publicationName":"Blood","elsevierCoverDate":"2018-02-22","elsevierCoverDisplayDate":"22 February 2018","elsevierCitationCount":"50"},{"title":"A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","googleId":"4LOBGToPCkcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2249/39554","googleCitationCount":50,"googleAuthor":"","doi":"10.1182/blood-2018-06-860593","elsevierAuthor":"Chen L.S.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"39"},{"title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy","googleId":"P1qDII-0hKAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/488/262309","googleCitationCount":55,"googleAuthor":"DS Siegel","doi":"10.1182/blood-2018-99-116953","elsevierCitationCount":0},{"title":"The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications","googleId":"EGw_UWNVDH8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1617/36115","googleCitationCount":73,"googleAuthor":"H Medyouf","doi":"10.1182/blood-2016-11-696070","elsevierAuthor":"Medyouf H.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"56"},{"title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","googleId":"gtwqc_ytA6EJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/49/39283","googleCitationCount":60,"googleAuthor":"E Bachy","doi":"10.1182/blood-2017-11-816405","elsevierAuthor":"Bachy E.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"42"},{"title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","googleId":"0vKIyZ7BFA0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/2/174/37014","googleCitationCount":66,"googleAuthor":"P Soubeyran","doi":"10.1182/blood-2017-07-793984","elsevierAuthor":"Lamy T.","publicationName":"Blood","elsevierCoverDate":"2018-01-11","elsevierCoverDisplayDate":"11 January 2018","elsevierCitationCount":"54"},{"title":"Ferritin is secreted via 2 distinct nonclassical vesicular pathways","googleId":"xUJ4nPwYt8AJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/342/38393","googleCitationCount":64,"googleAuthor":"M Truman-Rosentsvit","doi":"10.1182/blood-2017-02-768580","elsevierAuthor":"Truman-Rosentsvit M.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"52"},{"title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia","googleId":"_ri9Xp1qMvAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/895/266293","googleCitationCount":53,"googleAuthor":"SA Grupp","doi":"10.1182/blood-2018-99-112599","elsevierCitationCount":0},{"title":"Novel approaches to hemophilia therapy: successes and challenges","googleId":"iWwiAbD7ShYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2251/36664","googleCitationCount":65,"googleAuthor":"BJ Samelson-Jones","doi":"10.1182/blood-2017-08-742312","elsevierAuthor":"Zhang F.","publicationName":"Human Gene Therapy","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"1"},{"title":"MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts","googleId":"05iJJ7eesBgJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/11/1290/36448","googleCitationCount":67,"googleAuthor":"RM O'Connell","doi":"10.1182/blood-2016-10-697698","elsevierAuthor":"Wallace J.","publicationName":"Blood","elsevierCoverDate":"2017-09-14","elsevierCoverDisplayDate":"14 September 2017","elsevierCitationCount":"57"},{"title":"Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial","googleId":"jjuVZLuxupEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/421/275722","googleCitationCount":55,"googleAuthor":"","doi":"10.1182/blood-2018-99-118808","elsevierAuthor":"Trujillo Santos A.J.","publicationName":"Revista Clinica Espanola","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0"},{"title":"Immunoassay for human serum erythroferrone","googleId":"TETijAx8GHwJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1243/36345","googleCitationCount":70,"googleAuthor":"T Ganz","doi":"10.1182/blood-2017-04-777987","elsevierAuthor":"Ganz T.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"52"},{"title":"Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","googleId":"SZABTb60FXcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/3091/263862","googleCitationCount":55,"googleAuthor":"DP Steensma","doi":"10.1182/blood-2018-99-119990","elsevierAuthor":"Adès L.","publicationName":"HemaSphere","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"0"},{"title":"Activated protein C, protease activated receptor 1, and neuroprotection","googleId":"6dJ8Uy-5SFAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/159/39239","googleCitationCount":50,"googleAuthor":"JH Griffin","doi":"10.1182/blood-2018-02-769026","elsevierAuthor":"Griffin J.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"34"},{"title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","googleId":"kzhyPbSDIpEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2344/36657","googleCitationCount":65,"googleAuthor":"S Aguila","doi":"10.1182/blood-2017-05-786699","elsevierAuthor":"Lavin M.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"51"},{"title":"Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year …","googleId":"E4JNWjcrHn4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/890/83379","googleCitationCount":64,"googleAuthor":"A Wei","doi":"10.1182/blood.V130.Suppl_1.890.890","elsevierCitationCount":0},{"title":"Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","googleId":"E-cbmfRtsNIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/177/36096","googleCitationCount":88,"googleAuthor":"SK Tasian","doi":"10.1182/blood-2016-05-707653","elsevierAuthor":"Tasian S.K.","publicationName":"Blood","elsevierCoverDate":"2017-01-12","elsevierCoverDisplayDate":"12 January 2017","elsevierCitationCount":"68"},{"title":"SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia","googleId":"nSvMx4S9ZYkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/24/2631/36872","googleCitationCount":61,"googleAuthor":"BG Mar","doi":"10.1182/blood-2017-03-775569","elsevierAuthor":"Mar B.G.","publicationName":"Blood","elsevierCoverDate":"2017-12-14","elsevierCoverDisplayDate":"14 December 2017","elsevierCitationCount":"47"},{"title":"Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review","googleId":"Ua1-5xIne8IJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1538/35953","googleCitationCount":70,"googleAuthor":"D Winkelhorst","doi":"10.1182/blood-2016-10-739656","elsevierAuthor":"Winkelhorst D.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"42"},{"title":"Runx transcription factors in the development and function of the definitive hematopoietic system","googleId":"Tme9pTKAkskJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2061/36387","googleCitationCount":70,"googleAuthor":"","doi":"10.1182/blood-2016-12-689109","elsevierAuthor":"De Bruijn M.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"40"},{"title":"Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","googleId":"Gkm_C7Jg-EAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1985/39605","googleCitationCount":51,"googleAuthor":"T Colley","doi":"10.1182/blood-2017-12-823393","elsevierAuthor":"Bercusson A.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"39"},{"title":"SCL/TAL1: a multifaceted regulator from blood development to disease","googleId":"pxFfMq-p5-gJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2051/36413","googleCitationCount":67,"googleAuthor":"MS Kristiansen","doi":"10.1182/blood-2016-12-754051","elsevierAuthor":"Porcher C.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"39"},{"title":"von Willebrand factor regulation of blood vessel formation","googleId":"tbNZu4TdwGkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/132/39222","googleCitationCount":54,"googleAuthor":"","doi":"10.1182/blood-2018-01-769018","elsevierAuthor":"Maaland A.F.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group","googleId":"mcoWZ4HCsXcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/8/815/39461","googleCitationCount":46,"googleAuthor":"","doi":"10.1182/blood-2018-04-841676","elsevierAuthor":"Roberts K.G.","publicationName":"Blood","elsevierCoverDate":"2018-08-23","elsevierCoverDisplayDate":"23 August 2018","elsevierCitationCount":"31"},{"title":"Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome","googleId":"HJfq3KjWJ-MJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1557/35898","googleCitationCount":86,"googleAuthor":"S Dhanraj","doi":"10.1182/blood-2016-08-735431","elsevierAuthor":"Dhanraj S.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"56"},{"title":"How I treat CLL patients with ibrutinib","googleId":"t877E0PQEGwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120325234","googleCitationCount":63,"googleAuthor":"","doi":"10.1182/blood-2017-08-764712","elsevierAuthor":"Brown J.R.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"40"},{"title":"How I treat chronic myelomonocytic leukemia","googleId":"m1XH1J5II1gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/2/126/36728","googleCitationCount":66,"googleAuthor":"","doi":"10.1182/blood-2017-04-736421","elsevierAuthor":"Solary E.","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"51"},{"title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy","googleId":"nfUW7kEEPR8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/22/2980/36039","googleCitationCount":67,"googleAuthor":"RD Lopes","doi":"10.1182/blood-2016-08-731638","elsevierAuthor":"Lopes R.D.","publicationName":"Blood","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"50"},{"title":"Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death","googleId":"si8_Kjo9a1YJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2183/39501","googleCitationCount":49,"googleAuthor":"T Tokunaga","doi":"10.1182/blood-2018-04-842260","elsevierAuthor":"Ueki S.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"40"},{"title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","googleId":"MnSBZ7tDYKMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/9/935/39421","googleCitationCount":51,"googleAuthor":"JC Aster","doi":"10.1182/blood-2017-11-818617","elsevierAuthor":"Ng S.","publicationName":"Blood","elsevierCoverDate":"2018-08-30","elsevierCoverDisplayDate":"30 August 2018","elsevierCitationCount":"32"},{"title":"How I manage monoclonal gammopathy of undetermined significance","googleId":"nRC6XZPFTEcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/2/163/37011","googleCitationCount":59,"googleAuthor":"RS Go","doi":"10.1182/blood-2017-09-807560","elsevierAuthor":"Go R.","publicationName":"Blood","elsevierCoverDate":"2018-01-11","elsevierCoverDisplayDate":"11 January 2018","elsevierCitationCount":"35"},{"title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma","googleId":"B7StvKe_mycJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1768/35817","googleCitationCount":66,"googleAuthor":"N Beeharry","doi":"10.1182/blood-2016-09-736892","elsevierAuthor":"Gayle S.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"55"},{"title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","googleId":"lAOJAE0-cAsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/625/36788","googleCitationCount":64,"googleAuthor":"P Milani","doi":"10.1182/blood-2017-02-767467","elsevierAuthor":"Milani P.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"58"},{"title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","googleId":"lI_pzqyYez4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2384/35973","googleCitationCount":68,"googleAuthor":"R Warfvinge","doi":"10.1182/blood-2016-07-728873","elsevierAuthor":"Warfvinge R.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"53"},{"title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","googleId":"B7aoy4S9wDsJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1430/36633","googleCitationCount":56,"googleAuthor":"","doi":"10.1182/blood-2017-06-789552","elsevierAuthor":"Girard-Guyonvarc’h C.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"40"},{"title":"Platelets kill circulating parasites of all major Plasmodium species in human malaria","googleId":"A1wTz1arp1wJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1332/39622","googleCitationCount":44,"googleAuthor":"S Kho","doi":"10.1182/blood-2018-05-849307","elsevierAuthor":"Kho S.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"27"},{"title":"Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","googleId":"7Pl-VShWYB8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1617/36676","googleCitationCount":53,"googleAuthor":"A Lequeux","doi":"10.1182/blood-2017-06-792267","elsevierAuthor":"Wierz M.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"42"},{"title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","googleId":"XsBKRqX8tgQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/310/36915","googleCitationCount":64,"googleAuthor":"","doi":"10.1182/blood-2016-12-758599","elsevierAuthor":"Erdmann T.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"50"},{"title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy","googleId":"FTIak2Y2QVcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1437/35927","googleCitationCount":83,"googleAuthor":"F Petitprez","doi":"10.1182/blood-2016-08-737163","elsevierAuthor":"Chauvet S.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"63"},{"title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","googleId":"f5XLfaQ0LgcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/22/3037/36042","googleCitationCount":66,"googleAuthor":"","doi":"10.1182/blood-2016-12-757740","elsevierAuthor":"Gopal A.K.","publicationName":"Blood","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"51"},{"title":"How I treat myeloma with new agents","googleId":"DAR0O_g85BcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/13/1507/36520","googleCitationCount":57,"googleAuthor":"P Moreau","doi":"10.1182/blood-2017-05-743203","elsevierAuthor":"Moreau P.","publicationName":"Blood","elsevierCoverDate":"2017-09-28","elsevierCoverDisplayDate":"28 September 2017","elsevierCitationCount":"40"},{"title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","googleId":"_kjEX5gTdZUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/556/263334","googleCitationCount":44,"googleAuthor":"AE Seif","doi":"10.1182/blood-2018-99-112572","elsevierCitationCount":0},{"title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","googleId":"njZF8tP4sZUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/22/2323/107704","googleCitationCount":37,"googleAuthor":"DC Fajgenbaum","doi":"10.1182/blood-2018-05-848671","elsevierAuthor":"Fajgenbaum D.C.","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"18"},{"title":"Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry","googleId":"VdvsM8Mb2j8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1209/36348","googleCitationCount":59,"googleAuthor":"H Ariffin","doi":"10.1182/blood-2017-05-782383","elsevierAuthor":"Moriyama T.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"50"},{"title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","googleId":"noFGATS8fiwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1456/36613","googleCitationCount":53,"googleAuthor":"","doi":"10.1182/blood-2017-07-795476","elsevierAuthor":"Cottereau A.S.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"41"},{"title":"Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2","googleId":"vLB1lGLJgU0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/24/2682/36885","googleCitationCount":63,"googleAuthor":"H Hashem","doi":"10.1182/blood-2017-07-798660","elsevierAuthor":"Hashem H.","publicationName":"Blood","elsevierCoverDate":"2017-12-14","elsevierCoverDisplayDate":"14 December 2017","elsevierCitationCount":"52"},{"title":"HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab …","googleId":"YgtEAYakuxUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/85/83407","googleCitationCount":55,"googleAuthor":"RF Sidonio","doi":"10.1182/blood.V130.Suppl_1.85.85","elsevierCitationCount":0},{"title":"Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide …","googleId":"5j5CuC1DoGMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/121/262862","googleCitationCount":47,"googleAuthor":"","doi":"10.1182/blood-2018-99-112093","elsevierAuthor":"Alsina M.","publicationName":"American Journal of Hematology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"1 February 2021","elsevierCitationCount":"0"},{"title":"Autophagy, a key mechanism of oncogenesis and resistance in leukemia","googleId":"iNSgY1z5xdsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/547/36143","googleCitationCount":76,"googleAuthor":"","doi":"10.1182/blood-2016-07-692707","elsevierAuthor":"Auberger P.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"57"},{"title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","googleId":"Vk8iu0oWM4gJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1095/36554","googleCitationCount":78,"googleAuthor":"","doi":"10.1182/blood-2016-09-692541","elsevierAuthor":"Lunning M.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"48"},{"title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","googleId":"NMZxwu42tR4J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/486/72473","googleCitationCount":55,"googleAuthor":"GA Salles","doi":"10.1182/blood.V130.Suppl_1.486.486","elsevierCitationCount":0},{"title":"Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory …","googleId":"YOCxW7phMx4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/505/80932","googleCitationCount":58,"googleAuthor":"AL Garfall","doi":"10.1182/blood.V130.Suppl_1.505.505","elsevierCitationCount":0},{"title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","googleId":"vmSQFnrYEZcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2475/37076","googleCitationCount":46,"googleAuthor":"CU Rank","doi":"10.1182/blood-2018-01-827949","elsevierAuthor":"Rank C.U.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"36"},{"title":"High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis","googleId":"80vMapDqEMIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/8/1007/36950","googleCitationCount":58,"googleAuthor":"","doi":"10.1182/blood-2017-01-761718","elsevierAuthor":"Bonometti A.","publicationName":"Journal of Cutaneous Pathology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","googleId":"MDX3-Jiby-8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1635/39368","googleCitationCount":41,"googleAuthor":"BS Hoppe","doi":"10.1182/blood-2018-03-837633","elsevierAuthor":"Moreno A.C.","publicationName":"Advances in Radiation Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"0"},{"title":"Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1","googleId":"XJaFxJkewl8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2896/36277","googleCitationCount":58,"googleAuthor":"","doi":"10.1182/blood-2016-09-742825","elsevierAuthor":"Sugimoto M.A.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"0"},{"title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","googleId":"c-5-i-YpsxIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/554/37074","googleCitationCount":62,"googleAuthor":"","doi":"10.1182/blood-2016-12-755496","elsevierAuthor":"Pedersen M.B.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"39"},{"title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","googleId":"LZgDcnOzfOAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/970/36366","googleCitationCount":73,"googleAuthor":"H Schrezenmeier","doi":"10.1182/blood-2016-08-732800","elsevierAuthor":"Harder M.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"60"},{"title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","googleId":"D7un5yyaE1MJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/4/417/38488","googleCitationCount":57,"googleAuthor":"","doi":"10.1182/blood-2017-07-797019","elsevierAuthor":"Aukema S.M.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"45"},{"title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","googleId":"axw4OM55jtwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/4/426/38537","googleCitationCount":48,"googleAuthor":"","doi":"10.1182/blood-2017-05-786657","elsevierAuthor":"Yamaura T.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"37"},{"title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","googleId":"XRf1Tk9ogcwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1438/105719","googleCitationCount":44,"googleAuthor":"CE Allen","doi":"10.1182/blood-2018-01-828277","elsevierAuthor":"Allen C.E.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"33"},{"title":"Radius: a phase 2 randomized trial investigating standard of care±midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML","googleId":"qm_5oLStC1sJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/662/266179","googleCitationCount":41,"googleAuthor":"MM Patnaik","doi":"10.1182/blood-2018-99-113582","elsevierCitationCount":0},{"title":"Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in …","googleId":"wUlaEowlA1IJ","googleLink":"https://cms.cws.net/content/beta.myelomasociety.org/files/2018ash/Wan-Hong%20Zhao%20-%20ASH%20presentation%20_Abstract%20955.pdf","googleCitationCount":40,"googleAuthor":""},{"title":"T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency","googleId":"WQc23I5TiIUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/22/2362/107711","googleCitationCount":39,"googleAuthor":"I Brigida","doi":"10.1182/blood-2018-07-863431","elsevierAuthor":"Brigida I.","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"26"},{"title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","googleId":"HRF1IfVXkFEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1675/39370","googleCitationCount":44,"googleAuthor":"SA Minnie","doi":"10.1182/blood-2018-01-825240","elsevierAuthor":"Minnie S.A.","publicationName":"Blood","elsevierCoverDate":"2019-11-21","elsevierCoverDisplayDate":"21 November 2019","elsevierCitationCount":"0"},{"title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","googleId":"VkMPmnC5LhsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/351/103892","googleCitationCount":42,"googleAuthor":"","doi":"10.1182/blood-2018-02-778530","elsevierAuthor":"Boissel N.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"26"},{"title":"The potential role of γδ T cells after allogeneic HCT for leukemia","googleId":"JnYPV9ccOSQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/10/1063/36406","googleCitationCount":47,"googleAuthor":"K Schilbach","doi":"10.1182/blood-2017-08-752162","elsevierAuthor":"Handgretinger R.","publicationName":"Blood","elsevierCoverDate":"2018-03-08","elsevierCoverDisplayDate":"8 March 2018","elsevierCitationCount":"35"},{"title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","googleId":"xbzOUeYRTgYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/289/38308","googleCitationCount":49,"googleAuthor":"A Petit","doi":"10.1182/blood-2017-04-778829","elsevierAuthor":"Petit A.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"40"},{"title":"How I treat breast implant–associated anaplastic large cell lymphoma","googleId":"YoSwGwY-R_gJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1889/39611","googleCitationCount":37,"googleAuthor":"MW Clemens","doi":"10.1182/blood-2018-03-785972","elsevierAuthor":"Mehta-Shah N.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"28"},{"title":"T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10","googleId":"zCCpPKwPzBIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2557/36263","googleCitationCount":56,"googleAuthor":"R Kapur","doi":"10.1182/blood-2016-12-758185","elsevierAuthor":"Kapur R.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"47"},{"title":"Somatic mutations and clonal hematopoiesis in congenital neutropenia","googleId":"6r6DczkUJ-8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/4/408/38500","googleCitationCount":50,"googleAuthor":"CA Miller","doi":"10.1182/blood-2017-08-801985","elsevierAuthor":"Xia J.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"36"},{"title":"Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 …","googleId":"0xf3rnUIDokJ","googleLink":"https://research.vumc.nl/en/publications/autologous-stem-cell-transplantation-versus-bortezomib-melphalan-","googleCitationCount":50,"googleAuthor":"M Cavo"},{"title":"Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition","googleId":"CFyBTvztbIAJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1639/36848","googleCitationCount":44,"googleAuthor":"P Gallipoli","doi":"10.1182/blood-2017-12-820035","elsevierAuthor":"Gallipoli P.","publicationName":"Blood","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"April 2018","elsevierCitationCount":"29"},{"title":"Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond–like syndrome","googleId":"CcIfZAPzLKYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1318/39626","googleCitationCount":40,"googleAuthor":"","doi":"10.1182/blood-2017-12-820308","elsevierAuthor":"Bellanné-Chantelot C.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"28"},{"title":"Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","googleId":"Jb-ASGzxXyoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/15/1604/39340","googleCitationCount":38,"googleAuthor":"TH Kim","doi":"10.1182/blood-2018-04-848028","elsevierAuthor":"Kim T.H.","publicationName":"Blood","elsevierCoverDate":"2018-10-11","elsevierCoverDisplayDate":"11 October 2018","elsevierCitationCount":"29"},{"title":"Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL)","googleId":"LueD7KVBV28J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/898/266319","googleCitationCount":39,"googleAuthor":"","doi":"10.1182/blood-2018-99-117445","elsevierCitationCount":0},{"title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","googleId":"gFLEjuyGWg0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1654/36819","googleCitationCount":43,"googleAuthor":"C Steidl","doi":"10.1182/blood-2017-09-772632","elsevierAuthor":"Mottok A.","publicationName":"Blood","elsevierCoverDate":"2018-04-12","elsevierCoverDisplayDate":"12 April 2018","elsevierCitationCount":"27"},{"title":"Eltrombopag: a powerful chelator of cellular or extracellular iron (III) alone or combined with a second chelator","googleId":"t3ApJfKFFhAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/17/1923/36515","googleCitationCount":49,"googleAuthor":"E Vlachodimitropoulou","doi":"10.1182/blood-2016-10-740241","elsevierAuthor":"Vlachodimitropoulou E.","publicationName":"Blood","elsevierCoverDate":"2017-10-26","elsevierCoverDisplayDate":"26 October 2017","elsevierCitationCount":"42"},{"title":"How I treat first relapse of myeloma","googleId":"cCeQ-5AebrQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/8/963/36946","googleCitationCount":50,"googleAuthor":"","doi":"10.1182/blood-2017-03-726703","elsevierAuthor":"Harousseau J.","publicationName":"Blood","elsevierCoverDate":"2017-08-24","elsevierCoverDisplayDate":"24 August 2017","elsevierCitationCount":"38"},{"title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","googleId":"NTdGreE-aDUJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2368/35949","googleCitationCount":54,"googleAuthor":"JM Soucie","doi":"10.1182/blood-2016-02-683169","elsevierAuthor":"Manco-Johnson M.J.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"58"},{"title":"Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells","googleId":"VtdI_FGO4_IJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/2/176/36706","googleCitationCount":56,"googleAuthor":"","doi":"10.1182/blood-2016-12-757377","elsevierAuthor":"Durham B.H.","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"46"},{"title":"Apoptosis in megakaryocytes and platelets: the life and death of a lineage","googleId":"BFzxWxTmmmQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/6/605/39214","googleCitationCount":47,"googleAuthor":"K McArthur","doi":"10.1182/blood-2017-11-742684","elsevierAuthor":"McArthur K.","publicationName":"Blood","elsevierCoverDate":"2018-02-08","elsevierCoverDisplayDate":"8 February 2018","elsevierCitationCount":"31"},{"title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","googleId":"8euDDpv54w8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/537/37109","googleCitationCount":53,"googleAuthor":"","doi":"10.1182/blood-2017-04-778175","elsevierAuthor":"Berentsen S.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"38"},{"title":"Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies","googleId":"DRGcpMg2eWwJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/633/266374","googleCitationCount":37,"googleAuthor":"I Paz-Priel","doi":"10.1182/blood-2018-99-118492","elsevierAuthor":"Pierre F.","publicationName":"Swiss Medical Weekly","elsevierCoverDate":"2020-12-18","elsevierCoverDisplayDate":"18 December 2020","elsevierCitationCount":"0"},{"title":"Biomarkers for posttransplantation outcomes","googleId":"JtXEAoXEfkMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/20/2193/6540","googleCitationCount":41,"googleAuthor":"S Paczesny","doi":"10.1182/blood-2018-02-791509","elsevierAuthor":"Paczesny S.","publicationName":"Blood","elsevierCoverDate":"2018-05-17","elsevierCoverDisplayDate":"17 May 2018","elsevierCitationCount":"25"},{"title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric …","googleId":"LhU-9iwzajgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/896/266300","googleCitationCount":45,"googleAuthor":"R Benjamin","doi":"10.1182/blood-2018-99-111356","elsevierCitationCount":0},{"title":"Stem and progenitor cell alterations in myelodysplastic syndromes","googleId":"IxMoXxtdlhkJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1586/36080","googleCitationCount":52,"googleAuthor":"B Will","doi":"10.1182/blood-2016-10-696062","elsevierAuthor":"Shastri A.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"37"},{"title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque–triggered thrombus formation in humans","googleId":"8XCu70CZVPQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/24/2605/37238","googleCitationCount":41,"googleAuthor":"H Deckmyn","doi":"10.1182/blood-2017-09-808808","elsevierAuthor":"Busygina K.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"34"},{"title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","googleId":"wLxBSwI2ccIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/8/995/36968","googleCitationCount":50,"googleAuthor":"O Havranek","doi":"10.1182/blood-2016-10-747303","elsevierAuthor":"Havranek O.","publicationName":"Blood","elsevierCoverDate":"2017-08-24","elsevierCoverDisplayDate":"24 August 2017","elsevierCitationCount":"34"},{"title":"Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?","googleId":"sUcWlSOlHskJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120337691","googleCitationCount":66,"googleAuthor":"","doi":"10.1182/blood-2016-08-731885","elsevierAuthor":"Rosenblatt J.","publicationName":"Blood","elsevierCoverDate":"2017-01-19","elsevierCoverDisplayDate":"19 January 2017","elsevierCitationCount":"50"},{"title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p. Q575E)","googleId":"LZSsqurMUgEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/12/1430/36502","googleCitationCount":54,"googleAuthor":"J Park","doi":"10.1182/blood-2017-02-768234","elsevierAuthor":"Park J.","publicationName":"Blood","elsevierCoverDate":"2017-09-21","elsevierCoverDisplayDate":"21 September 2017","elsevierCitationCount":"42"},{"title":"PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke","googleId":"KQF_AwPlNNoJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/11/1163/36458","googleCitationCount":46,"googleAuthor":"RK Sinha","doi":"10.1182/blood-2017-10-810895","elsevierAuthor":"Sinha R.","publicationName":"Blood","elsevierCoverDate":"2018-03-15","elsevierCoverDisplayDate":"15 March 2018","elsevierCitationCount":"35"},{"title":"First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with …","googleId":"AJI9QA7SsC4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/99/83577","googleCitationCount":49,"googleAuthor":"G Martinelli","doi":"10.1182/blood.V130.Suppl_1.99.99","elsevierCitationCount":0},{"title":"Anti-CD37 chimeric antigen receptor T cells are active against B-and T-cell lymphomas","googleId":"FTWQMkKA28YJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1495/39349","googleCitationCount":35,"googleAuthor":"I Scarfò","doi":"10.1182/blood-2018-04-842708","elsevierAuthor":"Scarfò I.","publicationName":"Blood","elsevierCoverDate":"2018-12-06","elsevierCoverDisplayDate":"6 December 2018","elsevierCitationCount":"0"},{"title":"The interplay of leukemia cells and the bone marrow microenvironment","googleId":"SUsYnku1d8QJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1507/36671","googleCitationCount":39,"googleAuthor":"D Duarte","doi":"10.1182/blood-2017-12-784132","elsevierAuthor":"Duarte D.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"30"},{"title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","googleId":"rCEeOQ3YKg0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/9/39263","googleCitationCount":39,"googleAuthor":"C Herbaux","doi":"10.1182/blood-2018-02-811174","elsevierAuthor":"Herbaux C.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"28"},{"title":"S100A9 induces differentiation of acute myeloid leukemia cells through TLR4","googleId":"ogZ9q2WaEPEJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/14/1980/35876","googleCitationCount":50,"googleAuthor":"","doi":"10.1182/blood-2016-09-738005","elsevierAuthor":"Laouedj M.","publicationName":"Blood","elsevierCoverDate":"2017-04-06","elsevierCoverDisplayDate":"6 April 2017","elsevierCitationCount":"37"},{"title":"How I Treat Flt3-Mutated Aml","googleId":"EFJ0_p9XiQUJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/565/36161","googleCitationCount":64,"googleAuthor":"KW Pratz","doi":"10.1182/blood-2016-09-693648","elsevierAuthor":"Pratz K.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"44"},{"title":"Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia Α with inhibitors: results from the HAVEN 2 study","googleId":"lIpoBCsboeUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/632/266365","googleCitationCount":40,"googleAuthor":"RF Sidonio","doi":"10.1182/blood-2018-99-118153","elsevierAuthor":"Davydkin I.L.","publicationName":"Pediatriya - Zhurnal im G.N. Speranskogo","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July-August 2020","elsevierCitationCount":"0"},{"title":"First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical …","googleId":"WnRGjeK8-NQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/901/266370","googleCitationCount":36,"googleAuthor":"K Chen","doi":"10.1182/blood-2018-99-110579","elsevierAuthor":"Agrawal V.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial","googleId":"23gBj5UpFs8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1247/36360","googleCitationCount":50,"googleAuthor":"TH Hamza","doi":"10.1182/blood-2017-01-757930","elsevierAuthor":"Uhl L.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"35"},{"title":"Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice","googleId":"8FYVg7Szz9wJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1426/105722","googleCitationCount":34,"googleAuthor":"T Yago","doi":"10.1182/blood-2018-05-850859","elsevierAuthor":"Yago T.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"28"},{"title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged≥ 60 years with HL","googleId":"HLvbvG3spycJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/26/2829/36593","googleCitationCount":47,"googleAuthor":"","doi":"10.1182/blood-2017-06-787200","elsevierAuthor":"Friedberg J.W.","publicationName":"Blood","elsevierCoverDate":"2017-12-28","elsevierCoverDisplayDate":"28 December 2017","elsevierCitationCount":"45"},{"title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","googleId":"jKepa1BxbtIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1386/105720","googleCitationCount":40,"googleAuthor":"RA Luchtel","doi":"10.1182/blood-2018-03-838524","elsevierAuthor":"Luchtel R.A.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"28"},{"title":"α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","googleId":"yY0gxQ_mWssJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/12/1372/36620","googleCitationCount":40,"googleAuthor":"RJ Soiffer","doi":"10.1182/blood-2017-11-815746","elsevierAuthor":"Magenau J.M.","publicationName":"Blood","elsevierCoverDate":"2018-03-22","elsevierCoverDisplayDate":"22 March 2018","elsevierCitationCount":"35"},{"title":"A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","googleId":"FzDOzKm_zY0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/5/521/39398","googleCitationCount":36,"googleAuthor":"C Nichols","doi":"10.1182/blood-2018-02-830992","elsevierAuthor":"Robinson H.","publicationName":"Blood","elsevierCoverDate":"2018-08-02","elsevierCoverDisplayDate":"2 August 2018","elsevierCitationCount":"26"},{"title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or …","googleId":"vcgao4TmPVoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4198/275591","googleCitationCount":39,"googleAuthor":"J Svoboda","doi":"10.1182/blood-2018-99-119502","elsevierAuthor":"Hull C.M.","publicationName":"Expert Opinion on Biological Therapy","elsevierCoverDate":"2019-08-03","elsevierCoverDisplayDate":"3 August 2019","elsevierCitationCount":"2"},{"title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies","googleId":"77s8QrXEtjoJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/88/35825","googleCitationCount":65,"googleAuthor":"","doi":"10.1182/blood-2016-08-731240","elsevierAuthor":"Deng C.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"54"},{"title":"Posttransplant chimeric antigen receptor therapy","googleId":"HASw_Ici6q0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/10/1045/36415","googleCitationCount":42,"googleAuthor":"","doi":"10.1182/blood-2017-08-752121","elsevierAuthor":"Smith M.","publicationName":"Blood","elsevierCoverDate":"2018-03-08","elsevierCoverDisplayDate":"8 March 2018","elsevierCitationCount":"25"},{"title":"Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia","googleId":"a94fA7EiiaYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/2/205/36724","googleCitationCount":48,"googleAuthor":"O Niss","doi":"10.1182/blood-2017-02-767624","elsevierAuthor":"Niss O.","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"38"},{"title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","googleId":"-hnzR2hz-dQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/440/37099","googleCitationCount":47,"googleAuthor":"F Scherer","doi":"10.1182/blood-2017-03-735639","elsevierAuthor":"Scherer F.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"29"},{"title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","googleId":"Z31dG_pwEJsJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/490/262047","googleCitationCount":35,"googleAuthor":"B Sahaf","doi":"10.1182/blood-2018-99-110142","elsevierCitationCount":0},{"title":"None of the above: thrombotic microangiopathy beyond TTP and HUS","googleId":"5fWajFIINL4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120333577","googleCitationCount":51,"googleAuthor":"S Vasu","doi":"10.1182/blood-2016-11-743104","elsevierAuthor":"Masias C.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"37"},{"title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy …","googleId":"cTfz8bFAgCEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1009/262598","googleCitationCount":37,"googleAuthor":"","doi":"10.1182/blood-2018-99-117964","elsevierCitationCount":0},{"title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","googleId":"iEOltpzFr0UJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/465/262217","googleCitationCount":34,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood-2018-99-119424","elsevierAuthor":"Garcia-Manero G.","publicationName":"American Journal of Hematology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"2"},{"title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate-or high-risk MDS with thrombocytopenia","googleId":"ThykdeYlS1oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/25/2629/39573","googleCitationCount":32,"googleAuthor":"M Dickinson","doi":"10.1182/blood-2018-06-855221","elsevierAuthor":"Dickinson M.","publicationName":"Blood","elsevierCoverDate":"2018-12-20","elsevierCoverDisplayDate":"20 December 2018","elsevierCitationCount":"26"},{"title":"B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma","googleId":"K1rTTR4joRUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/17/1805/39520","googleCitationCount":33,"googleAuthor":"J Zhang","doi":"10.1182/blood-2018-03-841015","elsevierAuthor":"Li L.","publicationName":"Blood","elsevierCoverDate":"2018-10-25","elsevierCoverDisplayDate":"25 October 2018","elsevierCitationCount":"26"},{"title":"Numerous niches for hematopoietic stem cells remain empty during homeostasis","googleId":"cJgcdO-lZ0oJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2124/36379","googleCitationCount":49,"googleAuthor":"M Shimoto","doi":"10.1182/blood-2016-09-740563","elsevierAuthor":"Shimoto M.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"36"},{"title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial","googleId":"DYtx97ZMFa0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/9/883/39413","googleCitationCount":37,"googleAuthor":"KMJ Heitink-Pollé","doi":"10.1182/blood-2018-02-830844","elsevierAuthor":"Heitink-Pollé K.M.J.","publicationName":"Blood","elsevierCoverDate":"2018-08-30","elsevierCoverDisplayDate":"30 August 2018","elsevierCitationCount":"23"},{"title":"Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition","googleId":"OEWavOeyFLYJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/e1/36101","googleCitationCount":61,"googleAuthor":"J Geiger","doi":"10.1182/blood-2016-05-714048","elsevierAuthor":"Beck F.","publicationName":"Blood","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"2017","elsevierCitationCount":"46"},{"title":"Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma","googleId":"FQXP5x4BWp4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/23/2552/36954","googleCitationCount":35,"googleAuthor":"","doi":"10.1182/blood-2017-07-794529","elsevierAuthor":"Higuchi H.","publicationName":"Blood","elsevierCoverDate":"2018-06-07","elsevierCoverDisplayDate":"7 June 2018","elsevierCitationCount":"28"},{"title":"Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial","googleId":"anMnUsW8uE8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/223/39261","googleCitationCount":37,"googleAuthor":"N van Geloven","doi":"10.1182/blood-2018-02-831289","elsevierAuthor":"van der Meer P.F.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"27"},{"title":"l-Glutamine for sickle cell anemia: more questions than answers","googleId":"QVMyKsIomcoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/7/689/39431","googleCitationCount":38,"googleAuthor":"CT Quinn","doi":"10.1182/blood-2018-03-834440","elsevierAuthor":"Quinn C.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"28"},{"title":"Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells","googleId":"8mdeSj9ROZwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/14/1927/35870","googleCitationCount":46,"googleAuthor":"M Jung","doi":"10.1182/blood-2016-08-734236","elsevierAuthor":"Schlums H.","publicationName":"Blood","elsevierCoverDate":"2017-04-06","elsevierCoverDisplayDate":"6 April 2017","elsevierCitationCount":"40"},{"title":"HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities","googleId":"Z-75W5dtAV4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/9/1089/36983","googleCitationCount":47,"googleAuthor":"BE Shaw","doi":"10.1182/blood-2017-03-742346","elsevierAuthor":"Fleischhauer K.","publicationName":"Blood","elsevierCoverDate":"2017-08-31","elsevierCoverDisplayDate":"31 August 2017","elsevierCitationCount":"30"},{"title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","googleId":"tQ0-bKrVRq4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/10/1259/36372","googleCitationCount":45,"googleAuthor":"N Luebbering","doi":"10.1182/blood-2017-05-782870","elsevierAuthor":"Gloude N.","publicationName":"Blood","elsevierCoverDate":"2017-09-07","elsevierCoverDisplayDate":"7 September 2017","elsevierCitationCount":"36"},{"title":"Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM) …","googleId":"aUWGVKbk5dcJ","googleLink":"http://cms.cws.net/content/beta.myelomasociety.org/files/2017ash/Dimopoulos_POLLUX-ASH%202017.pdf","googleCitationCount":43,"googleAuthor":"MA Dimopoulos"},{"title":"Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid …","googleId":"ea8c0UaLyKgJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/564/263255","googleCitationCount":33,"googleAuthor":"KW Pratz","doi":"10.1182/blood-2018-99-110975","elsevierAuthor":"Hogan F.L.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","googleId":"VmOXSMVzo9sJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/14/1620/107642","googleCitationCount":42,"googleAuthor":"","doi":"10.1182/blood-2017-02-749101","elsevierAuthor":"Wayne A.","publicationName":"Blood","elsevierCoverDate":"2017-10-05","elsevierCoverDisplayDate":"5 October 2017","elsevierCitationCount":"39"},{"title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","googleId":"fCBttAdjqpkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1293/39625","googleCitationCount":34,"googleAuthor":"QL Sievers","doi":"10.1182/blood-2018-01-821769","elsevierAuthor":"Sievers Q.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"29"},{"title":"Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome","googleId":"tuo2mbNEEgIJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/974/39169","googleCitationCount":41,"googleAuthor":"JI Arostegui","doi":"10.1182/blood-2017-10-810366","elsevierAuthor":"Rowczenio D.M.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"33"},{"title":"PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells","googleId":"qCD37zOzVj4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2493/36276","googleCitationCount":50,"googleAuthor":"F Michelet","doi":"10.1182/blood-2016-10-747436","elsevierAuthor":"Naudin C.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"31"},{"title":"Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell …","googleId":"t0Wr4WBO9dIJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/782/266037","googleCitationCount":31,"googleAuthor":"RE Gasiorowski","doi":"10.1182/blood-2018-99-118519","elsevierCitationCount":0},{"title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD …","googleId":"zh5RT_9l9UkJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/428/72735","googleCitationCount":44,"googleAuthor":"P Hillmen","doi":"10.1182/blood.V130.Suppl_1.428.428","elsevierCitationCount":0},{"title":"Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice","googleId":"nHSputFNqSIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2547/36270","googleCitationCount":44,"googleAuthor":"AS Revenko","doi":"10.1182/blood-2016-11-753202","elsevierAuthor":"Chen Z.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"36"},{"title":"The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a …","googleId":"G_UVAxRT8MYJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/723/83424","googleCitationCount":44,"googleAuthor":"M Swaminathan","doi":"10.1182/blood.V130.Suppl_1.723.723","elsevierCitationCount":0},{"title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","googleId":"WgHyEvdDhSsJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1576/36685","googleCitationCount":36,"googleAuthor":"Y Okuno","doi":"10.1182/blood-2017-07-798157","elsevierAuthor":"Murakami N.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"24"},{"title":"Biology and management of primary effusion lymphoma","googleId":"_mhePIxC_58J","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1879/39604","googleCitationCount":30,"googleAuthor":"K Shimada","doi":"10.1182/blood-2018-03-791426","elsevierAuthor":"Shimada K.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"19"},{"title":"Lysophosphatidic acid converts monocytes into macrophages in both mice and humans","googleId":"E3GIsxHQTfkJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/9/1177/36569","googleCitationCount":54,"googleAuthor":"","doi":"10.1182/blood-2016-10-743757","elsevierAuthor":"Ray R.","publicationName":"Blood","elsevierCoverDate":"2017-03-02","elsevierCoverDisplayDate":"2 March 2017","elsevierCitationCount":"46"},{"title":"Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed/refractory multiple …","googleId":"oNscQ-1PW3UJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/960/266056","googleCitationCount":31,"googleAuthor":"J Jin","doi":"10.1182/blood-2018-99-113220","elsevierAuthor":"Borrello I.","publicationName":"Journal of Clinical Investigation","elsevierCoverDate":"2019-06-03","elsevierCoverDisplayDate":"3 June 2019","elsevierCitationCount":"4"},{"title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","googleId":"G4K1W0E18rQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/525/104413","googleCitationCount":39,"googleAuthor":"P Milani","doi":"10.1182/blood-2017-04-780544","elsevierAuthor":"Palladini G.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"31"},{"title":"Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): PAVO, an open-label, multicenter, dose escalation …","googleId":"yKvFHkHPq4gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/838/83272","googleCitationCount":41,"googleAuthor":"H Nahi","doi":"10.1182/blood.V130.Suppl_1.838.838","elsevierCitationCount":0},{"title":"Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia","googleId":"FlCKHjvrwv4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/1012/39182","googleCitationCount":38,"googleAuthor":"DK Ragan","doi":"10.1182/blood-2017-06-789842","elsevierAuthor":"Guilliams K.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"27"},{"title":"How I treat the postthrombotic syndrome","googleId":"il3xEJ3AcawJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/20/2215/6532","googleCitationCount":35,"googleAuthor":"SR Kahn","doi":"10.1182/blood-2018-01-785956","elsevierAuthor":"Rabinovich A.","publicationName":"Blood","elsevierCoverDate":"2018-05-17","elsevierCoverDisplayDate":"17 May 2018","elsevierCitationCount":"29"},{"title":"Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow","googleId":"fijJKbBAG7YJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1714/39362","googleCitationCount":33,"googleAuthor":"DK Ragan","doi":"10.1182/blood-2018-04-841247","elsevierAuthor":"Ford A.L.","publicationName":"Blood","elsevierCoverDate":"2018-10-18","elsevierCoverDisplayDate":"18 October 2018","elsevierCitationCount":"28"},{"title":"Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial","googleId":"helsX8t9eG8J","googleLink":"https://www.beigenemedical.com/CongressDocuments/Song%20BGB-3111%20206%20ASH%20Abstract%202018.pdf","googleCitationCount":29,"googleAuthor":""},{"title":"Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance","googleId":"AFcw2cVTrJYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/11/1234/36473","googleCitationCount":55,"googleAuthor":"S Bhattacharjee","doi":"10.1182/blood-2017-11-814665","elsevierAuthor":"Bhattacharjee S.","publicationName":"Blood","elsevierCoverDate":"2018-03-15","elsevierCoverDisplayDate":"15 March 2018","elsevierCitationCount":"36"},{"title":"BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","googleId":"vrwrkUl93IcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2047/36740","googleCitationCount":35,"googleAuthor":"","doi":"10.1182/blood-2017-10-811752","elsevierAuthor":"Chen J.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"27"},{"title":"Novel therapeutics for hemophilia and other bleeding disorders","googleId":"G08sm5TEHCgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/23/39267","googleCitationCount":33,"googleAuthor":"MU Callaghan","doi":"10.1182/blood-2017-09-743385","elsevierAuthor":"Callaghan M.U.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"24"},{"title":"Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia","googleId":"TRS9nNjrCwwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/7/717/39444","googleCitationCount":34,"googleAuthor":"TW LeBlanc","doi":"10.1182/blood-2018-03-842575","elsevierAuthor":"LeBlanc T.W.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"30"},{"title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","googleId":"5HcjUrRK3yMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/489/37125","googleCitationCount":45,"googleAuthor":"","doi":"10.1182/blood-2016-12-759621","elsevierAuthor":"Tsuyama N.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"26"},{"title":"Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy …","googleId":"mn3x7coI-YIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/685/266430","googleCitationCount":31,"googleAuthor":"M Cavo","doi":"10.1182/blood-2018-99-115163","elsevierAuthor":"Barraco D.","publicationName":"Drugs in Context","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"0"},{"title":"SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells","googleId":"62TqIg3N58AJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/7/881/37002","googleCitationCount":40,"googleAuthor":"","doi":"10.1182/blood-2017-03-776070","elsevierAuthor":"Mortera-Blanco T.","publicationName":"Blood","elsevierCoverDate":"2017-08-17","elsevierCoverDisplayDate":"17 August 2017","elsevierCitationCount":"28"},{"title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","googleId":"JlZcDyXft8IJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/955/39171","googleCitationCount":42,"googleAuthor":"","doi":"10.1182/blood-2017-06-792333","elsevierAuthor":"Dimier N.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"31"},{"title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","googleId":"eByKotZIJskJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2375/35964","googleCitationCount":45,"googleAuthor":"","doi":"10.1182/blood-2016-12-758409","elsevierAuthor":"Cox T.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"27"},{"title":"Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: a phase II trial","googleId":"fWvIBLP-2wgJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/429/72836","googleCitationCount":42,"googleAuthor":"N Jain","doi":"10.1182/blood.V130.Suppl_1.429.429","elsevierCitationCount":0},{"title":"Platelets and von Willebrand factor in atherogenesis","googleId":"GoK--PZ2-hYJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/11/1415/35899","googleCitationCount":44,"googleAuthor":"","doi":"10.1182/blood-2016-07-692673","elsevierAuthor":"Wu M.D.","publicationName":"Blood","elsevierCoverDate":"2017-03-16","elsevierCoverDisplayDate":"16 March 2017","elsevierCitationCount":"28"},{"title":"Eculizumab cessation in atypical hemolytic uremic syndrome","googleId":"b8mzrZBl4aoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/368/36895","googleCitationCount":46,"googleAuthor":"AR Moliterno","doi":"10.1182/blood-2017-02-770214","elsevierAuthor":"Merrill S.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"34"},{"title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","googleId":"sIwpWzkXU1UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/6/759/36328","googleCitationCount":54,"googleAuthor":"JH Myklebust","doi":"10.1182/blood-2016-05-718494","elsevierAuthor":"Myklebust J.H.","publicationName":"Blood","elsevierCoverDate":"2017-02-09","elsevierCoverDisplayDate":"9 February 2017","elsevierCitationCount":"41"},{"title":"CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation","googleId":"_pOzuqYdsCcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/19/2092/36695","googleCitationCount":41,"googleAuthor":"R Grieshaber-Bouyer","doi":"10.1182/blood-2017-03-768507","elsevierAuthor":"Bai M.","publicationName":"Blood","elsevierCoverDate":"2017-11-09","elsevierCoverDisplayDate":"9 November 2017","elsevierCitationCount":"31"},{"title":"ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies","googleId":"piiTH2hFrAMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/10/1094/36428","googleCitationCount":36,"googleAuthor":"","doi":"10.1182/blood-2017-10-813493","elsevierAuthor":"Zammarchi F.","publicationName":"Blood","elsevierCoverDate":"2018-03-08","elsevierCoverDisplayDate":"8 March 2018","elsevierCitationCount":"34"},{"title":"Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with iDH1-mutant untreated AML: results from a phase 1 dose escalation …","googleId":"QyQ1vKyBB48J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/561/263448","googleCitationCount":30,"googleAuthor":"S de Botton","doi":"10.1182/blood-2018-99-110595","elsevierCitationCount":0},{"title":"First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia","googleId":"UdnQH6gacm0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/23/2499/36743","googleCitationCount":41,"googleAuthor":"","doi":"10.1182/blood-2017-05-785683","elsevierAuthor":"Boidol B.","publicationName":"Blood","elsevierCoverDate":"2017-12-07","elsevierCoverDisplayDate":"7 December 2017","elsevierCitationCount":"31"},{"title":"New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease","googleId":"owYWPI1NfCgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4173/275835","googleCitationCount":27,"googleAuthor":"L Aresu","doi":"10.1182/blood-2018-99-112763","elsevierCitationCount":0},{"title":"Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma","googleId":"lsqD1uLFLZkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/9/1114/37003","googleCitationCount":39,"googleAuthor":"","doi":"10.1182/blood-2016-09-741983","elsevierAuthor":"Narita T.","publicationName":"Blood","elsevierCoverDate":"2017-08-31","elsevierCoverDisplayDate":"31 August 2017","elsevierCitationCount":"33"},{"title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","googleId":"_AP84RGfAKUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1535/39346","googleCitationCount":28,"googleAuthor":"EC Fink","doi":"10.1182/blood-2018-05-852798","elsevierAuthor":"Fink E.C.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"25"},{"title":"Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population","googleId":"Y3E3CTSBsFcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2882/36300","googleCitationCount":40,"googleAuthor":"N Hein","doi":"10.1182/blood-2016-05-718171","elsevierAuthor":"Hein N.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"31"},{"title":"Testing and monitoring direct oral anticoagulants","googleId":"NAdzjFqhir4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S000649712043023X","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood-2018-04-791541","elsevierAuthor":"Connors J.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"18"},{"title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","googleId":"OGpp5lgEGOIJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/1/84/107724","googleCitationCount":39,"googleAuthor":"JP Reddy","doi":"10.1182/blood-2017-04-773838","elsevierAuthor":"Akhtari M.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"30"},{"title":"Targeting BCL-2 in B-cell lymphomas","googleId":"vC_7szGrMcUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/9/1081/36985","googleCitationCount":39,"googleAuthor":"","doi":"10.1182/blood-2017-04-737338","elsevierAuthor":"Davids M.","publicationName":"Blood","elsevierCoverDate":"2017-08-31","elsevierCoverDisplayDate":"31 August 2017","elsevierCitationCount":"35"},{"title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","googleId":"vQfFD9SN-TAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/12/1636/36097","googleCitationCount":50,"googleAuthor":"","doi":"10.1182/blood-2016-10-740613","elsevierAuthor":"Löwenberg B.","publicationName":"Blood","elsevierCoverDate":"2017-03-23","elsevierCoverDisplayDate":"23 March 2017","elsevierCitationCount":"44"},{"title":"Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis","googleId":"LkFX5_K8afkJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/171/36075","googleCitationCount":52,"googleAuthor":"N Bouladoux","doi":"10.1182/blood-2016-06-723742","elsevierAuthor":"Iwamura C.","publicationName":"Blood","elsevierCoverDate":"2017-01-12","elsevierCoverDisplayDate":"12 January 2017","elsevierCitationCount":"42"},{"title":"GPIbα is required for platelet-mediated hepatic thrombopoietin generation","googleId":"nA5BgRDW1IUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/622/39439","googleCitationCount":32,"googleAuthor":"M Xu","doi":"10.1182/blood-2017-12-820779","elsevierAuthor":"Xu M.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"23"},{"title":"Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML","googleId":"V0MMG-ubV0MJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/397/37087","googleCitationCount":43,"googleAuthor":"A Yoshimi","doi":"10.1182/blood-2017-01-763219","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2017-09-28","elsevierCoverDisplayDate":"28 September 2017","elsevierCitationCount":"0"},{"title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","googleId":"CkbfT8ulTwMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2166/39517","googleCitationCount":27,"googleAuthor":"Y Liao","doi":"10.1182/blood-2018-05-850727","elsevierAuthor":"Fedele P.L.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"18"},{"title":"Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury","googleId":"yV8wVT8zox8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2001/36726","googleCitationCount":30,"googleAuthor":"J Zhang","doi":"10.1182/blood-2017-11-784108","elsevierAuthor":"Zhang J.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"20"},{"title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","googleId":"6LwlEQBuVeIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/655/36810","googleCitationCount":39,"googleAuthor":"G Cheloni","doi":"10.1182/blood-2016-10-745588","elsevierAuthor":"Cheloni G.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"32"},{"title":"Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress","googleId":"JiFKAR-1CIwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2078/39481","googleCitationCount":27,"googleAuthor":"DL Zhang","doi":"10.1182/blood-2018-04-842997","elsevierAuthor":"Zhang D.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"17"},{"title":"Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease","googleId":"DNaMjLV68WoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/5/469/39396","googleCitationCount":30,"googleAuthor":"","doi":"10.1182/blood-2018-03-838235","elsevierAuthor":"Lenglet M.","publicationName":"Blood","elsevierCoverDate":"2018-08-02","elsevierCoverDisplayDate":"2 August 2018","elsevierCitationCount":"23"},{"title":"Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor","googleId":"232u53Tu3IYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/643/36789","googleCitationCount":37,"googleAuthor":"F Seyfried","doi":"10.1182/blood-2017-03-769315","elsevierAuthor":"Münch V.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"27"},{"title":"How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","googleId":"deLDBAnDUK4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/448/36179","googleCitationCount":51,"googleAuthor":"","doi":"10.1182/blood-2016-08-693507","elsevierAuthor":"Williams K.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"36"},{"title":"Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis","googleId":"vMoD3HAujB0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/15/1757/36375","googleCitationCount":40,"googleAuthor":"FR Rosendaal","doi":"10.1182/blood-2017-06-791756","elsevierAuthor":"Rosendaal F.R.","publicationName":"Blood","elsevierCoverDate":"2017-10-12","elsevierCoverDisplayDate":"12 October 2017","elsevierCitationCount":"26"},{"title":"How I treat myelodysplastic syndromes of childhood","googleId":"R94NofwffiMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1406/36617","googleCitationCount":33,"googleAuthor":"","doi":"10.1182/blood-2017-09-765214","elsevierAuthor":"Locatelli F.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"20"},{"title":"Deep and durable responses in patients (Pts) with relapsed/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate …","googleId":"iaUMExlfWEcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/741/83640","googleCitationCount":38,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.741.741","elsevierCitationCount":0},{"title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?","googleId":"CfRhjWX1UB4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1871/39601","googleCitationCount":26,"googleAuthor":"D Gratzinger","doi":"10.1182/blood-2018-04-842559","elsevierAuthor":"Natkunam Y.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"16"},{"title":"Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow","googleId":"0aQDkVcHMuIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/19/2101/36703","googleCitationCount":40,"googleAuthor":"T Wun","doi":"10.1182/blood-2017-05-783027","elsevierAuthor":"Morikis V.A.","publicationName":"Blood","elsevierCoverDate":"2017-11-09","elsevierCoverDisplayDate":"9 November 2017","elsevierCitationCount":"29"},{"title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","googleId":"BM8yydwQwAgJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/19/2151/36908","googleCitationCount":35,"googleAuthor":"C Kearon","doi":"10.1182/blood-2017-09-805689","elsevierAuthor":"Kearon C.","publicationName":"Blood","elsevierCoverDate":"2018-05-10","elsevierCoverDisplayDate":"10 May 2018","elsevierCitationCount":"28"},{"title":"Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke","googleId":"GzPLT4P6LHcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/16/2280/35933","googleCitationCount":48,"googleAuthor":"F Simão","doi":"10.1182/blood-2016-09-740670","elsevierAuthor":"Simao F.","publicationName":"Blood","elsevierCoverDate":"2017-04-20","elsevierCoverDisplayDate":"20 April 2017","elsevierCitationCount":"46"},{"title":"Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)","googleId":"vF4Iw_ukxQoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/89/83367","googleCitationCount":36,"googleAuthor":"MU Callaghan","doi":"10.1182/blood.V130.Suppl_1.89.89","elsevierCitationCount":0},{"title":"How I treat the young patient with multiple myeloma","googleId":"CwMYah8XzpwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/11/1114/39366","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood-2017-05-693606","elsevierAuthor":"Gandolfi S.","publicationName":"Blood","elsevierCoverDate":"2018-09-13","elsevierCoverDisplayDate":"13 September 2018","elsevierCitationCount":"21"},{"title":"An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 …","googleId":"yhA8wJ2JxcgJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/145/79622","googleCitationCount":39,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.145.145","elsevierCitationCount":0},{"title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study","googleId":"C6332ChPG2kJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/16/2308/35914","googleCitationCount":42,"googleAuthor":"SM Davies","doi":"10.1182/blood-2016-09-743112","elsevierAuthor":"Mehta P.","publicationName":"Blood","elsevierCoverDate":"2017-04-20","elsevierCoverDisplayDate":"20 April 2017","elsevierCitationCount":"30"},{"title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","googleId":"HwvHxz4OvUEJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3304/107607","googleCitationCount":43,"googleAuthor":"JK Hitzler","doi":"10.1182/blood-2017-01-764324","elsevierAuthor":"Taub J.W.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"27"},{"title":"CD138 mediates selection of mature plasma cells by regulating their survival","googleId":"EfB3jtUMuvAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/20/2749/36120","googleCitationCount":44,"googleAuthor":"MJ McCarron","doi":"10.1182/blood-2017-01-761643","elsevierAuthor":"McCarron M.","publicationName":"Blood","elsevierCoverDate":"2017-05-18","elsevierCoverDisplayDate":"18 May 2017","elsevierCitationCount":"30"},{"title":"A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","googleId":"x1KKu6biHrwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/16/1805/36828","googleCitationCount":33,"googleAuthor":"","doi":"10.1182/blood-2017-08-802561","elsevierAuthor":"Sauter C.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"25"},{"title":"Hematopoietic transcription factor mutations: important players in inherited platelet defects","googleId":"3_A_IHEdj8YJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2873/36262","googleCitationCount":40,"googleAuthor":"AK Rao","doi":"10.1182/blood-2016-11-709881","elsevierAuthor":"Songdej N.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"26"},{"title":"Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks","googleId":"Kx3xsI7wD8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120606875","googleCitationCount":60,"googleAuthor":"M Ponzoni","doi":"10.1182/blood-2017-04-737445","elsevierAuthor":"Ponzoni M.","publicationName":"Blood","elsevierCoverDate":"2018-10-11","elsevierCoverDisplayDate":"11 October 2018","elsevierCitationCount":"32"},{"title":"Racial and ethnic disparities in hematologic malignancies","googleId":"_zmzK62RalcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/15/1699/36381","googleCitationCount":40,"googleAuthor":"K Kirtane","doi":"10.1182/blood-2017-04-778225","elsevierAuthor":"Kirtane K.","publicationName":"Blood","elsevierCoverDate":"2017-10-12","elsevierCoverDisplayDate":"12 October 2017","elsevierCitationCount":"30"},{"title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","googleId":"93aU_wpondMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1664/39361","googleCitationCount":31,"googleAuthor":"","doi":"10.1182/blood-2018-04-846626","elsevierAuthor":"Masarova L.","publicationName":"Blood","elsevierCoverDate":"2018-10-18","elsevierCoverDisplayDate":"18 October 2018","elsevierCitationCount":"23"},{"title":"Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions","googleId":"W8dbDZmP4LsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2917/36285","googleCitationCount":40,"googleAuthor":"M Yang","doi":"10.1182/blood-2016-11-750133","elsevierAuthor":"Yang M.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"27"},{"title":"A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens","googleId":"2vmbki8pkSMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1911/39623","googleCitationCount":26,"googleAuthor":"J Sun","doi":"10.1182/blood-2018-04-843763","elsevierAuthor":"Hu Z.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"23"},{"title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas","googleId":"AHOc9XnvIqEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/3/245/39241","googleCitationCount":28,"googleAuthor":"","doi":"10.1182/blood-2018-01-791335","elsevierAuthor":"Schmitz N.","publicationName":"Blood","elsevierCoverDate":"2018-07-19","elsevierCoverDisplayDate":"19 July 2018","elsevierCitationCount":"19"},{"title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","googleId":"UCfnlwpF0rMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/7/859/36974","googleCitationCount":37,"googleAuthor":"F Lo-Coco","doi":"10.1182/blood-2017-03-737403","elsevierAuthor":"Efficace F.","publicationName":"Blood","elsevierCoverDate":"2017-08-17","elsevierCoverDisplayDate":"17 August 2017","elsevierCitationCount":"31"},{"title":"Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia","googleId":"GAQ8U9xH3QIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2205/39487","googleCitationCount":27,"googleAuthor":"PS Rosenberg","doi":"10.1182/blood-2018-05-848937","elsevierAuthor":"Vlachos A.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"18"},{"title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma","googleId":"xnuqX9Y_keAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/303/263675","googleCitationCount":32,"googleAuthor":"G Morgan","doi":"10.1182/blood-2018-99-117026","elsevierCitationCount":0},{"title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","googleId":"4nfn7dJiEOYJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/643/36160","googleCitationCount":46,"googleAuthor":"","doi":"10.1182/blood-2016-09-738625","elsevierAuthor":"Socié G.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"33"},{"title":"Aged murine hematopoietic stem cells drive aging-associated immune remodeling","googleId":"Ixaoobr1ScgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/565/39425","googleCitationCount":28,"googleAuthor":"M Mulaw","doi":"10.1182/blood-2018-02-831065","elsevierAuthor":"Leins H.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"22"},{"title":"Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92","googleId":"KjCET0i80S4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/10/1050/39327","googleCitationCount":28,"googleAuthor":"N Amodio","doi":"10.1182/blood-2018-03-836601","elsevierAuthor":"Morelli E.","publicationName":"Blood","elsevierCoverDate":"2018-09-06","elsevierCoverDisplayDate":"6 September 2018","elsevierCitationCount":"27"},{"title":"How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa","googleId":"jggRYiqA4osJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/3/254/39246","googleCitationCount":28,"googleAuthor":"","doi":"10.1182/blood-2018-04-844472","elsevierAuthor":"Gopal S.","publicationName":"Blood","elsevierCoverDate":"2018-07-19","elsevierCoverDisplayDate":"19 July 2018","elsevierCitationCount":"15"},{"title":"Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab","googleId":"ZPNt14qapcwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2906/39156","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood-2017-09-804658","elsevierAuthor":"Topp M.S.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"25"},{"title":"Durable remission achieved from Bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma","googleId":"y2trD9t43E0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/956/266010","googleCitationCount":27,"googleAuthor":"Y Liu","doi":"10.1182/blood-2018-99-112786","elsevierCitationCount":0},{"title":"Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in …","googleId":"b_Bvx20Rg2oJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/639/83406","googleCitationCount":38,"googleAuthor":"AT Fathi","doi":"10.1182/blood.V130.Suppl_1.639.639","elsevierCitationCount":0},{"title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","googleId":"_eK8Fozbr-0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1568/36656","googleCitationCount":32,"googleAuthor":"E Kastritis","doi":"10.1182/blood-2017-12-819904","elsevierAuthor":"Kastritis E.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"25"},{"title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment","googleId":"Tjxpz2U3oUEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/7/758/39432","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood-2018-02-835991","elsevierAuthor":"Sakamoto Y.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"22"},{"title":"The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia","googleId":"6Md-9kRLuWQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/497/36192","googleCitationCount":46,"googleAuthor":"BG Mar","doi":"10.1182/blood-2016-05-714493","elsevierAuthor":"Li H.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"37"},{"title":"Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission","googleId":"ZIkjeQkTwVQJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/967/266133","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood-2018-99-115599","elsevierCitationCount":0},{"title":"Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells","googleId":"eszB14JriM4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/25/2762/36880","googleCitationCount":34,"googleAuthor":"Z Wu","doi":"10.1182/blood-2017-08-803353","elsevierAuthor":"Zhao X.","publicationName":"Blood","elsevierCoverDate":"2017-12-21","elsevierCoverDisplayDate":"21 December 2017","elsevierCitationCount":"26"},{"title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","googleId":"tSvonoKGcVMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1507/39348","googleCitationCount":31,"googleAuthor":"UA Shah","doi":"10.1182/blood-2018-01-824607","elsevierAuthor":"Shah U.A.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"24"},{"title":"CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia","googleId":"FvFANpsg3iQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/8/837/39482","googleCitationCount":27,"googleAuthor":"B Yan","doi":"10.1182/blood-2017-11-814319","elsevierAuthor":"Luo H.","publicationName":"Blood","elsevierCoverDate":"2018-08-23","elsevierCoverDisplayDate":"23 August 2018","elsevierCitationCount":"22"},{"title":"Treating relapsed/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","googleId":"G1_4MrzAgqIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1359/116253","googleCitationCount":36,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1359.1359","elsevierCitationCount":0},{"title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","googleId":"SxOFzLHSqkkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/26/2722/39681","googleCitationCount":27,"googleAuthor":"M Dreyling","doi":"10.1182/blood-2017-08-737502","elsevierAuthor":"Dreyling M.","publicationName":"Blood","elsevierCoverDate":"2018-12-27","elsevierCoverDisplayDate":"27 December 2018","elsevierCitationCount":"16"},{"title":"B-cell targeting in chronic graft-versus-host disease","googleId":"7TzesTm6Ug0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/13/1399/36612","googleCitationCount":29,"googleAuthor":"R Zeiser","doi":"10.1182/blood-2017-11-784017","elsevierAuthor":"Zeiser R.","publicationName":"Blood","elsevierCoverDate":"2018-03-29","elsevierCoverDisplayDate":"29 March 2018","elsevierCitationCount":"22"},{"title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","googleId":"ZMs52WBgwW8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/24/2555/39537","googleCitationCount":25,"googleAuthor":"","doi":"10.1182/blood-2018-07-863829","elsevierAuthor":"Garderet L.","publicationName":"Blood","elsevierCoverDate":"2018-12-13","elsevierCoverDisplayDate":"13 December 2018","elsevierCitationCount":"22"},{"title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","googleId":"Sgq1fJux6CoJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/25/3314/107626","googleCitationCount":40,"googleAuthor":"","doi":"10.1182/blood-2017-01-765057","elsevierAuthor":"Uffmann M.","publicationName":"Blood","elsevierCoverDate":"2017-06-22","elsevierCoverDisplayDate":"22 June 2017","elsevierCitationCount":"26"},{"title":"Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia-results from pre-planned …","googleId":"Xo_pf00FbT8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/LBA-2/83681","googleCitationCount":38,"googleAuthor":"TJ Kipps","doi":"10.1182/blood.V130.Suppl_1.LBA-2.LBA-2","elsevierCitationCount":0},{"title":"Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract","googleId":"Xb6qYiWmEOwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/20/2262/6534","googleCitationCount":30,"googleAuthor":"N Oishi","doi":"10.1182/blood-2018-01-830968","elsevierAuthor":"Sharma A.","publicationName":"Blood","elsevierCoverDate":"2018-05-17","elsevierCoverDisplayDate":"17 May 2018","elsevierCitationCount":"25"},{"title":"The enigma of monosomy 7","googleId":"zqR6-y-6ovcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2891/39117","googleCitationCount":30,"googleAuthor":"H Honda","doi":"10.1182/blood-2017-12-822262","elsevierAuthor":"Inaba T.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"21"},{"title":"The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment","googleId":"wmLEGvLFRP4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/82/35841","googleCitationCount":46,"googleAuthor":"E Muchtar","doi":"10.1182/blood-2016-06-721878","elsevierAuthor":"Muchtar E.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"33"},{"title":"Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response","googleId":"O8UrLJwU0UMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/3/307/39262","googleCitationCount":29,"googleAuthor":"S Bhatia","doi":"10.1182/blood-2017-10-810986","elsevierAuthor":"Bhatia S.","publicationName":"Blood","elsevierCoverDate":"2018-07-19","elsevierCoverDisplayDate":"19 July 2018","elsevierCitationCount":"19"},{"title":"The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis","googleId":"LkdQEGzqDCIJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/19/2111/36909","googleCitationCount":31,"googleAuthor":"R Kramann","doi":"10.1182/blood-2018-02-834820","elsevierAuthor":"Kramann R.","publicationName":"Blood","elsevierCoverDate":"2018-05-10","elsevierCoverDisplayDate":"10 May 2018","elsevierCitationCount":"24"},{"title":"Novel insights into the pathogenesis of T-cell lymphomas","googleId":"9nrVvWkYN9EJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2320/37107","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood-2017-11-764357","elsevierAuthor":"Van Arnam J.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"20"},{"title":"Emerging anticoagulant strategies","googleId":"bUUzw1F4-4kJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/147/36070","googleCitationCount":44,"googleAuthor":"PL Gross","doi":"10.1182/blood-2016-09-692996","elsevierAuthor":"Fredenburgh J.C.","publicationName":"Blood","elsevierCoverDate":"2017-01-12","elsevierCoverDisplayDate":"12 January 2017","elsevierCitationCount":"33"},{"title":"Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment","googleId":"qAYTnf9iUssJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/7/735/39451","googleCitationCount":29,"googleAuthor":"S Kaur","doi":"10.1182/blood-2018-01-829663","elsevierAuthor":"Kaur S.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"20"},{"title":"Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma","googleId":"Ks7OEX3LevkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2240/39544","googleCitationCount":28,"googleAuthor":"HW Tun","doi":"10.1182/blood-2018-02-835496","elsevierAuthor":"Tun H.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"20"},{"title":"Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial","googleId":"JiXhy7vTPEkJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/435/72570","googleCitationCount":32,"googleAuthor":"P Moreau","doi":"10.1182/blood.V130.Suppl_1.435.435","elsevierCitationCount":0},{"title":"Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial","googleId":"_t4JDIpVRDAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/436/72685","googleCitationCount":33,"googleAuthor":"C Pawlyn","doi":"10.1182/blood.V130.Suppl_1.436.436","elsevierCitationCount":0},{"title":"Results of the myeloproliferative neoplasms-research consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) …","googleId":"UKPGMAEer3MJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/577/263247","googleCitationCount":26,"googleAuthor":"JT Prchal","doi":"10.1182/blood-2018-99-111946","elsevierCitationCount":0},{"title":"Can histologic transformation of follicular lymphoma be predicted and prevented?","googleId":"qeSYWb7UNVEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/258/36907","googleCitationCount":37,"googleAuthor":"R Kridel","doi":"10.1182/blood-2017-03-691345","elsevierAuthor":"Kridel R.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"26"},{"title":"Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis","googleId":"wxIp7sWsdWMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/LBA-6/375116","googleCitationCount":24,"googleAuthor":"CE Allen","doi":"10.1182/blood-2018-120810","elsevierAuthor":"Chinello M.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients …","googleId":"iXivN_K2OUcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/784/266057","googleCitationCount":26,"googleAuthor":"P Johnson","doi":"10.1182/blood-2018-99-112988","elsevierAuthor":"Mondello P.","publicationName":"Hematological Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"5"},{"title":"Venetoclax with low-dose cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy","googleId":"-ofe-puQmBAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/284/263513","googleCitationCount":29,"googleAuthor":"A Wei","doi":"10.1182/blood-2018-99-118729","elsevierAuthor":"Juárez-Salcedo L.","publicationName":"Drugs in Context","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"12"},{"title":"Low relapse rate in younger patients≤ 60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine …","googleId":"TaY4a2mIeVoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/566/115728","googleCitationCount":35,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.566.566","elsevierCitationCount":0},{"title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell–depletion context","googleId":"HGfH18LebFAJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/14/1545/36669","googleCitationCount":32,"googleAuthor":"","doi":"10.1182/blood-2017-06-789578","elsevierAuthor":"Thai L.H.","publicationName":"Blood","elsevierCoverDate":"2018-04-05","elsevierCoverDisplayDate":"5 April 2018","elsevierCitationCount":"22"},{"title":"Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed/refractory chronic lymphocytic leukemia","googleId":"1eOgtV6-GlIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/693/266034","googleCitationCount":25,"googleAuthor":"FT Awan","doi":"10.1182/blood-2018-99-114169","elsevierCitationCount":0},{"title":"Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells","googleId":"VyYFGezvJtkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/3/321/39258","googleCitationCount":27,"googleAuthor":"A Paikari","doi":"10.1182/blood-2017-11-814335","elsevierAuthor":"Zhang Y.","publicationName":"Blood","elsevierCoverDate":"2018-07-19","elsevierCoverDisplayDate":"19 July 2018","elsevierCitationCount":"19"},{"title":"Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study","googleId":"lywfQAXTECIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/506/81040","googleCitationCount":32,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.506.506","elsevierCitationCount":0},{"title":"How and when I do allogeneic transplant in CLL","googleId":"eYbaX4vBl6oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/31/39270","googleCitationCount":27,"googleAuthor":"JG Gribben","doi":"10.1182/blood-2018-01-785998","elsevierAuthor":"Gribben J.G.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"19"},{"title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","googleId":"rs0uMaOnvS4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/20/2771/36116","googleCitationCount":34,"googleAuthor":"","doi":"10.1182/blood-2016-11-749978","elsevierAuthor":"Hovorkova L.","publicationName":"Blood","elsevierCoverDate":"2017-05-18","elsevierCoverDisplayDate":"18 May 2017","elsevierCitationCount":"30"},{"title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","googleId":"zmiVieZmkvMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1878/35820","googleCitationCount":36,"googleAuthor":"","doi":"10.1182/blood-2016-11-749507","elsevierAuthor":"Geyer M.B.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"31"},{"title":"Case series of potential Wernicke's encephalopathy in patients treated with Fedratinib","googleId":"a30xztsIFJYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4197/72746","googleCitationCount":31,"googleAuthor":"C Jamieson","doi":"10.1182/blood.V130.Suppl_1.4197.4197","elsevierCitationCount":0},{"title":"Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia","googleId":"Dk2viv9p50oJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1333/36009","googleCitationCount":35,"googleAuthor":"F Stölzel","doi":"10.1182/blood-2016-09-738161","elsevierAuthor":"Bochtler T.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"26"},{"title":"Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils","googleId":"8GHiyUdI824J","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/328/36939","googleCitationCount":34,"googleAuthor":"Z Khan","doi":"10.1182/blood-2016-11-752006","elsevierAuthor":"Khan Z.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"22"},{"title":"Thrombophilia risk is not increased in children after perinatal stroke","googleId":"y2ixQl9_XEwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/20/2793/36110","googleCitationCount":36,"googleAuthor":"A Mineyko","doi":"10.1182/blood-2016-11-750893","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"0"},{"title":"Adeno-Associated Mediated Gene Transfer for Hemophilia B: 8 Year Follow up and Impact of Removing Empty Viral Particles on Safety and Efficacy of Gene Transfer","googleId":"QXe-Pye7VMgJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/491/262157","googleCitationCount":23,"googleAuthor":"E Tuddenham","doi":"10.1182/blood-2018-99-118334","elsevierAuthor":"Cappella M.","publicationName":"Journal of Neuromuscular Diseases","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","googleId":"X0vlhY3_GtwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2273/39538","googleCitationCount":25,"googleAuthor":"C Baues","doi":"10.1182/blood-2018-05-852129","elsevierAuthor":"Kobe C.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"18"},{"title":"Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model","googleId":"xJnbEHWNea4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/22/2959/36063","googleCitationCount":32,"googleAuthor":"","doi":"10.1182/blood-2016-08-736454","elsevierAuthor":"Stoddart A.","publicationName":"Blood","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"24"},{"title":"Polycomb repressive complexes in hematological malignancies","googleId":"CzL4RJ_h9OYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/1/23/36222","googleCitationCount":35,"googleAuthor":"","doi":"10.1182/blood-2017-02-739490","elsevierAuthor":"Iwama A.","publicationName":"Blood","elsevierCoverDate":"2017-07-06","elsevierCoverDisplayDate":"6 July 2017","elsevierCitationCount":"28"},{"title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","googleId":"LEXJ3YcbZ3AJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/686/266439","googleCitationCount":24,"googleAuthor":"I Veletic","doi":"10.1182/blood-2018-99-115362","elsevierCitationCount":0},{"title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","googleId":"vhHwDpbsWI4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/9/1132/37008","googleCitationCount":31,"googleAuthor":"KR Machlus","doi":"10.1182/blood-2016-11-752840","elsevierAuthor":"Machlus K.","publicationName":"Blood","elsevierCoverDate":"2017-08-31","elsevierCoverDisplayDate":"31 August 2017","elsevierCitationCount":"26"},{"title":"How I treat primary mediastinal B-cell lymphoma","googleId":"QIXcMrtGflkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/8/782/39454","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood-2018-04-791566","elsevierAuthor":"Giulino-Roth L.","publicationName":"Blood","elsevierCoverDate":"2018-08-23","elsevierCoverDisplayDate":"23 August 2018","elsevierCitationCount":"19"},{"title":"Critical influences on the pathogenesis of follicular lymphoma","googleId":"-8pS6i17hPwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2297/37112","googleCitationCount":27,"googleAuthor":"R Küppers","doi":"10.1182/blood-2017-11-764365","elsevierAuthor":"Küppers R.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"15"},{"title":"IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma","googleId":"M-SMDHFIS1QJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2507/36261","googleCitationCount":37,"googleAuthor":"S Pandey","doi":"10.1182/blood-2016-08-737239","elsevierAuthor":"Pandey S.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"29"},{"title":"Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin …","googleId":"jO5VB86pDTQJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/928/266207","googleCitationCount":26,"googleAuthor":"M Hamadani","doi":"10.1182/blood-2018-99-118198","elsevierCitationCount":0},{"title":"High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT","googleId":"Z-OPRzGVdasJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1345/39606","googleCitationCount":25,"googleAuthor":"DM Arnold","doi":"10.1182/blood-2018-04-847483","elsevierAuthor":"Warkentin T.E.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"19"},{"title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","googleId":"bYYdVUcoMiwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120319480","googleCitationCount":24,"googleAuthor":"SR Cataland","doi":"10.1182/blood-2018-02-791533","elsevierAuthor":"Masias C.","publicationName":"Blood","elsevierCoverDate":"2018-08-30","elsevierCoverDisplayDate":"30 August 2018","elsevierCitationCount":"16"},{"title":"Obinutuzumab: what is there to learn from clinical trials?","googleId":"tnM2F4-UgZEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/5/581/36784","googleCitationCount":33,"googleAuthor":"","doi":"10.1182/blood-2017-03-771832","elsevierAuthor":"Cartron G.","publicationName":"Blood","elsevierCoverDate":"2017-08-03","elsevierCoverDisplayDate":"3 August 2017","elsevierCitationCount":"26"},{"title":"Slowed decay of mRNAs enhances platelet specific translation","googleId":"_r0fw1F9UhgJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/e38/35955","googleCitationCount":35,"googleAuthor":"EW Mills","doi":"10.1182/blood-2016-08-736108","elsevierAuthor":"Mills E.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"28"},{"title":"Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 Study","googleId":"ZxkkFyHA8LQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/651/83546","googleCitationCount":30,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.651.651","elsevierCitationCount":0},{"title":"Efficacy and safety of single-agent quizartinib (Q), a potent and selective FLT3 inhibitor (FLT3i), in patients (pts) with FLT3-internal tandem duplication (FLT3-ITD) …","googleId":"XV9mjEES24gJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/563/263148","googleCitationCount":23,"googleAuthor":"G Martinelli","doi":"10.1182/blood-2018-99-110439","elsevierAuthor":"Madanat Y.F.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"How I manage ibrutinib-refractory chronic lymphocytic leukemia","googleId":"f2NaKY6abQIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1270/36014","googleCitationCount":39,"googleAuthor":"","doi":"10.1182/blood-2016-09-693598","elsevierAuthor":"Woyach J.A.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"34"},{"title":"How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes","googleId":"m73mP-S0Xc8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/16/1657/39350","googleCitationCount":24,"googleAuthor":"DP Steensma","doi":"10.1182/blood-2018-06-860882","elsevierAuthor":"","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"0"},{"title":"Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP clarity study","googleId":"QQAMQDetDOAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/182/273012","googleCitationCount":27,"googleAuthor":"P Hillmen","doi":"10.1182/blood-2018-182","elsevierCitationCount":0},{"title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study","googleId":"PVUgggStiD0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2449/37071","googleCitationCount":29,"googleAuthor":"S Luminari","doi":"10.1182/blood-2017-11-816298","elsevierAuthor":"Cottereau A.S.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"21"},{"title":"TET2 deficiency leads to stem cell factor–dependent clonal expansion of dysfunctional erythroid progenitors","googleId":"P5qgNas7zkoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/22/2406/107713","googleCitationCount":23,"googleAuthor":"X Qu","doi":"10.1182/blood-2018-05-853291","elsevierAuthor":"Qu X.","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"16"},{"title":"SRC-3 is involved in maintaining hematopoietic stem cell quiescence by regulation of mitochondrial metabolism in mice","googleId":"YJxhZy-vpgwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/9/911/39423","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood-2018-02-831669","elsevierAuthor":"Hu M.","publicationName":"Blood","elsevierCoverDate":"2018-08-30","elsevierCoverDisplayDate":"30 August 2018","elsevierCitationCount":"21"},{"title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years","googleId":"UL1Cz43UMaAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/4/456/36177","googleCitationCount":40,"googleAuthor":"M Gavriatopoulou","doi":"10.1182/blood-2016-09-742411","elsevierAuthor":"Gavriatopoulou M.","publicationName":"Blood","elsevierCoverDate":"2017-01-26","elsevierCoverDisplayDate":"26 January 2017","elsevierCitationCount":"34"},{"title":"Phase 1 cohort expansion of flotetuzumab, a CD123× CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML)","googleId":"VJWyYwHaFfQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/764/266322","googleCitationCount":23,"googleAuthor":"GL Uy","doi":"10.1182/blood-2018-99-117085","elsevierCitationCount":0},{"title":"Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with …","googleId":"9GwtMS3HZXUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/579/263449","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood-2018-99-118715","elsevierCitationCount":0},{"title":"LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis","googleId":"IArPTxXwR30J","googleLink":"https://ashpublications.org/blood/article-abstract/131/1/95/107705","googleCitationCount":30,"googleAuthor":"J Schwaller","doi":"10.1182/blood-2017-05-786962","elsevierAuthor":"El Ashkar S.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"23"},{"title":"How I treat atypical chronic myeloid leukemia","googleId":"WzEre7UiWUEJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/7/838/36180","googleCitationCount":38,"googleAuthor":"","doi":"10.1182/blood-2016-08-693630","elsevierAuthor":"Gotlib J.","publicationName":"Blood","elsevierCoverDate":"2017-02-16","elsevierCoverDisplayDate":"16 February 2017","elsevierCitationCount":"25"},{"title":"Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis","googleId":"G-h6YCUcuxAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/7/946/36986","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood-2017-04-777722","elsevierAuthor":"Magina K.N.","publicationName":"Blood","elsevierCoverDate":"2017-08-17","elsevierCoverDisplayDate":"17 August 2017","elsevierCitationCount":"24"},{"title":"Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging …","googleId":"xObuEcVh8DMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/763/266313","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2018-99-119786","elsevierAuthor":"Khanal N.","publicationName":"Clinical Pharmacology and Therapeutics","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"2"},{"title":"Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis","googleId":"7qSO3jd37M4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2298/39522","googleCitationCount":20,"googleAuthor":"","doi":"10.1182/blood-2018-03-836783","elsevierAuthor":"Amin E.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"19"},{"title":"How I diagnose and treat venous thromboembolism in sickle cell disease","googleId":"qNajeWzMFLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120606541","googleCitationCount":23,"googleAuthor":"AS Shet","doi":"10.1182/blood-2018-03-822593","elsevierAuthor":"Shet A.","publicationName":"Blood","elsevierCoverDate":"2018-10-25","elsevierCoverDisplayDate":"25 October 2018","elsevierCitationCount":"11"},{"title":"Increased risk of leukemia among sickle cell disease patients in California","googleId":"UhUg7ExDGr0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/13/1597/36516","googleCitationCount":29,"googleAuthor":"A Brunson","doi":"10.1182/blood-2017-05-783233","elsevierAuthor":"Brunson A.","publicationName":"Blood","elsevierCoverDate":"2017-09-28","elsevierCoverDisplayDate":"28 September 2017","elsevierCitationCount":"22"},{"title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia","googleId":"Lay77fT0D6UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1876/35806","googleCitationCount":34,"googleAuthor":"S Perez","doi":"10.1182/blood-2016-10-748210","elsevierAuthor":"Ghia P.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"26"},{"title":"A phase 1/2 trial of investigational SPK-8011 in hemophilia A demonstrates durable expression and prevention of bleeds","googleId":"_5wv_m5RtkEJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/487/262202","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2018-99-115495","elsevierAuthor":"Arruda V.R.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia","googleId":"qydLLcx4EX0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/25/2750/36875","googleCitationCount":28,"googleAuthor":"","doi":"10.1182/blood-2017-05-784603","elsevierAuthor":"Serafin V.","publicationName":"Blood","elsevierCoverDate":"2017-12-21","elsevierCoverDisplayDate":"21 December 2017","elsevierCitationCount":"14"},{"title":"Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM)","googleId":"0UXqgSVihbkJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2/71272","googleCitationCount":29,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2.2","elsevierCitationCount":0},{"title":"Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL","googleId":"M4r_Ua6S2TUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/405/103901","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood-2018-03-836528","elsevierAuthor":"Testi A.M.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"12"},{"title":"The disulfide isomerase ERp72 supports arterial thrombosis in mice","googleId":"j-RHiaru1F8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/6/817/36797","googleCitationCount":29,"googleAuthor":"Y Wu","doi":"10.1182/blood-2016-12-755587","elsevierAuthor":"Zhou J.","publicationName":"Blood","elsevierCoverDate":"2017-08-10","elsevierCoverDisplayDate":"10 August 2017","elsevierCitationCount":"25"},{"title":"Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia","googleId":"IZN0p_u_0iMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/170/39232","googleCitationCount":24,"googleAuthor":"MK Hasan","doi":"10.1182/blood-2017-12-819383","elsevierAuthor":"Hasan K.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"19"},{"title":"Extravascular coagulation in hematopoietic stem and progenitor cell regulation","googleId":"8pbrGKQFMpwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/123/39213","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood-2017-12-768986","elsevierAuthor":"Nguyen T.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"16"},{"title":"Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","googleId":"hHLqttqVh7AJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/2/179/39226","googleCitationCount":26,"googleAuthor":"L Milan","doi":"10.1182/blood-2018-01-826958","elsevierAuthor":"Ceriani L.","publicationName":"Blood","elsevierCoverDate":"2018-07-12","elsevierCoverDisplayDate":"12 July 2018","elsevierCitationCount":"17"},{"title":"How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms","googleId":"9zMudGvsxqsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/22/2339/107700","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2018-03-785907","elsevierAuthor":"Odenike O.","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"17"},{"title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","googleId":"6r2VN6r1iG8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/1008/36353","googleCitationCount":37,"googleAuthor":"P Agarwal","doi":"10.1182/blood-2016-05-714089","elsevierAuthor":"Agarwal P.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"26"},{"title":"UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice","googleId":"ndRIy61Xj2MJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/24/2564/39547","googleCitationCount":20,"googleAuthor":"S Hussain","doi":"10.1182/blood-2018-05-848515","elsevierAuthor":"Hussain S.","publicationName":"Blood","elsevierCoverDate":"2018-12-13","elsevierCoverDisplayDate":"13 December 2018","elsevierCitationCount":"14"},{"title":"Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum","googleId":"WrQ7ZWDmW2gJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/10/1111/36416","googleCitationCount":24,"googleAuthor":"","doi":"10.1182/blood-2017-08-802918","elsevierAuthor":"Zhang M.Y.","publicationName":"Blood","elsevierCoverDate":"2018-03-08","elsevierCoverDisplayDate":"8 March 2018","elsevierCitationCount":"12"},{"title":"How I treat myelofibrosis after failure of JAK inhibitors","googleId":"xLRiUcvxIWUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S000649712032022X","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2018-02-785923","elsevierAuthor":"Pardanani A.","publicationName":"Blood","elsevierCoverDate":"2018-08-02","elsevierCoverDisplayDate":"2 August 2018","elsevierCitationCount":"12"},{"title":"Tissue-type plasminogen activator regulates macrophage activation and innate immunity","googleId":"n9dWkbAmajQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/11/1364/36463","googleCitationCount":29,"googleAuthor":"E Mantuano","doi":"10.1182/blood-2017-04-780205","elsevierAuthor":"Mantuano E.","publicationName":"Blood","elsevierCoverDate":"2017-09-14","elsevierCoverDisplayDate":"14 September 2017","elsevierCitationCount":"22"},{"title":"Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-cell acute …","googleId":"RlFvahsCVfcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/557/262977","googleCitationCount":22,"googleAuthor":"J Webster","doi":"10.1182/blood-2018-99-111845","elsevierCitationCount":0},{"title":"Initial results of the phase 2 treatment naive cohort in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia","googleId":"rXNwtDNKOKAJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/431/72605","googleCitationCount":28,"googleAuthor":"FT Awan","doi":"10.1182/blood.V130.Suppl_1.431.431","elsevierCitationCount":0},{"title":"Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 …","googleId":"jUvlwC6K6agJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/510/81019","googleCitationCount":31,"googleAuthor":"CC Hofmeister","doi":"10.1182/blood.V130.Suppl_1.510.510","elsevierCitationCount":0},{"title":"Vaccine therapy in hematologic malignancies","googleId":"5VL86YpymBcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/24/2640/37160","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood-2017-11-785873","elsevierAuthor":"Avigan D.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"17"},{"title":"Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing","googleId":"9NeUiJECPSsJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2915/39188","googleCitationCount":28,"googleAuthor":"C Li","doi":"10.1182/blood-2018-03-838540","elsevierAuthor":"Li C.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"23"},{"title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT …","googleId":"JTZM0nvRy-gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/402/72665","googleCitationCount":31,"googleAuthor":"MV Mateos","doi":"10.1182/blood.V130.Suppl_1.402.402","elsevierCitationCount":0},{"title":"A phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed …","googleId":"BwLp8lmC804J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4193/275540","googleCitationCount":22,"googleAuthor":"NN Shah","doi":"10.1182/blood-2018-99-110194","elsevierCitationCount":0},{"title":"How I treat type 2B von Willebrand disease","googleId":"VTMR4hCcbEIJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/12/1292/36611","googleCitationCount":24,"googleAuthor":"","doi":"10.1182/blood-2017-06-742692","elsevierAuthor":"Kruse-Jarres R.","publicationName":"Blood","elsevierCoverDate":"2018-03-22","elsevierCoverDisplayDate":"22 March 2018","elsevierCitationCount":"18"},{"title":"Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated …","googleId":"EXXk84CzKRcJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3145/80795","googleCitationCount":27,"googleAuthor":"MV Mateos","doi":"10.1182/blood.V130.Suppl_1.3145.3145","elsevierCitationCount":0},{"title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","googleId":"Uyik2sm60B8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2026/39485","googleCitationCount":23,"googleAuthor":"N Yusufova","doi":"10.1182/blood-2018-02-831438","elsevierAuthor":"Lu X.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"18"},{"title":"Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 …","googleId":"oMDWR35utgQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/726/83457","googleCitationCount":28,"googleAuthor":"AS Mims","doi":"10.1182/blood.V130.Suppl_1.726.726","elsevierCitationCount":0},{"title":"Ibrutinib+ obinutuzumab versus chlorambucil+ obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL …","googleId":"5Mf4iQKG2koJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/691/266013","googleCitationCount":22,"googleAuthor":"C Moreno","doi":"10.1182/blood-2018-99-111370","elsevierCitationCount":0},{"title":"Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients","googleId":"JczyQRBSej4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/971/266187","googleCitationCount":23,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood-2018-99-111582","elsevierCitationCount":0},{"title":"Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding","googleId":"-DQRW9_hKqQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/24/3210/36304","googleCitationCount":32,"googleAuthor":"","doi":"10.1182/blood-2016-12-758250","elsevierAuthor":"Belderbos M.","publicationName":"Journal of Experimental Medicine","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"1"},{"title":"Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients …","googleId":"Tl9fp07TfbUJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/813/83471","googleCitationCount":27,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.813.813","elsevierCitationCount":0},{"title":"Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center","googleId":"32qy4YD6-X8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/830/83667","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.830.830","elsevierAuthor":"Davis J.S.","publicationName":"Clinical Microbiology Reviews","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"1"},{"title":"CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL)","googleId":"QGR6LR8KrNwJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/680/266379","googleCitationCount":21,"googleAuthor":"CA Ramos","doi":"10.1182/blood-2018-99-111202","elsevierCitationCount":0},{"title":"Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma","googleId":"u-5r3O-2e1cJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/7/771/39304","googleCitationCount":27,"googleAuthor":"","doi":"10.1182/blood-2017-09-805663","elsevierAuthor":"Kohnken R.","publicationName":"Blood","elsevierCoverDate":"2018-02-15","elsevierCoverDisplayDate":"15 February 2018","elsevierCitationCount":"21"},{"title":"Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice","googleId":"n6sfSD7GlP4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/563/104412","googleCitationCount":24,"googleAuthor":"","doi":"10.1182/blood-2017-08-801738","elsevierAuthor":"Zhou Y.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"24"},{"title":"Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): updated analysis of the keynote-170 phase 2 trial","googleId":"6VbGTaLrmsQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2833/80639","googleCitationCount":27,"googleAuthor":"PL Zinzani","doi":"10.1182/blood.V130.Suppl_1.2833.2833","elsevierCitationCount":0},{"title":"T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model","googleId":"Mt0R9I4pt4gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/2/146/36705","googleCitationCount":27,"googleAuthor":"DM Woods","doi":"10.1182/blood-2016-08-731505","elsevierAuthor":"Woods D.M.","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"20"},{"title":"Promising activity of nelfinavir-Bortezomib-Dexamethasone in proteasome inhibitor–refractory multiple myeloma","googleId":"MmufFIq9YDoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2097/39455","googleCitationCount":19,"googleAuthor":"U Novak","doi":"10.1182/blood-2018-05-851170","elsevierAuthor":"Driessen C.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"15"},{"title":"BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors","googleId":"fCnRB9Yox0YJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/582/36170","googleCitationCount":34,"googleAuthor":"","doi":"10.1182/blood-2016-07-731091","elsevierAuthor":"Comoli P.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"23"},{"title":"Differentiation-based model of hematopoietic stem cell functions and lineage pathways","googleId":"mmE0xYO9EGQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/11/1106/39354","googleCitationCount":21,"googleAuthor":"T Höfer","doi":"10.1182/blood-2018-03-791517","elsevierAuthor":"Höfer T.","publicationName":"Blood","elsevierCoverDate":"2018-09-13","elsevierCoverDisplayDate":"13 September 2018","elsevierCitationCount":"12"},{"title":"Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis","googleId":"y0SFdbUb-fgJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2161/36398","googleCitationCount":32,"googleAuthor":"EW Livingston","doi":"10.1182/blood-2016-08-734053","elsevierAuthor":"Sun J.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"26"},{"title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","googleId":"i3F4eGeJH2gJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/5/547/39375","googleCitationCount":23,"googleAuthor":"F Paoloni","doi":"10.1182/blood-2018-03-835413","elsevierAuthor":"Rossi G.","publicationName":"Blood","elsevierCoverDate":"2018-08-02","elsevierCoverDisplayDate":"2 August 2018","elsevierCitationCount":"15"},{"title":"Safety, efficacy and MRD negativity of a combination of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia-results from …","googleId":"JiHaJQatsAoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/430/72939","googleCitationCount":27,"googleAuthor":"JG Gribben","doi":"10.1182/blood.V130.Suppl_1.430.430","elsevierCitationCount":0},{"title":"Hypoxia downregulates protein S expression","googleId":"zF_Q16ZlSs4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/452/103891","googleCitationCount":20,"googleAuthor":"VS Pilli","doi":"10.1182/blood-2018-04-841585","elsevierAuthor":"Pilli V.S.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"16"},{"title":"Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients","googleId":"0wO_rVLI-dwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2143/36374","googleCitationCount":29,"googleAuthor":"D Pinato","doi":"10.1182/blood-2016-10-747477","elsevierAuthor":"Pria A.D.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"21"},{"title":"Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells","googleId":"brC3XBGBzq4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/25/2670/39591","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2018-06-856203","elsevierAuthor":"Kabrani E.","publicationName":"Blood","elsevierCoverDate":"2018-12-20","elsevierCoverDisplayDate":"20 December 2018","elsevierCitationCount":"16"},{"title":"Treatment with combination of dabrafenib and trametinib in patients with recurrent/refractory BRAF V600E-mutated hairy cell leukemia (HCL)","googleId":"ZqdPa-OsnEkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/391/264975","googleCitationCount":19,"googleAuthor":"P Moreau","doi":"10.1182/blood-2018-99-113135","elsevierCitationCount":0},{"title":"How I manage the toxicities of myeloma drugs","googleId":"bo7tal7qPwwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/17/2359/35945","googleCitationCount":28,"googleAuthor":"M Delforge","doi":"10.1182/blood-2017-01-725705","elsevierAuthor":"Delforge M.","publicationName":"Blood","elsevierCoverDate":"2017-04-27","elsevierCoverDisplayDate":"27 April 2017","elsevierCitationCount":"21"},{"title":"CK2β regulates thrombopoiesis and Ca2+-triggered platelet activation in arterial thrombosis","googleId":"aNX_W853PQIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/25/2774/36887","googleCitationCount":24,"googleAuthor":"","doi":"10.1182/blood-2017-05-784413","elsevierAuthor":"Münzer P.","publicationName":"Blood","elsevierCoverDate":"2017-12-21","elsevierCoverDisplayDate":"21 December 2017","elsevierCitationCount":"18"},{"title":"Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","googleId":"dGNGeGxvYA0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2628/79868","googleCitationCount":27,"googleAuthor":"BA Jonas","doi":"10.1182/blood.V130.Suppl_1.2628.2628","elsevierCitationCount":0},{"title":"Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia","googleId":"uyoBVFXNcB8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/255/79927","googleCitationCount":25,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.255.255","elsevierCitationCount":0},{"title":"Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results …","googleId":"deyXuhRZYpMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1812/272936","googleCitationCount":20,"googleAuthor":"JM Watts","doi":"10.1182/blood-2018-99-111264","elsevierAuthor":"Fernández Delgado N.D.","publicationName":"Revista Cubana de Hematologia, Inmunologia y Hemoterapia","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"First-in-human study of the EZH1/2 dual inhibitor DS-3201b in patients with relapsed or refractory non-Hodgkin lymphomas—preliminary results","googleId":"y7chqx8iSsEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4070/72772","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4070.4070","elsevierCitationCount":0},{"title":"Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling","googleId":"Fwu4w0-G05cJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/6/674/39225","googleCitationCount":22,"googleAuthor":"E Liu","doi":"10.1182/blood-2017-02-768218","elsevierAuthor":"Rothmeier A.","publicationName":"Blood","elsevierCoverDate":"2018-02-08","elsevierCoverDisplayDate":"8 February 2018","elsevierCitationCount":"21"},{"title":"Donor-derived MDS/AML in families with germline GATA2 mutation","googleId":"-TwsK9OWwjoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1994/39608","googleCitationCount":19,"googleAuthor":"AP Hsu","doi":"10.1182/blood-2018-07-861070","elsevierAuthor":"Galera P.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"14"},{"title":"An international registry of survivors with Hb Bart's hydrops fetalis syndrome","googleId":"OE64qzUUBYkJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1251/35989","googleCitationCount":32,"googleAuthor":"","doi":"10.1182/blood-2016-08-697110","elsevierAuthor":"Songdej D.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"18"},{"title":"Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high …","googleId":"-55YAA4vmJEJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/905/266416","googleCitationCount":20,"googleAuthor":"R Assi","doi":"10.1182/blood-2018-99-116078","elsevierCitationCount":0},{"title":"A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding","googleId":"6UiyL2QOQeAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/24/e35/39549","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2018-02-831982","elsevierAuthor":"Baaten C.C.F.M.J.","publicationName":"Blood","elsevierCoverDate":"2018-12-13","elsevierCoverDisplayDate":"13 December 2018","elsevierCitationCount":"14"},{"title":"A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 …","googleId":"MvjCwiozu9sJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3229/263918","googleCitationCount":19,"googleAuthor":"","doi":"10.1182/blood-2018-99-110427","elsevierCitationCount":0},{"title":"Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease","googleId":"IytcZRQyDnQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/101/39273","googleCitationCount":20,"googleAuthor":"MD Chatfield","doi":"10.1182/blood-2018-02-830562","elsevierAuthor":"Sandhu K.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"15"},{"title":"Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study","googleId":"noXNh4hfngMJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/725/83443","googleCitationCount":25,"googleAuthor":"S De Botton","doi":"10.1182/blood.V130.Suppl_1.725.725","elsevierCitationCount":0},{"title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis","googleId":"LuPAiPrxhdcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/934/36327","googleCitationCount":30,"googleAuthor":"","doi":"10.1182/blood-2016-09-728006","elsevierAuthor":"Skeith L.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"19"},{"title":"Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition","googleId":"knvzpuNa-xIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/647/39443","googleCitationCount":18,"googleAuthor":"S Wu","doi":"10.1182/blood-2018-01-830901","elsevierAuthor":"Wu S.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"9"},{"title":"Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy","googleId":"Gd8jISl7FPMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2466/37086","googleCitationCount":23,"googleAuthor":"W Yang","doi":"10.1182/blood-2017-11-815506","elsevierAuthor":"Nishii R.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"17"},{"title":"Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph+ ALL or CML in lymphoid blast phase","googleId":"OIOOB-bSbgEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/143/79401","googleCitationCount":23,"googleAuthor":"N Jain","doi":"10.1182/blood.V130.Suppl_1.143.143","elsevierCitationCount":0},{"title":"Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes","googleId":"pDhun_bdzGwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2309/39535","googleCitationCount":17,"googleAuthor":"S Narumi","doi":"10.1182/blood-2017-05-787390","elsevierAuthor":"Nagata Y.","publicationName":"Blood","elsevierCoverDate":"2018-11-22","elsevierCoverDisplayDate":"22 November 2018","elsevierCitationCount":"12"},{"title":"Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","googleId":"hCWn1x2W0L8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/527/81027","googleCitationCount":26,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.527.527","elsevierCitationCount":0},{"title":"Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma","googleId":"3rhp_nM3BoMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/155/272957","googleCitationCount":16,"googleAuthor":"MA Dimopoulos","doi":"10.1182/blood-2018-155","elsevierCitationCount":0},{"title":"Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk chronic lymphocytic leukemia (CLL)","googleId":"itzQOtNNn3sJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/696/272996","googleCitationCount":20,"googleAuthor":"N Jain","doi":"10.1182/blood-2018-186","elsevierCitationCount":0},{"title":"Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis …","googleId":"famW1lH6PXEJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/412/72819","googleCitationCount":23,"googleAuthor":"J Dixon","doi":"10.1182/blood.V130.Suppl_1.412.412","elsevierCitationCount":0},{"title":"FCR achieves long-term durable remissions in patients with IGHV-mutated CLL","googleId":"0C68S4YVuUsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2278/36650","googleCitationCount":23,"googleAuthor":"C Chai-Adisaksopha","doi":"10.1182/blood-2017-07-731588","elsevierAuthor":"Chai-Adisaksopha C.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"18"},{"title":"Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom's macroglobulinemia: update of pivotal clinical trial","googleId":"6CoPKUUOBf4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2766/80388","googleCitationCount":27,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2766.2766","elsevierCitationCount":0},{"title":"Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations","googleId":"BMHsjWu1wBsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/7/879/36202","googleCitationCount":31,"googleAuthor":"CT Berger","doi":"10.1182/blood-2016-09-740217","elsevierAuthor":"Nordmann T.M.","publicationName":"Blood","elsevierCoverDate":"2017-02-16","elsevierCoverDisplayDate":"16 February 2017","elsevierCitationCount":"26"},{"title":"Acute hyperviscosity: syndromes and management","googleId":"8ub3jRMRTeEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120607212","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2018-06-846816","elsevierAuthor":"Gertz M.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"14"},{"title":"Cellubrevin/vesicle-associated membrane protein-3–mediated endocytosis and trafficking regulate platelet functions","googleId":"C9yyWrur4UwJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/26/2872/36595","googleCitationCount":23,"googleAuthor":"S Joshi","doi":"10.1182/blood-2017-02-768176","elsevierAuthor":"Banerjee M.","publicationName":"Blood","elsevierCoverDate":"2017-12-28","elsevierCoverDisplayDate":"28 December 2017","elsevierCitationCount":"16"},{"title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B …","googleId":"6KJV6ZOE0wIJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2821/80501","googleCitationCount":23,"googleAuthor":"AF Herrera","doi":"10.1182/blood.V130.Suppl_1.2821.2821","elsevierCitationCount":0},{"title":"Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) …","googleId":"wPAVL3UC_WIJ","googleLink":"http://eprints.whiterose.ac.uk/157106/2/Bahlis%20manuscript_FINAL.pdf","googleCitationCount":17,"googleAuthor":"N Bahlis"},{"title":"GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting","googleId":"Jpr5iLZSbmAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/17/1851/39491","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2018-04-845545","elsevierAuthor":"Revel-Vilk S.","publicationName":"Blood","elsevierCoverDate":"2018-10-25","elsevierCoverDisplayDate":"25 October 2018","elsevierCitationCount":"10"},{"title":"Making HSCs in vitro: don't forget the hemogenic endothelium","googleId":"pjLkWCrH3WwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1372/105718","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood-2018-04-784140","elsevierAuthor":"Blaser B.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"12"},{"title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","googleId":"O0YoltVGBo4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/5/501/39392","googleCitationCount":21,"googleAuthor":"SR Panch","doi":"10.1182/blood-2018-02-835330","elsevierAuthor":"Ciceri S.","publicationName":"Catalysts","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0"},{"title":"Subclonal TP53 copy number is associated with prognosis in multiple myeloma","googleId":"JliS6aqMpy8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/23/2465/39997","googleCitationCount":17,"googleAuthor":"AL Sherborne","doi":"10.1182/blood-2018-06-857250","elsevierAuthor":"Shah V.","publicationName":"Blood","elsevierCoverDate":"2018-12-06","elsevierCoverDisplayDate":"6 December 2018","elsevierCitationCount":"12"},{"title":"Anti-BCMA BiTE® AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment","googleId":"freVGQqiJLMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/592/263439","googleCitationCount":19,"googleAuthor":"L Lin","doi":"10.1182/blood-2018-99-118425","elsevierAuthor":"Verkleij C.P.M.","publicationName":"Oncotarget","elsevierCoverDate":"2020-11-10","elsevierCoverDisplayDate":"10 November 2020","elsevierCitationCount":"0"},{"title":"Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+ R) in patients with chronic lymphocytic leukemia (CLL)","googleId":"oBS_OKrnphIJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/427/72618","googleCitationCount":25,"googleAuthor":"JA Burger","doi":"10.1182/blood.V130.Suppl_1.427.427","elsevierCitationCount":0},{"title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001) …","googleId":"HCvct5JAVwoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3110/80532","googleCitationCount":22,"googleAuthor":"SZ Usmani","doi":"10.1182/blood.V130.Suppl_1.3110.3110","elsevierCitationCount":0},{"title":"A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia","googleId":"pTYf0_uf0hsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/22/2410/36564","googleCitationCount":21,"googleAuthor":"AW Daman","doi":"10.1182/blood-2017-04-777052","elsevierAuthor":"Oda S.","publicationName":"Blood","elsevierCoverDate":"2017-11-30","elsevierCoverDisplayDate":"30 November 2017","elsevierCitationCount":"17"},{"title":"Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly …","googleId":"_Fam6pvhSz8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/595/263465","googleCitationCount":16,"googleAuthor":"EM Ocio","doi":"10.1182/blood-2018-99-111244","elsevierCitationCount":0},{"title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma","googleId":"bVj8MZYdGKUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1486/39342","googleCitationCount":21,"googleAuthor":"G Salles","doi":"10.1182/blood-2018-05-853499","elsevierAuthor":"Morschhauser F.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"17"},{"title":"Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment","googleId":"-Cvy5HlUL-AJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/21/2354/36660","googleCitationCount":24,"googleAuthor":"","doi":"10.1182/blood-2017-03-771857","elsevierAuthor":"Berthaut I.","publicationName":"Blood","elsevierCoverDate":"2017-11-23","elsevierCoverDisplayDate":"23 November 2017","elsevierCitationCount":"18"},{"title":"Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations","googleId":"6HOn0MW1-sgJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2989/39100","googleCitationCount":23,"googleAuthor":"SO Ciurea","doi":"10.1182/blood-2018-02-832360","elsevierAuthor":"Ciurea S.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"17"},{"title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","googleId":"A_VCg3ivX1AJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4326/72822","googleCitationCount":24,"googleAuthor":"JC Byrd","doi":"10.1182/blood.V130.Suppl_1.4326.4326","elsevierCitationCount":0},{"title":"Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib","googleId":"Mx9Fvly816MJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2260/39546","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood-2017-12-822569","elsevierAuthor":"De Weerdt I.","publicationName":"Blood","elsevierCoverDate":"2019-10-10","elsevierCoverDisplayDate":"10 October 2019","elsevierCitationCount":"0"},{"title":"Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with …","googleId":"eZz5_s7yPEoJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/767/266352","googleCitationCount":17,"googleAuthor":"BA Jonas","doi":"10.1182/blood-2018-99-116013","elsevierCitationCount":0},{"title":"EBV/LMP-specific T cells maintain remissions of T-and B-cell EBV lymphomas after allogeneic bone marrow transplantation","googleId":"Csfq3rHDPXEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/22/2351/107706","googleCitationCount":18,"googleAuthor":"S Gottschalk","doi":"10.1182/blood-2018-07-863654","elsevierAuthor":"McLaughlin L.P.","publicationName":"Blood","elsevierCoverDate":"2018-11-29","elsevierCoverDisplayDate":"29 November 2018","elsevierCitationCount":"9"},{"title":"Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI)","googleId":"x7-S79ShjPYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/LBA-1/375115","googleCitationCount":19,"googleAuthor":"AA Khorana","doi":"10.1182/blood-2018-120738","elsevierAuthor":"Roopkumar J.","publicationName":"Cancer Treatment and Research","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"1"},{"title":"Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy","googleId":"oa0c_9uTsBYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/4/264991","googleCitationCount":20,"googleAuthor":"C Pecquet","doi":"10.1182/blood-2018-99-118348","elsevierCitationCount":0},{"title":"Origins of myelodysplastic syndromes after aplastic anemia","googleId":"D_DtrGYwCawJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/17/1953/36504","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2017-02-767731","elsevierAuthor":"Negoro E.","publicationName":"Blood","elsevierCoverDate":"2017-10-26","elsevierCoverDisplayDate":"26 October 2017","elsevierCitationCount":"17"},{"title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies","googleId":"lYRjHogaUAsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/14/1628/107654","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2016-08-736066","elsevierAuthor":"Bobrowicz M.","publicationName":"Blood","elsevierCoverDate":"2017-10-05","elsevierCoverDisplayDate":"5 October 2017","elsevierCitationCount":"21"},{"title":"Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma","googleId":"8vRMSiXAG-UJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/561/36141","googleCitationCount":30,"googleAuthor":"CA Thompson","doi":"10.1182/blood-2016-08-685073","elsevierAuthor":"Cohen J.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"24"},{"title":"Tackling early morbidity and mortality in myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 …","googleId":"etk4iDfCSmIJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/903/83541","googleCitationCount":22,"googleAuthor":"T Planche","doi":"10.1182/blood.V130.Suppl_1.903.903","elsevierCitationCount":0},{"title":"Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective","googleId":"Wm6nA0mgYnsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/369/103906","googleCitationCount":19,"googleAuthor":"","doi":"10.1182/blood-2018-02-778480","elsevierAuthor":"Dunleavy K.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"14"},{"title":"Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid …","googleId":"iDZCNMCcflQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/722/83413","googleCitationCount":22,"googleAuthor":"K Pratz","doi":"10.1182/blood.V130.Suppl_1.722.722","elsevierCitationCount":0},{"title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for firstline treatment of patients with CLL with mutated IGHV and without TP53 aberrations","googleId":"X6AVqwAe0rMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/695/272866","googleCitationCount":18,"googleAuthor":"N Jain","doi":"10.1182/blood-2018-185","elsevierAuthor":"Bosch F.","publicationName":"Leukemia","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"1"},{"title":"Glutamine via α-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis","googleId":"ApMYf7W1lgYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/10/987/39324","googleCitationCount":20,"googleAuthor":"JE Cox","doi":"10.1182/blood-2018-01-829036","elsevierAuthor":"Burch J.","publicationName":"Blood","elsevierCoverDate":"2018-09-06","elsevierCoverDisplayDate":"6 September 2018","elsevierCitationCount":"12"},{"title":"Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis","googleId":"9hb-8F21NxEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1265/39645","googleCitationCount":17,"googleAuthor":"E Pronier","doi":"10.1182/blood-2018-03-837468","elsevierAuthor":"Pronier E.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"7"},{"title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","googleId":"DiAx05ICdSsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/96/266049","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood-2018-99-120013","elsevierCitationCount":0},{"title":"Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?","googleId":"yyQ1h-uVXqoJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/23/3059/36036","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2016-05-672196","elsevierAuthor":"Le Gouill S.","publicationName":"Blood","elsevierCoverDate":"2017-06-08","elsevierCoverDisplayDate":"8 June 2017","elsevierCitationCount":"16"},{"title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","googleId":"_4oyGnStLDEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2036/36738","googleCitationCount":19,"googleAuthor":"J Gunawardana","doi":"10.1182/blood-2017-09-808907","elsevierAuthor":"Vigano E.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"15"},{"title":"Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of …","googleId":"Cx54HLu6sbgJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/781/266032","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2018-99-112403","elsevierCitationCount":0},{"title":"A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium","googleId":"7W-C2C8t3zMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/10/1145/36403","googleCitationCount":19,"googleAuthor":"T Triche","doi":"10.1182/blood-2017-09-803809","elsevierAuthor":"Sun W.","publicationName":"Blood","elsevierCoverDate":"2018-03-08","elsevierCoverDisplayDate":"8 March 2018","elsevierCitationCount":"10"},{"title":"Final analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis","googleId":"6Vq0buVaTCAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/509/80897","googleCitationCount":24,"googleAuthor":"MY Mapara","doi":"10.1182/blood.V130.Suppl_1.509.509","elsevierCitationCount":0},{"title":"Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model","googleId":"xgtX7yOoAb8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/21/2286/39548","googleCitationCount":14,"googleAuthor":"S Altamura","doi":"10.1182/blood-2018-05-852277","elsevierAuthor":"Artuso I.","publicationName":"Blood","elsevierCoverDate":"2019-07-04","elsevierCoverDisplayDate":"4 July 2019","elsevierCitationCount":"0"},{"title":"Interim analysis of phase II study of venetoclax with 10-day decitabine (DEC10-VEN) in acute myeloid leukemia and myelodysplastic syndrome","googleId":"gIKdyO00dosJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/286/263731","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2018-99-113749","elsevierCitationCount":0},{"title":"Hematopoiesis and the bacterial microbiome","googleId":"8_0MceyG8FQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/559/39408","googleCitationCount":18,"googleAuthor":"MT Baldridge","doi":"10.1182/blood-2018-02-832519","elsevierAuthor":"Yan H.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"13"},{"title":"Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models","googleId":"ZcUcrSXf5BAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/18/2526/36271","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood-2017-01-763581","elsevierAuthor":"Dourado K.","publicationName":"Blood","elsevierCoverDate":"2017-05-04","elsevierCoverDisplayDate":"4 May 2017","elsevierCitationCount":"17"},{"title":"Results of the pivotal STORM study (part 2) in penta-refractory multiple myeloma (MM): deep and durable responses with oral selinexor plus low dose dexamethasone …","googleId":"yJupHEn8MBIJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/598/263468","googleCitationCount":17,"googleAuthor":"MA Dimopoulos","doi":"10.1182/blood-2018-99-116663","elsevierCitationCount":0},{"title":"Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia","googleId":"QoeWNAQgkJMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/20/2205/6533","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2017-12-822908","elsevierAuthor":"Blumberg R.","publicationName":"Blood","elsevierCoverDate":"2018-05-17","elsevierCoverDisplayDate":"17 May 2018","elsevierCitationCount":"15"},{"title":"High complete response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: results of an open-label, phase II study","googleId":"BC-EmC-GCBcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/414/72599","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.414.414","elsevierCitationCount":0},{"title":"Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 trial","googleId":"rrecnPT3TwgJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/905/83562","googleCitationCount":20,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.905.905","elsevierCitationCount":0},{"title":"p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma","googleId":"VkibMNw2NREJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1308/36029","googleCitationCount":28,"googleAuthor":"F Cottini","doi":"10.1182/blood-2016-09-738500","elsevierAuthor":"Hideshima T.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"15"},{"title":"Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study","googleId":"p2vhau-RH4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120319868","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2018-01-829630","elsevierAuthor":"De Latour R.P.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"21"},{"title":"Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma","googleId":"broE9WU-_bkJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/502/81052","googleCitationCount":21,"googleAuthor":"R Mathur","doi":"10.1182/blood.V130.Suppl_1.502.502","elsevierCitationCount":0},{"title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","googleId":"W6F4YfnpBksJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1666/36825","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2017-10-772665","elsevierAuthor":"Bröckelmann P.","publicationName":"Blood","elsevierCoverDate":"2018-04-12","elsevierCoverDisplayDate":"12 April 2018","elsevierCitationCount":"13"},{"title":"Standardization of 18F-FDG PET/CT according to Deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined …","googleId":"PN0fpfYUP20J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/257/264029","googleCitationCount":16,"googleAuthor":"L Dozza","doi":"10.1182/blood-2018-99-111321","elsevierAuthor":"Paschali A.","publicationName":"European Journal of Nuclear Medicine and Molecular Imaging","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Evaluation of sustained minimal residual disease (MRD) negativity in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with daratumumab in …","googleId":"2NIu09rrPM8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/3272/264829","googleCitationCount":16,"googleAuthor":"JF San-Miguel","doi":"10.1182/blood-2018-99-113177","elsevierCitationCount":0},{"title":"Patients with CD3G mutations reveal a role for human CD3γ in Treg diversity and suppressive function","googleId":"8PAPwVL-8X0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/21/2335/37150","googleCitationCount":18,"googleAuthor":"JH Rowe","doi":"10.1182/blood-2018-02-835561","elsevierAuthor":"Rowe J.H.","publicationName":"Blood","elsevierCoverDate":"2018-05-24","elsevierCoverDisplayDate":"24 May 2018","elsevierCitationCount":"13"},{"title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","googleId":"ROt8KNrR17gJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1987/36751","googleCitationCount":23,"googleAuthor":"K Chen","doi":"10.1182/blood-2018-01-826495","elsevierAuthor":"Hammond S.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"14"},{"title":"CD20-Tcb (RG6026), a Novel 2: 1 Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's …","googleId":"0Ch-1tUN-DMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/226/261591","googleCitationCount":19,"googleAuthor":"M Hutchings","doi":"10.1182/blood-2018-99-110207","elsevierAuthor":"Cremasco F.","publicationName":"PLoS ONE","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0"},{"title":"Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients","googleId":"3ycGxuOrkLAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/24/2608/39539","googleCitationCount":16,"googleAuthor":"R Sklavenitis-Pistofidis","doi":"10.1182/blood-2018-07-863241","elsevierAuthor":"Sklavenitis-Pistofidis R.","publicationName":"Blood","elsevierCoverDate":"2018-12-13","elsevierCoverDisplayDate":"13 December 2018","elsevierCitationCount":"13"},{"title":"The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation","googleId":"9ms_RlAVRaQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/11/1336/36444","googleCitationCount":22,"googleAuthor":"DC Moreira","doi":"10.1182/blood-2016-12-758458","elsevierAuthor":"Mizukawa B.","publicationName":"Blood","elsevierCoverDate":"2017-09-14","elsevierCoverDisplayDate":"14 September 2017","elsevierCitationCount":"15"},{"title":"A phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as frontline therapy for adults with B-cell acute lymphoblastic leukemia (B …","googleId":"YmIcwypsNtcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/32/263589","googleCitationCount":17,"googleAuthor":"NJ Short","doi":"10.1182/blood-2018-99-117470","elsevierCitationCount":0},{"title":"Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia","googleId":"CjsQMKxVsEcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/1/35/36236","googleCitationCount":22,"googleAuthor":"","doi":"10.1182/blood-2017-03-771238","elsevierAuthor":"Del Padre M.","publicationName":"Blood","elsevierCoverDate":"2017-07-06","elsevierCoverDisplayDate":"6 July 2017","elsevierCitationCount":"17"},{"title":"Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria …","googleId":"CivyX6QAIe8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2314/261691","googleCitationCount":15,"googleAuthor":"P Deschatelets","doi":"10.1182/blood-2018-99-110827","elsevierCitationCount":0},{"title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid …","googleId":"LO72d8w_aBsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/690/266005","googleCitationCount":15,"googleAuthor":"A Rambaldi","doi":"10.1182/blood-2018-99-110388","elsevierCitationCount":0},{"title":"14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling","googleId":"6yNnbHXs6IEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2436/37082","googleCitationCount":16,"googleAuthor":"Y Chen","doi":"10.1182/blood-2017-09-742650","elsevierAuthor":"Chen Y.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"10"},{"title":"Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia","googleId":"RafapmwfW_QJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2888/263549","googleCitationCount":15,"googleAuthor":"JJ Castillo","doi":"10.1182/blood-2018-99-112325","elsevierCitationCount":0},{"title":"Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) …","googleId":"brWxstncHM0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1683/272963","googleCitationCount":18,"googleAuthor":"AF Herrera","doi":"10.1182/blood-2018-99-118551","elsevierCitationCount":0},{"title":"Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed …","googleId":"znUqApkxJukJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/553/263018","googleCitationCount":16,"googleAuthor":"K Sasaki","doi":"10.1182/blood-2018-99-115162","elsevierCitationCount":0},{"title":"Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1/2 ACE-CL-001 study","googleId":"qDM7bvia93wJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/692/266024","googleCitationCount":14,"googleAuthor":"JC Byrd","doi":"10.1182/blood-2018-99-110451","elsevierCitationCount":0},{"title":"Tissue tolerance: a distinct concept to control acute GVHD severity","googleId":"DcNFxVE_cnQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1747/35833","googleCitationCount":24,"googleAuthor":"P Reddy","doi":"10.1182/blood-2016-09-740431","elsevierAuthor":"Wu S.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"17"},{"title":"The believe trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red …","googleId":"Cl4HHHQJ5b4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/163/272861","googleCitationCount":18,"googleAuthor":"MD Cappellini","doi":"10.1182/blood-2018-163","elsevierCitationCount":0},{"title":"Nilotinib (Tasigna®) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a …","googleId":"zqT4CvBa0AYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/31/263951","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood-2018-99-114552","elsevierAuthor":"Chew S.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus …","googleId":"_oOWFxh2kJcJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/743/83661","googleCitationCount":22,"googleAuthor":"D Siegel","doi":"10.1182/blood.V130.Suppl_1.743.743","elsevierCitationCount":0},{"title":"Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies","googleId":"3jTCTFopp8oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/10/999/39303","googleCitationCount":14,"googleAuthor":"CC Oakes","doi":"10.1182/blood-2018-02-692970","elsevierAuthor":"Oakes C.","publicationName":"Blood","elsevierCoverDate":"2018-09-06","elsevierCoverDisplayDate":"6 September 2018","elsevierCitationCount":"10"},{"title":"Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma","googleId":"r7CkeVtsvSEJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2876/263920","googleCitationCount":18,"googleAuthor":"M Wang","doi":"10.1182/blood-2018-99-110327","elsevierCitationCount":0},{"title":"B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation","googleId":"uxtpRKWn6TEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2967/39148","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2017-10-809822","elsevierAuthor":"Miggelbrink A.M.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"14"},{"title":"LCL161, an oral Smac mimetic/IAP antagonist for patients with myelofibrosis (MF): novel translational findings among long-term responders in a phase 2 clinical trial","googleId":"v0rmMtvrEmAJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/687/265961","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood-2018-99-119753","elsevierCitationCount":0},{"title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","googleId":"rSzJx5pw0acJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1871/273136","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood-2018-99-109973","elsevierAuthor":"Badillo M.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0"},{"title":"REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to …","googleId":"A3r635WvPgwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1944/261532","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood-2018-99-112500","elsevierCitationCount":0},{"title":"Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome","googleId":"GbuSvKYDh68J","googleLink":"https://ashpublications.org/blood/article-abstract/129/21/2928/36266","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood-2016-11-745638","elsevierAuthor":"Hoenig M.","publicationName":"Blood","elsevierCoverDate":"2017-05-25","elsevierCoverDisplayDate":"25 May 2017","elsevierCitationCount":"20"},{"title":"Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous …","googleId":"7dibSzRC2MsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/817/83520","googleCitationCount":19,"googleAuthor":"M Bagot","doi":"10.1182/blood.V130.Suppl_1.817.817","elsevierCitationCount":0},{"title":"Transplant strategies in relapsed/refractory Hodgkin lymphoma","googleId":"hInpw9IGJhQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1689/36839","googleCitationCount":16,"googleAuthor":"GL Shah","doi":"10.1182/blood-2017-09-772673","elsevierAuthor":"Shah G.","publicationName":"Blood","elsevierCoverDate":"2018-04-12","elsevierCoverDisplayDate":"12 April 2018","elsevierCitationCount":"13"},{"title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","googleId":"qV_qrNM-HqEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1679/36837","googleCitationCount":16,"googleAuthor":"PWM Johnson","doi":"10.1182/blood-2017-09-772640","elsevierAuthor":"Lim S.H.","publicationName":"Blood","elsevierCoverDate":"2018-04-12","elsevierCoverDisplayDate":"12 April 2018","elsevierCitationCount":"11"},{"title":"Heterodimerization of TPO and IFNγ impairs human hematopoietic stem/progenitor cell signaling and survival in chronic inflammation","googleId":"AaH6XqoX0dUJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4/72032","googleCitationCount":23,"googleAuthor":"LJ Alvarado","doi":"10.1182/blood.V130.Suppl_1.4.4","elsevierCitationCount":0},{"title":"Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis","googleId":"_mQmIzU5C6cJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2088/39466","googleCitationCount":14,"googleAuthor":"A Worth","doi":"10.1182/blood-2018-01-827485","elsevierAuthor":"Lucchini G.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"11"},{"title":"Incidence of differentiation syndrome with ivosidenib (IVO) and enasidenib (ENA) for treatment of patients with relapsed or refractory (R/R) isocitrate dehydrogenase …","googleId":"Ox4IN6QpWdMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/288/263959","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2018-99-117426","elsevierCitationCount":0},{"title":"Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome","googleId":"XtCxpQ9FlxwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/19/2173/36901","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood-2017-07-795385","elsevierAuthor":"Ohwada C.","publicationName":"Blood","elsevierCoverDate":"2018-05-10","elsevierCoverDisplayDate":"10 May 2018","elsevierCitationCount":"10"},{"title":"Bortezomib, lenalidomide and dexamethasone (VRD-GEM) as induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results …","googleId":"-fgCRXNUYdsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2017/71490","googleCitationCount":19,"googleAuthor":"A Oriol","doi":"10.1182/blood.V130.Suppl_1.2017.2017","elsevierCitationCount":0},{"title":"Ruxopeg, a multi-center Bayesian phase 1/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with …","googleId":"n3gvQXDZuxcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/581/263204","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood-2018-99-110785","elsevierCitationCount":0},{"title":"A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib","googleId":"ZVkMvQNRiSUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/14/1676/107637","googleCitationCount":19,"googleAuthor":"AR Mato","doi":"10.1182/blood-2017-05-786988","elsevierAuthor":"Winter A.M.","publicationName":"Blood","elsevierCoverDate":"2017-10-05","elsevierCoverDisplayDate":"5 October 2017","elsevierCitationCount":"16"},{"title":"Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia","googleId":"IW4tUboBRGUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2767/80399","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2767.2767","elsevierCitationCount":0},{"title":"Treatment strategies for adolescent and young adult patients with acute myeloid leukemia","googleId":"WU1OlMhS9F4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/362/103887","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2017-12-778472","elsevierAuthor":"O’Dwyer K.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"11"},{"title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","googleId":"h7f_JjLAfKMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/670/39417","googleCitationCount":16,"googleAuthor":"MAV Willrich","doi":"10.1182/blood-2018-05-848986","elsevierAuthor":"Mills J.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"10"},{"title":"Histone acetyltransferase activity of MOF is required for adult but not early fetal hematopoiesis in mice","googleId":"Sekh6vL0W4sJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/1/48/35846","googleCitationCount":23,"googleAuthor":"","doi":"10.1182/blood-2016-05-714568","elsevierAuthor":"Valerio D.G.","publicationName":"Blood","elsevierCoverDate":"2017-01-05","elsevierCoverDisplayDate":"5 January 2017","elsevierCitationCount":"18"},{"title":"Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models","googleId":"daFVuIHxVgwJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/562/263035","googleCitationCount":13,"googleAuthor":"D Sharon","doi":"10.1182/blood-2018-99-119688","elsevierAuthor":"Becker J.S.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis","googleId":"Trwn0Yq1s8UJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/508/81242","googleCitationCount":20,"googleAuthor":"A Perrot","doi":"10.1182/blood.V130.Suppl_1.508.508","elsevierCitationCount":0},{"title":"The combination of duvelisib, a PI3K-δ, γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis …","googleId":"cinRKp0T6tkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/683/266410","googleCitationCount":13,"googleAuthor":"SM Horwitz","doi":"10.1182/blood-2018-99-115241","elsevierCitationCount":0},{"title":"miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients","googleId":"mm93Z6AFK50J","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2179/39502","googleCitationCount":16,"googleAuthor":"V Balatti","doi":"10.1182/blood-2018-04-845115","elsevierAuthor":"Balatti V.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"13"},{"title":"Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly …","googleId":"xMcWzeHCk2EJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/LBA-4/83700","googleCitationCount":19,"googleAuthor":"MV Mateos","doi":"10.1182/blood.V130.Suppl_1.LBA-4.LBA-4","elsevierCitationCount":0},{"title":"Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study","googleId":"92f7ncS6eckJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1490/79591","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1490.1490","elsevierCitationCount":0},{"title":"Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study","googleId":"PT8007jpvigJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2923/263955","googleCitationCount":13,"googleAuthor":"JM Zijlstra","doi":"10.1182/blood-2018-99-112235","elsevierCitationCount":0},{"title":"Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy","googleId":"zeS8Ux_el0sJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4121/72839","googleCitationCount":17,"googleAuthor":"J Svoboda","doi":"10.1182/blood.V130.Suppl_1.4121.4121","elsevierCitationCount":0},{"title":"A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study …","googleId":"WX7yNtLebA4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1377/116449","googleCitationCount":22,"googleAuthor":"BJP Huntly","doi":"10.1182/blood.V130.Suppl_1.1377.1377","elsevierCitationCount":0},{"title":"Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis","googleId":"xi4Nul3sAMEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1413/105721","googleCitationCount":15,"googleAuthor":"P Gopalasingam","doi":"10.1182/blood-2017-10-802975","elsevierAuthor":"Geer M.J.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"11"},{"title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269/AALL1521): dose …","googleId":"YYjfG3Icdm0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/555/263236","googleCitationCount":13,"googleAuthor":"SK Tasian","doi":"10.1182/blood-2018-99-110221","elsevierCitationCount":0},{"title":"MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice","googleId":"pRQIW9KXb9YJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1974/36765","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2017-06-789321","elsevierAuthor":"Wu Y.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"11"},{"title":"Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients","googleId":"xcmQSPThWYEJ","googleLink":"https://www.viridiantherapeutics.com/publications/2017/12/Phase-1-Study-of-the-Safety-and-Efficacy-of-MRG-106-a-Synthetic-Inhibitor-of-microRNA-155-in-CTCL-Patients.pdf","googleCitationCount":17,"googleAuthor":""},{"title":"BIVV001: the first investigational factor VIII therapy to break through the VWF ceiling in hemophilia A, with potential for extended protection for one week or longer","googleId":"tUeyQ6jDXsUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/636/266400","googleCitationCount":14,"googleAuthor":"A Shapiro","doi":"10.1182/blood-2018-99-113575","elsevierCitationCount":0},{"title":"Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?","googleId":"zYcgVd99zsIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/25/2619/39564","googleCitationCount":14,"googleAuthor":"SJ Cameron","doi":"10.1182/blood-2017-08-743237","elsevierAuthor":"Cameron S.","publicationName":"Blood","elsevierCoverDate":"2018-12-20","elsevierCoverDisplayDate":"20 December 2018","elsevierCitationCount":"6"},{"title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","googleId":"nTKsMZn8jkEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1452/105712","googleCitationCount":17,"googleAuthor":"N Russell","doi":"10.1182/blood-2018-05-851824","elsevierAuthor":"Russell N.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"15"},{"title":"Atezolizumab in combination with daratumumab with or without lenalidomide or pomalidomide: a phase Ib study in patients with multiple myeloma","googleId":"CLEDhu4VQXIJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/597/263467","googleCitationCount":12,"googleAuthor":"R Vij","doi":"10.1182/blood-2018-99-114960","elsevierCitationCount":0},{"title":"Duration of Deep Molecular Response Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia-Results …","googleId":"Y2cgh76ILh8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/313/80751","googleCitationCount":18,"googleAuthor":"J Richter","doi":"10.1182/blood.V130.Suppl_1.313.313","elsevierCitationCount":0},{"title":"Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate …","googleId":"GkquuG69-XkJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1510/79833","googleCitationCount":18,"googleAuthor":"SM Horwitz","doi":"10.1182/blood.V130.Suppl_1.1510.1510","elsevierCitationCount":0},{"title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","googleId":"y2JNLRyCfCIJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/19/2624/36163","googleCitationCount":19,"googleAuthor":"AR Cooper","doi":"10.1182/blood-2016-12-756734","elsevierAuthor":"Cooper A.","publicationName":"Blood","elsevierCoverDate":"2017-05-11","elsevierCoverDisplayDate":"11 May 2017","elsevierCitationCount":"16"},{"title":"A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome …","googleId":"jq2XFLkRcDoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4076/72833","googleCitationCount":18,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4076.4076","elsevierCitationCount":0},{"title":"Safety, efficacy, and biomarkers of response to azacitidine (AZA) with nivolumab (Nivo) and AZA with nivo and ipilimumab (Ipi) in relapsed/refractory acute myeloid …","googleId":"NUQSgWrYtJkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/906/266423","googleCitationCount":15,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood-2018-99-120157","elsevierCitationCount":0},{"title":"The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?","googleId":"owciG3ZdawAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/4/376/103907","googleCitationCount":14,"googleAuthor":"ML Metzger","doi":"10.1182/blood-2018-01-778548","elsevierAuthor":"Flerlage J.","publicationName":"Blood","elsevierCoverDate":"2018-07-26","elsevierCoverDisplayDate":"26 July 2018","elsevierCitationCount":"10"},{"title":"TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma","googleId":"mucfRRYM7AUJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/25/2789/37161","googleCitationCount":16,"googleAuthor":"M Słabicki","doi":"10.1182/blood-2017-09-806679","elsevierAuthor":"Jethwa A.","publicationName":"Blood","elsevierCoverDate":"2018-06-21","elsevierCoverDisplayDate":"21 June 2018","elsevierCitationCount":"11"},{"title":"Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?","googleId":"k7oXXKEJ1fQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/17/39265","googleCitationCount":15,"googleAuthor":"A Carbone","doi":"10.1182/blood-2018-02-833806","elsevierAuthor":"Carbone A.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"13"},{"title":"Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma","googleId":"PS4DC4dQGDsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/26/2744/39690","googleCitationCount":11,"googleAuthor":"L Thurner","doi":"10.1182/blood-2018-03-836932","elsevierAuthor":"Thurner L.","publicationName":"Blood","elsevierCoverDate":"2018-12-27","elsevierCoverDisplayDate":"27 December 2018","elsevierCitationCount":"8"},{"title":"GO-8: preliminary results of a phase I/II dose escalation trial of gene therapy for haemophilia a using a novel human factor VIII variant","googleId":"_8Bx7vZhE50J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/489/262419","googleCitationCount":14,"googleAuthor":"E Tuddenham","doi":"10.1182/blood-2018-99-118256","elsevierAuthor":"Arruda V.R.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Phase 2 trial of ixazomib, lenalidomide, dexamethasone and daratumumab in patients with newly diagnosed multiple myeloma","googleId":"QUaentiAaFsJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/304/263787","googleCitationCount":12,"googleAuthor":"E Muchtar","doi":"10.1182/blood-2018-99-111065","elsevierCitationCount":0},{"title":"Results of the randomized, double-blind, placebo-controlled, phase 3 Hercules study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura","googleId":"rsS0aVbbBTMJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/LBA-1/83673","googleCitationCount":21,"googleAuthor":"SR Cataland","doi":"10.1182/blood.V130.Suppl_1.LBA-1.LBA-1","elsevierCitationCount":0},{"title":"Daratumumab in combination with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma (RRMM) patients with≥ 2 prior lines of therapy …","googleId":"uecWcve-X3IJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1824/79552","googleCitationCount":16,"googleAuthor":"BM Weiss","doi":"10.1182/blood.V130.Suppl_1.1824.1824","elsevierCitationCount":0},{"title":"Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation","googleId":"v0rS3llUdZMJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/2/191/37024","googleCitationCount":19,"googleAuthor":"H Bai","doi":"10.1182/blood-2017-04-780379","elsevierAuthor":"Li Y.","publicationName":"Blood","elsevierCoverDate":"2018-01-11","elsevierCoverDisplayDate":"11 January 2018","elsevierCitationCount":"8"},{"title":"Perioperative anticoagulant use for surgery evaluation (PAUSE) study: a perioperative management plan for patients with atrial fibrillation who are receiving a direct …","googleId":"OksSQFUvy5cJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/LBA-5/375113","googleCitationCount":13,"googleAuthor":"J Douketis","doi":"10.1182/blood-2018-120770","elsevierCitationCount":0},{"title":"Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies","googleId":"RFQokmDOLtIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2815/80433","googleCitationCount":20,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2815.2815","elsevierCitationCount":0},{"title":"AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses","googleId":"PJsPl7KKMYQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/1/131/107701","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood-2017-02-768762","elsevierAuthor":"Gillissen M.","publicationName":"Blood","elsevierCoverDate":"2018-01-04","elsevierCoverDisplayDate":"4 January 2018","elsevierCitationCount":"9"},{"title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","googleId":"10JkLZC9TSAJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/804/266281","googleCitationCount":14,"googleAuthor":"M Bustoros","doi":"10.1182/blood-2018-99-117871","elsevierCitationCount":0},{"title":"CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","googleId":"RBJR55rBLl0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/6/577/39433","googleCitationCount":16,"googleAuthor":"A Patil","doi":"10.1182/blood-2018-01-828418","elsevierAuthor":"Patil A.","publicationName":"Blood","elsevierCoverDate":"2018-08-09","elsevierCoverDisplayDate":"9 August 2018","elsevierCitationCount":"12"},{"title":"A personalized prediction model to risk stratify patients with myelodysplastic syndromes","googleId":"FGPgsPlLeLkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/793/266156","googleCitationCount":15,"googleAuthor":"A Nazha","doi":"10.1182/blood-2018-99-114774","elsevierCitationCount":0},{"title":"FNDC3B is another novel partner fused to RARA in the t (3; 17)(q26; q21) variant of acute promyelocytic leukemia","googleId":"mZXbMvDmDs4J","googleLink":"https://ashpublications.org/blood/article-abstract/129/19/2705/36168","googleCitationCount":19,"googleAuthor":"","doi":"10.1182/blood-2017-02-767707","elsevierAuthor":"Cheng C.K.","publicationName":"Blood","elsevierCoverDate":"2017-05-11","elsevierCoverDisplayDate":"11 May 2017","elsevierCitationCount":"14"},{"title":"Two-year follow-up of keynote-087 study: pembrolizumab monotherapy in relapsed/refractory classic hodgkin lymphoma","googleId":"7Io1FAdfiM4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2900/263697","googleCitationCount":13,"googleAuthor":"PL Zinzani","doi":"10.1182/blood-2018-99-117045","elsevierCitationCount":0},{"title":"Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML) …","googleId":"AmhgHGo9bhsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/889/83356","googleCitationCount":16,"googleAuthor":"C Recher","doi":"10.1182/blood.V130.Suppl_1.889.889","elsevierCitationCount":0},{"title":"A phase I/Ib study of nivolumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation (alloHCT)","googleId":"C_uDzMCqSssJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/705/266170","googleCitationCount":12,"googleAuthor":"HT Kim","doi":"10.1182/blood-2018-99-117671","elsevierAuthor":"Thummalapalli R.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Silica particles contribute to the procoagulant activity of DNA and polyphosphate isolated using commercial kits","googleId":"XJeDJkIP14QJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/1/88/36216","googleCitationCount":18,"googleAuthor":"JH Morrissey","doi":"10.1182/blood-2017-03-772848","elsevierAuthor":"Smith S.","publicationName":"Blood","elsevierCoverDate":"2017-07-06","elsevierCoverDisplayDate":"6 July 2017","elsevierCitationCount":"14"},{"title":"Update on a phase II study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma","googleId":"w9XAWCxqXgQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/437/72787","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.437.437","elsevierCitationCount":0},{"title":"Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial","googleId":"a3ImEJAJ3zQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/484/72278","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.484.484","elsevierCitationCount":0},{"title":"Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T cell vector leads to a high objective response rate in …","googleId":"fxDfG4dMKKoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/742/83650","googleCitationCount":16,"googleAuthor":"S Mailankody","doi":"10.1182/blood.V130.Suppl_1.742.742","elsevierCitationCount":0},{"title":"Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress","googleId":"ulgNQmWFbnwJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/8/1031/36957","googleCitationCount":19,"googleAuthor":"A Pantaleo","doi":"10.1182/blood-2016-11-748053","elsevierAuthor":"Pantaleo A.","publicationName":"Blood","elsevierCoverDate":"2017-08-24","elsevierCoverDisplayDate":"24 August 2017","elsevierCitationCount":"14"},{"title":"How I treat the older adult with sickle cell disease","googleId":"yRYxtAzZ4T0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/17/1750/39513","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood-2018-03-818161","elsevierAuthor":"Thein S.L.","publicationName":"Blood","elsevierCoverDate":"2018-10-25","elsevierCoverDisplayDate":"25 October 2018","elsevierCitationCount":"7"},{"title":"Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia","googleId":"MjFi3l9Q0NcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1855/35845","googleCitationCount":21,"googleAuthor":"","doi":"10.1182/blood-2016-09-739334","elsevierAuthor":"Cao M.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"16"},{"title":"CA180-372: An international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive …","googleId":"pWF_xZzJ3zQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/98/83454","googleCitationCount":15,"googleAuthor":"M Devidas","doi":"10.1182/blood.V130.Suppl_1.98.98","elsevierCitationCount":0},{"title":"Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell …","googleId":"ekYJjfW9UUMJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/887/83335","googleCitationCount":16,"googleAuthor":"C Graham","doi":"10.1182/blood.V130.Suppl_1.887.887","elsevierCitationCount":0},{"title":"Emicizumab subcutaneous dosing every 4 weeks for the management of hemophilia A: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open …","googleId":"-Slgy2WQisgJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/86/83527","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.86.86","elsevierCitationCount":0},{"title":"Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from transcend …","googleId":"6vGQKnKuMnYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/300/263833","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood-2018-99-110462","elsevierAuthor":"Cortés-Hernández A.","publicationName":"Methods in Molecular Biology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1"},{"title":"Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (m IDH2) acute myeloid leukemia (AML)","googleId":"HIsR0dYlZ58J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/638/83396","googleCitationCount":18,"googleAuthor":"S De Botton","doi":"10.1182/blood.V130.Suppl_1.638.638","elsevierCitationCount":0},{"title":"A single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with …","googleId":"94bgMk5b6PUJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/631/266354","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood-2018-99-118050","elsevierAuthor":"Arruda V.R.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA)","googleId":"mpAG1zrcRBQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3623/264815","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2018-99-119468","elsevierCitationCount":0},{"title":"Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE)","googleId":"oGHoa_xzp3MJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/314/80808","googleCitationCount":17,"googleAuthor":"JV García Gutiérrez","doi":"10.1182/blood.V130.Suppl_1.314.314","elsevierCitationCount":0},{"title":"CD207+ CD1a+ cells circulate in pediatric patients with active Langerhans cell histiocytosis","googleId":"1iDQgRBwsewJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/17/1898/36511","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood-2017-05-782730","elsevierAuthor":"Silva E.A.C.","publicationName":"Blood","elsevierCoverDate":"2017-10-26","elsevierCoverDisplayDate":"26 October 2017","elsevierCitationCount":"11"},{"title":"A phase 2 study of actinium-225 (225Ac)-lintuzumab in older patients with previously untreated acute myeloid leukemia (AML) unfit for intensive chemotherapy","googleId":"ZOoe1aJfiloJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2638/79974","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2638.2638","elsevierCitationCount":0},{"title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. the EMN011 trial","googleId":"mU7cN3GAjtYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/801/266248","googleCitationCount":11,"googleAuthor":"M Cavo","doi":"10.1182/blood-2018-99-114029","elsevierCitationCount":0},{"title":"Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia","googleId":"JitPY_PTT7sJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/254/80241","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.254.254","elsevierCitationCount":0},{"title":"Nrf2 regulates CD4+ T cell–induced acute graft-versus-host disease in mice","googleId":"ZTvhVQW5_1UJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/26/2763/39706","googleCitationCount":9,"googleAuthor":"JJ Tsai","doi":"10.1182/blood-2017-10-812941","elsevierAuthor":"Tsai J.J.","publicationName":"Blood","elsevierCoverDate":"2018-12-27","elsevierCoverDisplayDate":"27 December 2018","elsevierCitationCount":"9"},{"title":"MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)","googleId":"a99hjAGxnDQJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/184/273230","googleCitationCount":12,"googleAuthor":"TJ Kipps","doi":"10.1182/blood-2018-184","elsevierCitationCount":0},{"title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study …","googleId":"FDiotPHI7DwJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/925/266183","googleCitationCount":12,"googleAuthor":"C Baues","doi":"10.1182/blood-2018-99-114519","elsevierCitationCount":0},{"title":"Current results of lentiglobin gene therapy in patients with severe sickle cell disease treated under a refined protocol in the phase 1 Hgb-206 study","googleId":"QBFcVIfFXyoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1026/262786","googleCitationCount":17,"googleAuthor":"MY Mapara","doi":"10.1182/blood-2018-99-113480","elsevierCitationCount":0},{"title":"Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice","googleId":"lK7LC6s6JM8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2188/39514","googleCitationCount":12,"googleAuthor":"V Radojcic","doi":"10.1182/blood-2018-03-841155","elsevierAuthor":"Radojcic V.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"9"},{"title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT","googleId":"TpqvARLzxKcJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/16/1846/36850","googleCitationCount":17,"googleAuthor":"","doi":"10.1182/blood-2017-09-805879","elsevierAuthor":"Berger G.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"11"},{"title":"Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis","googleId":"LPD9fDnan4MJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/23/2541/36947","googleCitationCount":15,"googleAuthor":"G Kleinstern","doi":"10.1182/blood-2017-11-814608","elsevierAuthor":"Kleinstern G.","publicationName":"Blood","elsevierCoverDate":"2018-06-07","elsevierCoverDisplayDate":"7 June 2018","elsevierCitationCount":"10"},{"title":"PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma","googleId":"YdLqT6pr0yUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4055/72601","googleCitationCount":15,"googleAuthor":"W Ding","doi":"10.1182/blood.V130.Suppl_1.4055.4055","elsevierCitationCount":0},{"title":"NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells","googleId":"jDhXCG6zXfwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/590/263209","googleCitationCount":11,"googleAuthor":"A Leivas","doi":"10.1182/blood-2018-99-114522","elsevierCitationCount":0},{"title":"Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma","googleId":"JFaUGZniZT8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1680/272925","googleCitationCount":11,"googleAuthor":"J Gauthier","doi":"10.1182/blood-2018-99-116745","elsevierCitationCount":0},{"title":"The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up …","googleId":"I2NAQH9Uu90J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/721/83399","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.721.721","elsevierCitationCount":0},{"title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid …","googleId":"ThDfFrQ99JYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/318/114734","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.318.318","elsevierCitationCount":0},{"title":"Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R","googleId":"7zLGBRufPyYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/188/71362","googleCitationCount":15,"googleAuthor":"JS Abramson","doi":"10.1182/blood.V130.Suppl_1.188.188","elsevierCitationCount":0},{"title":"Enhancer dysfunction in leukemia","googleId":"51ZzqdKmHQQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120322965","googleCitationCount":14,"googleAuthor":"AS Bhagwat","doi":"10.1182/blood-2017-11-737379","elsevierAuthor":"Bhagwat A.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"10"},{"title":"Every 2 weeks or every 4 weeks subcutaneous injection of emicizumab in pediatric patients with severe hemophilia a without inhibitors: a multi-center, open-label …","googleId":"VEE02vNsHhAJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1186/262605","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-115792","elsevierCitationCount":0},{"title":"HDP101, a novel B-cell maturation antigen (BCMA)-targeted antibody conjugated to α-Amanitin, is active against myeloma with preferential efficacy against pre …","googleId":"oPId81kBba8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/593/263463","googleCitationCount":11,"googleAuthor":"RK Singh","doi":"10.1182/blood-2018-99-118412","elsevierCitationCount":0},{"title":"Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first …","googleId":"mwOxW1aYTeAJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/596/263466","googleCitationCount":12,"googleAuthor":"MD Levin","doi":"10.1182/blood-2018-99-114668","elsevierCitationCount":0},{"title":"Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide/dexamethasone for relapsed multiple myeloma: results of the …","googleId":"QMtm3iHGIlkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/253/264089","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2018-99-111203","elsevierCitationCount":0},{"title":"Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA","googleId":"TYV8t0f2LVAJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/6/723/36306","googleCitationCount":22,"googleAuthor":"AA Thompson","doi":"10.1182/blood-2016-07-727719","elsevierAuthor":"Liem R.I.","publicationName":"Blood","elsevierCoverDate":"2017-02-09","elsevierCoverDisplayDate":"9 February 2017","elsevierCitationCount":"14"},{"title":"Murine pre–B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor","googleId":"ah8S6RV1IlwJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/18/1899/39617","googleCitationCount":11,"googleAuthor":"H Qin","doi":"10.1182/blood-2017-12-815548","elsevierAuthor":"Qin H.","publicationName":"Blood","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"1 November 2018","elsevierCitationCount":"5"},{"title":"Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the daliah trial …","googleId":"MZu9Z18lXn0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/580/263094","googleCitationCount":11,"googleAuthor":"DL Hansen","doi":"10.1182/blood-2018-99-111255","elsevierCitationCount":0},{"title":"101HEMB01 is a phase 1/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate/severe hemophilia B that demonstrated …","googleId":"KBJhsGvjf0QJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3331/114571","googleCitationCount":16,"googleAuthor":"S Pipe","doi":"10.1182/blood.V130.Suppl_1.3331.3331","elsevierCitationCount":0},{"title":"Maintaining perioperative hemostasis in patients with severe hemophilia A and inhibitors receiving emicizumab prophylaxis","googleId":"WH4E2FUxSJYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/635/266393","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-115089","elsevierCitationCount":0},{"title":"Molecular patterns of response and outcome in the chemotherapy and venetoclax in elderly AML trial (CAVEAT study)","googleId":"fPaBmYjO4A0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/333/264495","googleCitationCount":13,"googleAuthor":"AH Wei","doi":"10.1182/blood-2018-99-114243","elsevierAuthor":"Juárez-Salcedo L.","publicationName":"Drugs in Context","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"12"},{"title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","googleId":"SwXZ-D_9HmwJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3153/114444","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.3153.3153","elsevierCitationCount":0},{"title":"Clinical responses to CAR. CD30-T cells in patients with CD30+ lymphomas relapsed after multiple treatments including brentuximab vedotin","googleId":"tXv_yMc7RBkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/681/266391","googleCitationCount":13,"googleAuthor":"SI Park","doi":"10.1182/blood-2018-99-113534","elsevierCitationCount":0},{"title":"GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis","googleId":"x20LPNpI3roJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/7/908/37004","googleCitationCount":16,"googleAuthor":"M Suzuki","doi":"10.1182/blood-2016-12-756767","elsevierAuthor":"Katayama S.","publicationName":"Blood","elsevierCoverDate":"2017-08-17","elsevierCoverDisplayDate":"17 August 2017","elsevierCitationCount":"11"},{"title":"Phase 1 study of the IDH1m inhibitor FT-2102 as a single agent in patients with IDH1m acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","googleId":"W6xLTTwqKL8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1453/272864","googleCitationCount":12,"googleAuthor":"J Watts","doi":"10.1182/blood-2018-99-114263","elsevierAuthor":"Becker J.S.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature","googleId":"QAq67cSz3a0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/20/2154/39511","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-05-849893","elsevierAuthor":"Chapman M.A.","publicationName":"Blood","elsevierCoverDate":"2018-11-15","elsevierCoverDisplayDate":"15 November 2018","elsevierCitationCount":"7"},{"title":"OP-106 Horizon—melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide; updated results and first report on PFS","googleId":"BswtMgWUK-AJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/600/266001","googleCitationCount":11,"googleAuthor":"E Ocio","doi":"10.1182/blood-2018-99-113095","elsevierCitationCount":0},{"title":"Targeted therapy for fusion-driven high-risk acute leukemia","googleId":"ve2U1XlBe3QJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1241/39602","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-04-784157","elsevierAuthor":"Pikman Y.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"7"},{"title":"A mutation of the human EPHB2 gene leads to a major platelet functional defect","googleId":"N2xWvsFF7sMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2067/39483","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-04-845644","elsevierAuthor":"Berrou E.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"7"},{"title":"Updated safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma","googleId":"4zW3Ot9NmZsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1592/272930","googleCitationCount":10,"googleAuthor":"CS Tam","doi":"10.1182/blood-2018-99-117224","elsevierCitationCount":0},{"title":"Placental therapy: an insight to their biological and therapeutic properties","googleId":"p3va-Uuk-QgJ","googleLink":"https://www.researchgate.net/profile/Dmytro_Klokol2/publication/322873736_Placental_therapy_An_insight_to_their_biological_and_therapeutic_properties/links/5c90afaaa6fdcc38175cf47e/Placental-therapy-An-insight-to-their-biological-and-therapeutic-properties.pdf","googleCitationCount":16,"googleAuthor":"D Klokol"},{"title":"Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 study","googleId":"2JC83FCbWQAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/498/81070","googleCitationCount":17,"googleAuthor":"JC Byrd","doi":"10.1182/blood.V130.Suppl_1.498.498","elsevierCitationCount":0},{"title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","googleId":"mlGOjHSD5_oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/14/1519/39338","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2018-02-836437","elsevierAuthor":"Eichenauer D.","publicationName":"Blood","elsevierCoverDate":"2018-10-04","elsevierCoverDisplayDate":"4 October 2018","elsevierCitationCount":"10"},{"title":"Venous thromboembolism in cancer patients receiving immunotherapy","googleId":"tfyh3eeMgrEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2510/264382","googleCitationCount":10,"googleAuthor":"AS Kim","doi":"10.1182/blood-2018-99-116439","elsevierCitationCount":0},{"title":"The search for new antithrombotic mechanisms and therapies that may spare hemostasis","googleId":"Xa468UTcwKYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120322746","googleCitationCount":14,"googleAuthor":"Y Wang","doi":"10.1182/blood-2017-10-784074","elsevierAuthor":"Plow E.F.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"11"},{"title":"A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed/refractory Hodgkin …","googleId":"Z7DtFtSCMs0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1620/273257","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-118506","elsevierCitationCount":0},{"title":"Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective …","googleId":"qvOe-pEKOXoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/320/114497","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.320.320","elsevierCitationCount":0},{"title":"Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed/refractory non …","googleId":"G-DOMMLlJDUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1658/273195","googleCitationCount":13,"googleAuthor":"GP Collins","doi":"10.1182/blood-2018-99-115986","elsevierCitationCount":0},{"title":"Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease","googleId":"0TlOLJPsrbMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/601/266011","googleCitationCount":10,"googleAuthor":"NN Shah","doi":"10.1182/blood-2018-99-116342","elsevierCitationCount":0},{"title":"Activation of PPARγ by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia","googleId":"ITu_TezOVlQJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1802/35835","googleCitationCount":17,"googleAuthor":"DB Tukaramrao","doi":"10.1182/blood-2016-08-736405","elsevierAuthor":"Finch E.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"15"},{"title":"Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t (15; 17)(q22; q12)/PML-RARA","googleId":"y1oXBTRqL1EJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/8/935/104414","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood-2017-09-807370","elsevierAuthor":"Yao L.","publicationName":"Blood","elsevierCoverDate":"2018-02-22","elsevierCoverDisplayDate":"22 February 2018","elsevierCitationCount":"11"},{"title":"RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML","googleId":"gwLZ6apD-osJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2485/37075","googleCitationCount":11,"googleAuthor":"DGJ Cucchi","doi":"10.1182/blood-2017-12-819508","elsevierAuthor":"Cucchi D.G.J.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"9"},{"title":"Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma","googleId":"iKMQZdYD9i0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/152/79460","googleCitationCount":15,"googleAuthor":"CS Tam","doi":"10.1182/blood.V130.Suppl_1.152.152","elsevierCitationCount":0},{"title":"Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL","googleId":"ODa-XKRFbsYJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/4/421/38492","googleCitationCount":14,"googleAuthor":"E Leroy","doi":"10.1182/blood-2017-07-797597","elsevierAuthor":"Degryse S.","publicationName":"Blood","elsevierCoverDate":"2018-01-25","elsevierCoverDisplayDate":"25 January 2018","elsevierCitationCount":"9"},{"title":"EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice","googleId":"M_R8j2TFWJsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/23/2516/36778","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood-2017-07-796821","elsevierAuthor":"Fish K.","publicationName":"Blood","elsevierCoverDate":"2017-12-07","elsevierCoverDisplayDate":"7 December 2017","elsevierCitationCount":"7"},{"title":"Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody","googleId":"Eu6YCWhM7QAJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/500/80847","googleCitationCount":15,"googleAuthor":"M Balazs","doi":"10.1182/blood.V130.Suppl_1.500.500","elsevierCitationCount":0},{"title":"Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the myeloma XI study","googleId":"PGfElRWd7E8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/553/115718","googleCitationCount":15,"googleAuthor":"MW Jenner","doi":"10.1182/blood.V130.Suppl_1.553.553","elsevierCitationCount":0},{"title":"Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes …","googleId":"a7rYALnXA9QJ","googleLink":"https://ashpublications.org/blood/article/132/Suppl_1/351/264522","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-112017","elsevierCitationCount":0},{"title":"Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: an interim analysis","googleId":"qwFY55Lc7G0J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/481/72427","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.481.481","elsevierCitationCount":0},{"title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33/CD3 T-cell Engager, in patients with relapsed/refractory acute myeloid leukemia (AML)","googleId":"yIs_-YSAF7UJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1455/272888","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-111529","elsevierCitationCount":0},{"title":"Novel CD19/CD22 bicistronic chimeric antigen receptors outperform single or bivalent cars in eradicating CD19+ CD22+, CD19-, and CD22-pre-B leukemia","googleId":"3kc9jtqyRREJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/810/83439","googleCitationCount":16,"googleAuthor":"H Qin","doi":"10.1182/blood.V130.Suppl_1.810.810","elsevierCitationCount":0},{"title":"Neutrophils, NETs, and immunothrombosis","googleId":"gQWrQE0ji3sJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/13/1360/105710","googleCitationCount":11,"googleAuthor":"SP Grover","doi":"10.1182/blood-2018-08-868067","elsevierAuthor":"Grover S.","publicationName":"Blood","elsevierCoverDate":"2018-09-27","elsevierCoverDisplayDate":"27 September 2018","elsevierCitationCount":"6"},{"title":"Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3 …","googleId":"lBiqiewRKFwJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1436/262951","googleCitationCount":10,"googleAuthor":"AD Goldberg","doi":"10.1182/blood-2018-99-117016","elsevierCitationCount":0},{"title":"Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI≥ 40","googleId":"YQYYocBykkUJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1105/116251","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1105.1105","elsevierCitationCount":0},{"title":"How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation","googleId":"Gx1w-Nw9ProJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120327476","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood-2017-04-551606","elsevierAuthor":"Alvarnas J.","publicationName":"Blood","elsevierCoverDate":"2017-11-02","elsevierCoverDisplayDate":"2 November 2017","elsevierCitationCount":"12"},{"title":"AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin …","googleId":"741PclHY6gYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/445/275452","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2018-99-110861","elsevierCitationCount":0},{"title":"Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis","googleId":"LQCPNi7_kxAJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/15/79700","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.15.15","elsevierCitationCount":0},{"title":"Normal plasma IgG inhibits HIT antibody–mediated platelet activation: implications for therapeutic plasma exchange","googleId":"nbimHebxNb0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/6/703/39216","googleCitationCount":13,"googleAuthor":"CG Jones","doi":"10.1182/blood-2017-08-803031","elsevierAuthor":"Jones C.","publicationName":"Blood","elsevierCoverDate":"2018-02-08","elsevierCoverDisplayDate":"8 February 2018","elsevierCitationCount":"10"},{"title":"Integrated analysis of randomized controlled trials evaluating bortezomib+ lenalidomide+ dexamethasone or bortezomib+ thalidomide+ dexamethasone induction in …","googleId":"RXI4Tp3D0uUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3245/264523","googleCitationCount":12,"googleAuthor":"A Oriol","doi":"10.1182/blood-2018-99-112659","elsevierCitationCount":0},{"title":"The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo …","googleId":"v50bpSVZ3-UJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2580/80286","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2580.2580","elsevierCitationCount":0},{"title":"FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models","googleId":"dMUyN3Dv8lQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1348/116131","googleCitationCount":15,"googleAuthor":"RS Mali","doi":"10.1182/blood.V130.Suppl_1.1348.1348","elsevierCitationCount":0},{"title":"Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development","googleId":"4LA84_E6yS0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/12/1279/39659","googleCitationCount":8,"googleAuthor":"Q Wang","doi":"10.1182/blood-2018-02-835850","elsevierAuthor":"Wang Q.","publicationName":"Blood","elsevierCoverDate":"2018-09-20","elsevierCoverDisplayDate":"20 September 2018","elsevierCitationCount":"2"},{"title":"Nivolumab for relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT): extended follow-up of the …","googleId":"PFtnjbORk6cJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2897/263642","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-112067","elsevierCitationCount":0},{"title":"Flipping the switch: initial results of genetic targeting of the fetal to adult globin switch in sickle cell patients","googleId":"RlmiBO8I6SYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1023/262755","googleCitationCount":12,"googleAuthor":"C Brendel","doi":"10.1182/blood-2018-99-116733","elsevierCitationCount":0},{"title":"Improvement in global longitudinal strain (GLS) correlates with NT-Probnp response in patients with cardiac amyloidosis treated on a Phase 1b study of anti-amyloid …","googleId":"J4_y0D1zHwMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/958/266030","googleCitationCount":10,"googleAuthor":"MS Maurer","doi":"10.1182/blood-2018-99-118464","elsevierCitationCount":0},{"title":"DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis","googleId":"3aaUsNH9HSUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/17/1842/39486","googleCitationCount":10,"googleAuthor":"CK Ward-Caviness","doi":"10.1182/blood-2018-02-831347","elsevierAuthor":"Ward-Caviness C.K.","publicationName":"Blood","elsevierCoverDate":"2019-07-11","elsevierCoverDisplayDate":"11 July 2019","elsevierCitationCount":"0"},{"title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","googleId":"lxwK1I_N8r8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2729/264326","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-120170","elsevierCitationCount":0},{"title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes","googleId":"CnW_ETMm29oJ","googleLink":"https://isoplexis.com/wp-content/uploads/2019/01/ASH-2018-Moffitt-Poster.pdf","googleCitationCount":10,"googleAuthor":"G Li"},{"title":"Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia","googleId":"5FdryFPgDPsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/815/83499","googleCitationCount":13,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood.V130.Suppl_1.815.815","elsevierCitationCount":0},{"title":"CAR T cell therapy targeting G protein-coupled receptor class c group 5 member D (GPRC5D), a novel target for the immunotherapy of multiple myeloma","googleId":"qUkitJ__fBYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/589/263087","googleCitationCount":9,"googleAuthor":"M Staehr","doi":"10.1182/blood-2018-99-110471","elsevierCitationCount":0},{"title":"A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin …","googleId":"69CJ-Uli9e8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/679/266357","googleCitationCount":17,"googleAuthor":"F Hong","doi":"10.1182/blood-2018-99-115390","elsevierCitationCount":0},{"title":"Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study","googleId":"hQk0ihAuAPkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/682/266402","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-117848","elsevierCitationCount":0},{"title":"Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+ AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD …","googleId":"jjCWT3Eo9FYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/6/115772","googleCitationCount":14,"googleAuthor":"W Jurczak","doi":"10.1182/blood.V130.Suppl_1.6.6","elsevierCitationCount":0},{"title":"Remissions in relapse/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy","googleId":"qo6OmL0cHbYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/902/266381","googleCitationCount":10,"googleAuthor":"X Poire","doi":"10.1182/blood-2018-99-111326","elsevierCitationCount":0},{"title":"CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies","googleId":"ftBXyBKY53oJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/3/297/36918","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood-2016-12-756585","elsevierAuthor":"Al Sayed M.","publicationName":"Blood","elsevierCoverDate":"2017-07-20","elsevierCoverDisplayDate":"20 July 2017","elsevierCitationCount":"13"},{"title":"CX3CR1-dependent endothelial margination modulates Ly6Chigh monocyte systemic deployment upon inflammation in mice","googleId":"jjlWcAXjvh0J","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1296/36008","googleCitationCount":18,"googleAuthor":"P Hamon","doi":"10.1182/blood-2016-08-732164","elsevierAuthor":"Hamon P.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"16"},{"title":"Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA …","googleId":"4cewsxJw2nAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/824/83594","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.824.824","elsevierCitationCount":0},{"title":"Preliminary results from an ongoing phase 1/2 study of INCB057643, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced …","googleId":"WPVPNqdefasJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4048/72957","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4048.4048","elsevierCitationCount":0},{"title":"Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements","googleId":"sY_yD3XOBeQJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/95/266432","googleCitationCount":10,"googleAuthor":"FL Locke","doi":"10.1182/blood-2018-99-116539","elsevierCitationCount":0},{"title":"Synergistic activity of IDH1 inhibitor Bay-1436032 with azacitidine in IDH1 mutant acute myeloid leukemia","googleId":"OEc4rYFDk-cJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1352/116180","googleCitationCount":12,"googleAuthor":"R Gabdoulline","doi":"10.1182/blood.V130.Suppl_1.1352.1352","elsevierCitationCount":0},{"title":"Lentiglobin gene therapy for patients with transfusion-dependent β-thalassemia (TDT): results from the phase 3 Northstar-2 and Northstar-3 studies","googleId":"ktsQmXV7sIUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1025/262776","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood-2018-99-112667","elsevierCitationCount":0},{"title":"Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy","googleId":"XRtwoSMqbrMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/10/1397/36017","googleCitationCount":18,"googleAuthor":"EJ Duncavage","doi":"10.1182/blood-2016-10-745273","elsevierAuthor":"Duncavage E.J.","publicationName":"Blood","elsevierCoverDate":"2017-03-09","elsevierCoverDisplayDate":"9 March 2017","elsevierCitationCount":"15"},{"title":"PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis","googleId":"lqgTw1N9dY4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/466/262333","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-118577","elsevierCitationCount":0},{"title":"Lyra: a phase 2 study of daratumumab (Dara) plus cyclophosphamide, bortezomib, and dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with …","googleId":"nu7_nycvyOYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/152/273100","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-152","elsevierCitationCount":0},{"title":"Low levels of neurologic toxicity with retained anti-lymphoma activity in a phase I clinical trial of T cells expressing a novel anti-CD19 CAR","googleId":"nHnMtK7iKK4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/697/266071","googleCitationCount":9,"googleAuthor":"","doi":"10.1182/blood-2018-99-113731","elsevierCitationCount":0},{"title":"Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease","googleId":"i3r-5XOzJ30J","googleLink":"https://ashpublications.org/blood/article-abstract/131/18/2074/36730","googleCitationCount":11,"googleAuthor":"S Takahashi","doi":"10.1182/blood-2017-06-792614","elsevierAuthor":"Takahashi S.","publicationName":"Blood","elsevierCoverDate":"2018-05-03","elsevierCoverDisplayDate":"3 May 2018","elsevierCitationCount":"9"},{"title":"Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated …","googleId":"EdD7MRTxN6YJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1597/272983","googleCitationCount":12,"googleAuthor":"D Cunningham","doi":"10.1182/blood-2018-99-115167","elsevierCitationCount":0},{"title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor with a CD28 costimulatory moiety cause remissions of poor …","googleId":"V_hvik81N70J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/524/81176","googleCitationCount":13,"googleAuthor":"M Wang","doi":"10.1182/blood.V130.Suppl_1.524.524","elsevierCitationCount":0},{"title":"Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (BR): initial results of a prospective, randomized multicenter …","googleId":"Zw4THW0iO68J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/483/72172","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.483.483","elsevierCitationCount":0},{"title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells","googleId":"x_log1i6cKgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2957/263812","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-113744","elsevierCitationCount":0},{"title":"Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-naive and CAR-exposed children and young adults with …","googleId":"twYkEMQVNBkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1319/116300","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1319.1319","elsevierCitationCount":0},{"title":"Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity","googleId":"OfHeQaJe_eoJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/8/991/36351","googleCitationCount":17,"googleAuthor":"S Sebastian","doi":"10.1182/blood-2016-09-738872","elsevierAuthor":"Sebastian S.","publicationName":"Blood","elsevierCoverDate":"2017-02-23","elsevierCoverDisplayDate":"23 February 2017","elsevierCitationCount":"15"},{"title":"Patient data supports the rationale of low dose cyclophosphamide to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage …","googleId":"6GNZyszddg0J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/121/116003","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.121.121","elsevierCitationCount":0},{"title":"Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma","googleId":"9iX4W2h852oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2040/39473","googleCitationCount":13,"googleAuthor":"A Sud","doi":"10.1182/blood-2018-06-855296","elsevierAuthor":"Sud A.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"8"},{"title":"Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study","googleId":"KeFQYxRQjI4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/507/81135","googleCitationCount":17,"googleAuthor":"JM Sloan","doi":"10.1182/blood.V130.Suppl_1.507.507","elsevierCitationCount":0},{"title":"Results of inter-B-NHL Ritux 2010-phase II study of DA-EPOCH-R for children and adolescents with primary mediastinal large B-cell lymphoma (PMLBL) on behalf of …","googleId":"v_LnSO3xa4IJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4124/72864","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4124.4124","elsevierCitationCount":0},{"title":"Association of circulating transcriptomic profiles with mortality in sickle cell disease","googleId":"bUrripQFDVcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/22/3009/36050","googleCitationCount":15,"googleAuthor":"AA Desai","doi":"10.1182/blood-2016-11-752279","elsevierAuthor":"Desai A.A.","publicationName":"Blood","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"9"},{"title":"Phase 1/1b study of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, as monotherapy or in combination with cytarabine for the treatment of …","googleId":"zKJl4T6mf8IJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4066/265250","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-118780","elsevierAuthor":"Sabat-Pospiech D.","publicationName":"Biochemical Society Transactions","elsevierCoverDate":"2019-09-10","elsevierCoverDisplayDate":"10 September 2019","elsevierCitationCount":"2"},{"title":"Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort","googleId":"ULqEWIvOV4YJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/928/83326","googleCitationCount":14,"googleAuthor":"M Mullins","doi":"10.1182/blood.V130.Suppl_1.928.928","elsevierCitationCount":0},{"title":"FT-2102, an IDH1m inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) or myelodysplastic ayndrome (MDS): results from a phase …","googleId":"llMwJKjYD98J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1452/272851","googleCitationCount":11,"googleAuthor":"J Watts","doi":"10.1182/blood-2018-99-114126","elsevierAuthor":"Becker J.S.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia","googleId":"YAgfKAm1z_gJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/909/265985","googleCitationCount":9,"googleAuthor":"","doi":"10.1182/blood-2018-99-119806","elsevierCitationCount":0},{"title":"Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy","googleId":"AcfX9_BTc3wJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/4656/262290","googleCitationCount":8,"googleAuthor":"B Sahaf","doi":"10.1182/blood-2018-99-120206","elsevierCitationCount":0},{"title":"Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: results from the …","googleId":"r0BciICOgG8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%A01/799/266209","googleCitationCount":9,"googleAuthor":"DS Siegel","doi":"10.1182/blood-2018-99-112289","elsevierCitationCount":0},{"title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis","googleId":"8vUXBDchCFgJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/6/829/36800","googleCitationCount":16,"googleAuthor":"O Leiva","doi":"10.1182/blood-2017-04-777417","elsevierAuthor":"Abbonante V.","publicationName":"Blood","elsevierCoverDate":"2017-08-10","elsevierCoverDisplayDate":"10 August 2017","elsevierCitationCount":"9"},{"title":"Initial report of the beat AML umbrella study for previously untreated AML: evidence of feasibility and early success in molecularly driven phase 1 and 2 studies","googleId":"y4DV5_yKI5oJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/559/263190","googleCitationCount":10,"googleAuthor":"AS Mims","doi":"10.1182/blood-2018-99-118494","elsevierCitationCount":0},{"title":"Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with …","googleId":"uW0hmU_dkrAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4190/275507","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-113052","elsevierCitationCount":0},{"title":"Argx-110 targeting CD70, in combination with azacitidine, shows favorable safety profile and promising anti-leukemia activity in newly diagnosed AML patients in an …","googleId":"7tpT9tK-1DcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2680/264264","googleCitationCount":9,"googleAuthor":"C Riether","doi":"10.1182/blood-2018-99-118302","elsevierAuthor":"Madanat Y.F.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Multiple Myeloma in Russia (First Results of the Registration Trial)","googleId":"kSQufOpiu4gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/5408/115763","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.5408.5408","elsevierCitationCount":0},{"title":"Uproleselan (GMI-1271), an e-selectin antagonist, improves the efficacy and safety of chemotherapy in relapsed/refractory (r/r) and newly diagnosed older patients …","googleId":"HvbDJXnOwKUJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/331/264778","googleCitationCount":9,"googleAuthor":"BA Jonas","doi":"10.1182/blood-2018-99-114286","elsevierAuthor":"Cardoso B.A.","publicationName":"Advances in Experimental Medicine and Biology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Single cell resolution profiling defines the innate and adaptive immune repertoires modulated by daratumumab and IMiDs treatment in multiple myeloma (MM)","googleId":"6NSGCZDHOlkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/123/116220","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.123.123","elsevierCitationCount":0},{"title":"Lenalidomide maintenance therapy post-autologous stem cell transplant: a healthcare cost-impact analysis in Europe","googleId":"UZxEMsYRleIJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3405/114434","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.3405.3405","elsevierCitationCount":0},{"title":"Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): a detailed analysis from the phase 3 ECHELON-1 study","googleId":"5F7jRYWqd54J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1618/273225","googleCitationCount":10,"googleAuthor":"AM Evens","doi":"10.1182/blood-2018-99-112178","elsevierCitationCount":0},{"title":"Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123× CD3 bispecific DART® molecule, in patients with relapsed/refractory acute …","googleId":"0lep1rK61hcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/444/275837","googleCitationCount":9,"googleAuthor":"S Rutella","doi":"10.1182/blood-2018-99-111539","elsevierAuthor":"Sivaccumar J.","publicationName":"Current Medicinal Chemistry","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1"},{"title":"Extracellular galectins as controllers of cytokines in hematological cancer","googleId":"0LTsz10Tic8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/5/484/39380","googleCitationCount":8,"googleAuthor":"M Gordon-Alonso","doi":"10.1182/blood-2018-04-846014","elsevierAuthor":"Gordon-Alonso M.","publicationName":"Blood","elsevierCoverDate":"2018-08-02","elsevierCoverDisplayDate":"2 August 2018","elsevierCitationCount":"5"},{"title":"Hif-1α and Hif-2α regulate hemogenic endothelium and hematopoietic stem cell formation in zebrafish","googleId":"mncXKe6gsxEJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/9/963/39200","googleCitationCount":10,"googleAuthor":"C Gerri","doi":"10.1182/blood-2017-07-797795","elsevierAuthor":"Gerri C.","publicationName":"Blood","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"7"},{"title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of obinutuzumab-or …","googleId":"PWcRRarpvWcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/396/265038","googleCitationCount":10,"googleAuthor":"C Pott","doi":"10.1182/blood-2018-99-115930","elsevierCitationCount":0},{"title":"Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a multicenter …","googleId":"DCn4U8BhRt4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4315/72677","googleCitationCount":12,"googleAuthor":"AR Mato","doi":"10.1182/blood.V130.Suppl_1.4315.4315","elsevierCitationCount":0},{"title":"Imetelstat treatment leads to durable transfusion independence (TI) in RBC transfusion-dependent (TD), non-del (5q) lower risk MDS relapsed/refractory to …","googleId":"Ms6LHzfU3JsJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/463/261993","googleCitationCount":8,"googleAuthor":"DP Steensma","doi":"10.1182/blood-2018-99-114877","elsevierCitationCount":0},{"title":"Outcome of patients with myelofibrosis after ruxolitinib failure: role of disease status and treatment strategies in 214 patients","googleId":"BhQVIvhs2boJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/4277/275515","googleCitationCount":8,"googleAuthor":"EM Elli","doi":"10.1182/blood-2018-99-116289","elsevierCitationCount":0},{"title":"T cell costimulation blockade with abatacept nearly eliminates early severe acute graft versus host disease after HLA-mismatched (7/8 HLA matched) unrelated donor …","googleId":"PHMF2dk4gXAJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/212/71222","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.212.212","elsevierCitationCount":0},{"title":"ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for the treatment of multiple myeloma","googleId":"3-BR2I8PqvgJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/591/263328","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-119227","elsevierCitationCount":0},{"title":"Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia","googleId":"tZS6yDoDYJoJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/26/2929/39170","googleCitationCount":10,"googleAuthor":"F Seyfried","doi":"10.1182/blood-2017-10-813576","elsevierAuthor":"Wang F.","publicationName":"Blood","elsevierCoverDate":"2018-06-28","elsevierCoverDisplayDate":"28 June 2018","elsevierCitationCount":"7"},{"title":"Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies","googleId":"5obI6J35-eMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/228/261811","googleCitationCount":11,"googleAuthor":"SJ Rodig","doi":"10.1182/blood-2018-99-110220","elsevierCitationCount":0},{"title":"Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study","googleId":"hG3PQQ6ktZQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/467/72288","googleCitationCount":13,"googleAuthor":"C Thiede","doi":"10.1182/blood.V130.Suppl_1.467.467","elsevierCitationCount":0},{"title":"Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study","googleId":"HDyFyQ-wwE4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/155/79780","googleCitationCount":13,"googleAuthor":"M Wang","doi":"10.1182/blood.V130.Suppl_1.155.155","elsevierCitationCount":0},{"title":"Clinical outcomes up to 3 years following Lentiglobin gene therapy for transfusion-dependent β-thalassemia in the Northstar Hgb-204 study","googleId":"IlCtUracjzEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/360/71822","googleCitationCount":14,"googleAuthor":"AA Thompson","doi":"10.1182/blood.V130.Suppl_1.360.360","elsevierCitationCount":0},{"title":"Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia","googleId":"NMaiKSuy7R4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1298/262849","googleCitationCount":7,"googleAuthor":"A Contejean","doi":"10.1182/blood-2018-99-113359","elsevierCitationCount":0},{"title":"Efficacy and safety of ibrutinib (IBR) after venetoclax (VEN) treatment in IBR-naïve patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): follow …","googleId":"hm7fjr35BGgJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/5548/263219","googleCitationCount":10,"googleAuthor":"R Greil","doi":"10.1182/blood-2018-99-118148","elsevierCitationCount":0},{"title":"Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients: two-year update of …","googleId":"qV3J0WDioFcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3270/264807","googleCitationCount":10,"googleAuthor":"MV Mateos","doi":"10.1182/blood-2018-99-112554","elsevierCitationCount":0},{"title":"A retrospective review of tocilizumab for the management of blinatumomab (a bispecific T cell engager)-induced cytokine release syndrome (CRS)","googleId":"JSDs6kdF42UJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/5211/265497","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-117353","elsevierAuthor":"Conde-Royo D.","publicationName":"Drugs in Context","elsevierCoverDate":"2020-10-14","elsevierCoverDisplayDate":"14 October 2020","elsevierCitationCount":"0"},{"title":"Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open-label, phase 1b study","googleId":"LKQJmCBiaB4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1869/71246","googleCitationCount":12,"googleAuthor":"JF San-Miguel","doi":"10.1182/blood.V130.Suppl_1.1869.1869","elsevierCitationCount":0},{"title":"Phase I-IIa clinical trial to assess safety and efficacy of MLM-CAR44. 1, a CD44v6 directed CAR-T in relapsed/refractory acute myeloid leukemia (AML) and multiple …","googleId":"XpjjCNfR7BcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/5790/262976","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-117974","elsevierCitationCount":0},{"title":"Safety and efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed and refractory multiple myeloma: final results from GEN501 and SIRIUS","googleId":"W8NhwPcmpygJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3107/80480","googleCitationCount":12,"googleAuthor":"SZ Usmani","doi":"10.1182/blood.V130.Suppl_1.3107.3107","elsevierCitationCount":0},{"title":"Nivolumab treatment beyond investigator-assessed progression: extended follow-up in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 …","googleId":"-AC7NDB2lIgJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2932/263562","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-114502","elsevierCitationCount":0},{"title":"Anti-CD123 targeted therapy with Talacotuzumab in advanced MDS and AML after failing hypomethylating agents-final results of the Samba trial","googleId":"NKbL6lhlFxYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4045/265010","googleCitationCount":9,"googleAuthor":"AS Kubasch","doi":"10.1182/blood-2018-99-113112","elsevierCitationCount":0},{"title":"Granulocyte colony-stimulating factor mobilizes dormant hematopoietic stem cells without proliferation in mice","googleId":"TS9pIykJ7MsJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/14/1901/35865","googleCitationCount":15,"googleAuthor":"JM Bernitz","doi":"10.1182/blood-2016-11-752923","elsevierAuthor":"Bernitz J.","publicationName":"Blood","elsevierCoverDate":"2017-04-06","elsevierCoverDisplayDate":"6 April 2017","elsevierCitationCount":"13"},{"title":"Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not …","googleId":"DC71xGP8Q3oJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/554/263122","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-111516","elsevierCitationCount":0},{"title":"Successful Plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease","googleId":"5zFWh6zyB84J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/990/83588","googleCitationCount":16,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.990.990","elsevierCitationCount":0},{"title":"Updated results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple …","googleId":"r_C1IDoI-IoJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1982/261951","googleCitationCount":9,"googleAuthor":"","doi":"10.1182/blood-2018-99-116464","elsevierCitationCount":0},{"title":"A phase 2 study of the safety and efficacy of INCB050465, a selective PI3Kδ inhibitor, in combination with ruxolitinib in patients with myelofibrosis","googleId":"PkqJeEGJol4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/353/264722","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2018-99-111338","elsevierAuthor":"Barraco D.","publicationName":"Drugs in Context","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"0"},{"title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso (lo) Ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II …","googleId":"srCcdOogSJkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/926/266188","googleCitationCount":9,"googleAuthor":"A Fosså","doi":"10.1182/blood-2018-99-119363","elsevierAuthor":"Carter J.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0"},{"title":"Deep and durable responses with selinexor, daratumumab, and dexamethasome (SDd) in patients with multiple myeloma (MM) previously exposed to proteasome …","googleId":"61i_3CuFYrkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/599/265968","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-117201","elsevierCitationCount":0},{"title":"Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of …","googleId":"r_uSn8xQ71QJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/322/114732","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.322.322","elsevierCitationCount":0},{"title":"Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-Mind","googleId":"CKWSLBm9PTYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4123/72857","googleCitationCount":12,"googleAuthor":"GA Salles","doi":"10.1182/blood.V130.Suppl_1.4123.4123","elsevierCitationCount":0},{"title":"Gene therapy for Beta thalassemia: preliminary results from the PHASE I/II Tiget-Bthal trial of autologous hematopoietic stem cells genetically modified with GLOBE …","googleId":"M3SgJUkB7mQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/355/114670","googleCitationCount":15,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.355.355","elsevierCitationCount":0},{"title":"Endothelial CD99 supports arrest of mouse neutrophils in venules and binds to neutrophil PILRs","googleId":"v0KmlHH35e8J","googleLink":"https://ashpublications.org/blood/article-abstract/129/13/1811/35847","googleCitationCount":14,"googleAuthor":"D Goswami","doi":"10.1182/blood-2016-08-733394","elsevierAuthor":"Goswami D.","publicationName":"Blood","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"12"},{"title":"Preliminary safety profile of the CD19-directed defined composition CAR T cell product JCAR017 in relapsed/refractory aggressive B-NHL patients: potential for …","googleId":"otdJLRcwEeQJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1552/79812","googleCitationCount":11,"googleAuthor":"JS Abramson","doi":"10.1182/blood.V130.Suppl_1.1552.1552","elsevierCitationCount":0},{"title":"Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: long-term follow-up of the randomized European MCL elderly trial","googleId":"aQUmdiP_XHoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/153/79564","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.153.153","elsevierCitationCount":0},{"title":"Validation of clinical prognostic models and integration of genetic biomarkers of drug resistance in CLL patients treated with ibrutinib","googleId":"SkWta7wv4hIJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/186/266059","googleCitationCount":9,"googleAuthor":"IE Ahn","doi":"10.1182/blood-2018-99-110326","elsevierCitationCount":0},{"title":"Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product in a first-in-human trial (PALL) in pediatric patients with CD19+ relapsed/refractory …","googleId":"4govcajwEnUJ","googleLink":"https://www.cellectis.com/uploads/files/Poster_PALL_ASH.pdf","googleCitationCount":12,"googleAuthor":"W Qasim"},{"title":"ASXL1 mutations gain a function","googleId":"KLkVdimZQIQJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/274/38319","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2017-12-816595","elsevierAuthor":"Kitamura T.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"8"},{"title":"Results of pivotal phase 2 trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","googleId":"ZjSBOjmpDbUJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1298/116033","googleCitationCount":13,"googleAuthor":"AA Lane","doi":"10.1182/blood.V130.Suppl_1.1298.1298","elsevierCitationCount":0},{"title":"Pre-clinical evaluation of B7-H3-specific chimeric antigen receptor T-cells for the treatment of acute myeloid leukemia","googleId":"3NGo4HmN-tMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/701/266136","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-99-113468","elsevierCitationCount":0},{"title":"Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi","googleId":"GLY9QFyJsrAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/11/1357/36459","googleCitationCount":14,"googleAuthor":"ACY Chua","doi":"10.1182/blood-2017-02-764787","elsevierAuthor":"Kosaisavee V.","publicationName":"Blood","elsevierCoverDate":"2017-09-14","elsevierCoverDisplayDate":"14 September 2017","elsevierCitationCount":"10"},{"title":"Maintenance therapy with the oral proteasome inhibitor (PI) Ixazomib significantly prolongs progression-free survival (PFS) following autologous stem cell …","googleId":"G8QjtImBvNkJ","googleLink":"https://cms.cws.net/content/beta.myelomasociety.org/files/2018ash/Dimopoulos%20ixazomib%20MM3_ASH_21NOV2018.pdf","googleCitationCount":9,"googleAuthor":"MA Dimopoulos"},{"title":"Thymic epithelial cells require p53 to support their long-term function in thymopoiesis in mice","googleId":"nTsSrv_AVQEJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/4/478/37105","googleCitationCount":13,"googleAuthor":"PM Rodrigues","doi":"10.1182/blood-2016-12-758961","elsevierAuthor":"Rodrigues P.","publicationName":"Blood","elsevierCoverDate":"2017-07-27","elsevierCoverDisplayDate":"27 July 2017","elsevierCitationCount":"8"},{"title":"KD025-208: a phase 2a study of KD025 for patients with chronic graft versus host disease (cGVHD)—pharmacodynamics and updated results","googleId":"SlxCObhdyD4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/602/266021","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-111896","elsevierCitationCount":0},{"title":"Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses …","googleId":"K1d-Nah4ARcJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1071/116325","googleCitationCount":12,"googleAuthor":"MU Callaghan","doi":"10.1182/blood.V130.Suppl_1.1071.1071","elsevierCitationCount":0},{"title":"A randomized Phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: Gfm's' pick a winner'trial","googleId":"hOLQ7MI4GkUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/467/262450","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-111756","elsevierCitationCount":0},{"title":"Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 …","googleId":"7T2m8PYK0CUJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/650/83533","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.650.650","elsevierCitationCount":0},{"title":"Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma","googleId":"QjTjLz6qe44J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1595/272961","googleCitationCount":9,"googleAuthor":"M Dreyling","doi":"10.1182/blood-2018-99-114842","elsevierCitationCount":0},{"title":"Blinatumomab+ tyrosine kinase inhibitors with no chemotherapy in BCR-ABL-positive or IKZF1-deleted or FLT3-ITD-positive relapsed/refractory acute lymphoblastic …","googleId":"dAuChLrYu9YJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3884/71680","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.3884.3884","elsevierCitationCount":0},{"title":"Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute …","googleId":"f3Lx9-phGSoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2662/80251","googleCitationCount":10,"googleAuthor":"AD Goldberg","doi":"10.1182/blood.V130.Suppl_1.2662.2662","elsevierCitationCount":0},{"title":"The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma …","googleId":"On93ylD8tiUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1001/262522","googleCitationCount":10,"googleAuthor":"SM Horwitz","doi":"10.1182/blood-2018-99-119944","elsevierCitationCount":0},{"title":"Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia","googleId":"ABIKeNdt_0QJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/15/2148/36445","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2016-06-724658","elsevierAuthor":"Nakata Y.","publicationName":"Blood","elsevierCoverDate":"2017-04-13","elsevierCoverDisplayDate":"13 April 2017","elsevierCitationCount":"8"},{"title":"ALX148 is a high affinity SIRPα fusion protein that blocks CD47, enhances the activity of anti-cancer antibodies and checkpoint inhibitors, and has a favorable safety …","googleId":"CmMUui0E0DoJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/112/116420","googleCitationCount":11,"googleAuthor":"TC Kuo","doi":"10.1182/blood.V130.Suppl_1.112.112","elsevierCitationCount":0},{"title":"Outcomes for initial patient cohorts with up to 33 months of follow-up in the Hgb-206 phase 1 trial","googleId":"Rkt_1_Wwy0QJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1080/262893","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-113477","elsevierCitationCount":0},{"title":"LYMRIT 37-01: a phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin's …","googleId":"S0JNWfndX9IJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2879/263950","googleCitationCount":8,"googleAuthor":"A Kolstad","doi":"10.1182/blood-2018-99-110555","elsevierCitationCount":0},{"title":"Bone marrow–specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis","googleId":"2VPJ6F3pvAAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2053/39484","googleCitationCount":8,"googleAuthor":"N Ahsan","doi":"10.1182/blood-2018-05-848408","elsevierAuthor":"Chorzalska A.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"6"},{"title":"Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies","googleId":"-_Y7kN58GV8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1353/116192","googleCitationCount":13,"googleAuthor":"AD Goldberg","doi":"10.1182/blood.V130.Suppl_1.1353.1353","elsevierCitationCount":0},{"title":"Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector …","googleId":"kCQQaoR4gpMJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3124/80759","googleCitationCount":10,"googleAuthor":"NWCJ Van De Donk","doi":"10.1182/blood.V130.Suppl_1.3124.3124","elsevierCitationCount":0},{"title":"MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association","googleId":"tARFuLxHn80J","googleLink":"https://ashpublications.org/blood/article-abstract/131/22/2500/37073","googleCitationCount":9,"googleAuthor":"PK Mistry","doi":"10.1182/blood-2018-02-834689","elsevierAuthor":"Weinreb N.J.","publicationName":"Blood","elsevierCoverDate":"2018-05-31","elsevierCoverDisplayDate":"31 May 2018","elsevierCitationCount":"6"},{"title":"Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients","googleId":"GWHY0GIbKb0J","googleLink":"https://ashpublications.org/blood/article-abstract/131/15/1698/36823","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2017-09-772681","elsevierAuthor":"Mehta-Shah N.","publicationName":"Blood","elsevierCoverDate":"2018-04-12","elsevierCoverDisplayDate":"12 April 2018","elsevierCitationCount":"6"},{"title":"GMI-1271 improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: results of a phase 1/2 study","googleId":"qENZd8q7cjEJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/894/83419","googleCitationCount":10,"googleAuthor":"BA Jonas","doi":"10.1182/blood.V130.Suppl_1.894.894","elsevierCitationCount":0},{"title":"An integrated safety analysis of the next generation PI3Kδ inhibitor umbralisib (TGR-1202) in patients with relapsed/refractory lymphoid malignancies","googleId":"Ko3gOuHH-m8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4037/72838","googleCitationCount":11,"googleAuthor":"AR Mato","doi":"10.1182/blood.V130.Suppl_1.4037.4037","elsevierCitationCount":0},{"title":"Temporal autoregulation during human PU. 1 locus SubTAD formation","googleId":"biaJ8HjTmfEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/25/2643/39578","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-02-834721","elsevierAuthor":"Schuetzmann D.","publicationName":"Blood","elsevierCoverDate":"2018-12-20","elsevierCoverDisplayDate":"20 December 2018","elsevierCitationCount":"4"},{"title":"Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T …","googleId":"5W4YHG8vqZIJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/193/71441","googleCitationCount":10,"googleAuthor":"JS Abramson","doi":"10.1182/blood.V130.Suppl_1.193.193","elsevierCitationCount":0},{"title":"Immune mediated mechanisms of resistance to daratumumab","googleId":"bHJfCt5Bl7UJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3201/263617","googleCitationCount":8,"googleAuthor":"A Dona","doi":"10.1182/blood-2018-99-117441","elsevierCitationCount":0},{"title":"Dasatinib versus imatinib in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of …","googleId":"LOtXQUSc-VAJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/788/266093","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2018-99-111978","elsevierCitationCount":0},{"title":"Emicizumab for the treatment of acquired hemophilia_A: lessons learned from 4 very different cases","googleId":"-85moJq74ZcJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2476/263968","googleCitationCount":9,"googleAuthor":"P Schellongowski","doi":"10.1182/blood-2018-99-116973","elsevierAuthor":"Mazzucconi M.G.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Patient-reported and neurocognitive outcomes in patients treated with axicabtagene ciloleucel","googleId":"O9J5r5ufHMoJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2289/261910","googleCitationCount":7,"googleAuthor":"HSL Jim","doi":"10.1182/blood-2018-99-111711","elsevierCitationCount":0},{"title":"Interim results from the first-in-human clinical trial of Adct-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed …","googleId":"4K3GTsEu6XYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/398/265272","googleCitationCount":9,"googleAuthor":"J Radford","doi":"10.1182/blood-2018-99-116081","elsevierAuthor":"Sorensen E.P.","publicationName":"JAMA Dermatology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"0"},{"title":"Results from the US Life after Stopping TKIs (LAST) study","googleId":"aqJQfESa1zIJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2903/80477","googleCitationCount":10,"googleAuthor":"JP Radich","doi":"10.1182/blood.V130.Suppl_1.2903.2903","elsevierCitationCount":0},{"title":"Successful treatment of MYC rearrangement positive large B cell lymphoma patients with R-CHOP21 plus lenalidomide: results of a multicenter phase II HOVON trial","googleId":"pm5f8EPRJYMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/786/266075","googleCitationCount":8,"googleAuthor":"MED Chamuleau","doi":"10.1182/blood-2018-99-110240","elsevierCitationCount":0},{"title":"Phase-1 study of PF-114 mesylate in CML failing prior tyrosine kinase-inhibitor therapy","googleId":"9sTKEBws17sJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/790/266127","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-116803","elsevierCitationCount":0},{"title":"Effect of rituximab in primary central nervous system lymphoma-results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study","googleId":"cIsCMV854U4J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/582/115581","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.582.582","elsevierCitationCount":0},{"title":"Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti …","googleId":"WB7Leg7N9Q8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1365/116323","googleCitationCount":14,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1365.1365","elsevierCitationCount":0},{"title":"Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two phase …","googleId":"t-u4yyg-UsUJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/626/266288","googleCitationCount":7,"googleAuthor":"RA Brodsky","doi":"10.1182/blood-2018-99-110858","elsevierCitationCount":0},{"title":"Immunodepletion of MDSC by AMV564, a novel tetravalent bispecific CD33/CD3 T cell engager restores immune homeostasis in MDS in vitro","googleId":"5q7EKDGeDjQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/51/81009","googleCitationCount":12,"googleAuthor":"P Cheng","doi":"10.1182/blood.V130.Suppl_1.51.51","elsevierCitationCount":0},{"title":"Prospective multicenter phase 3 study comparing 5-azacytidine (5-aza) induction followed by allogeneic stem cell transplantation versus continuous 5-aza according …","googleId":"NpX-XwPMlDsJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/208/261557","googleCitationCount":7,"googleAuthor":"N Kroeger","doi":"10.1182/blood-2018-99-115932","elsevierCitationCount":0},{"title":"Acalabrutinib in patients with relapsed/refractory (R/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL)","googleId":"orNny3nfdL4J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4424/275670","googleCitationCount":8,"googleAuthor":"IE Ahn","doi":"10.1182/blood-2018-99-110395","elsevierCitationCount":0},{"title":"Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy","googleId":"tM3OdXRptWMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2015/261845","googleCitationCount":7,"googleAuthor":"A Lakshman","doi":"10.1182/blood-2018-99-115078","elsevierCitationCount":0},{"title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma","googleId":"tBiH6jOF2KoJ","googleLink":"http://eprints.whiterose.ac.uk/143614/1/Open-Label%2C%20Phase%202%20Study%20of%20Bli...Aggressive%20B-Cell%20Non-Hodgkin%20Lymphoma.pdf","googleCitationCount":8,"googleAuthor":"A Rambaldi"},{"title":"Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA","googleId":"rzZuelJXCNwJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/23/3126/36040","googleCitationCount":12,"googleAuthor":"M Nakamura","doi":"10.1182/blood-2016-06-721712","elsevierAuthor":"Kato I.","publicationName":"Blood","elsevierCoverDate":"2017-06-08","elsevierCoverDisplayDate":"8 June 2017","elsevierCitationCount":"8"},{"title":"Results from the Hgb-207 (Northstar-2) Trial: a phase 3 study to evaluate safety and efficacy of lentiglobin gene therapy for transfusion-dependent β-thalassemia (TDT …","googleId":"wlCwELMbmAAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/526/80904","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.526.526","elsevierCitationCount":0},{"title":"Safety and efficacy data for combined checkpoint inhibition with ipilimumab (Ipi) and nivolumab (Nivo) as consolidation following autologous stem cell transplantation …","googleId":"QPJMsAQBVOkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/256/264413","googleCitationCount":8,"googleAuthor":"R Korngold","doi":"10.1182/blood-2018-99-113586","elsevierCitationCount":0},{"title":"Updated phase 1 results of Zuma-3: Kte-C19, an anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed/refractory acute lymphoblastic …","googleId":"iqHVE5EAodcJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/897/266310","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-111531","elsevierCitationCount":0},{"title":"Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma …","googleId":"dCVZvqY7dsgJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/818/83528","googleCitationCount":12,"googleAuthor":"SK Barta","doi":"10.1182/blood.V130.Suppl_1.818.818","elsevierCitationCount":0},{"title":"Safety and efficacy of Adct-402 (Loncastuximab Tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma …","googleId":"LLCPAPTpZDEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2874/263899","googleCitationCount":8,"googleAuthor":"P Caimi","doi":"10.1182/blood-2018-99-118133","elsevierCitationCount":0},{"title":"Safety and preliminary clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed …","googleId":"JPdJq2Fq210J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1550/79791","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.1550.1550","elsevierCitationCount":0},{"title":"Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance is a safe …","googleId":"SZhY4GAaf2QJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2021/71531","googleCitationCount":10,"googleAuthor":"A Perrot","doi":"10.1182/blood.V130.Suppl_1.2021.2021","elsevierCitationCount":0},{"title":"A phase Ib study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCDI) in patients with newly diagnosed multiple myeloma …","googleId":"2hOLQAd5pOsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/3160/114539","googleCitationCount":9,"googleAuthor":"EM Ocio","doi":"10.1182/blood.V130.Suppl_1.3160.3160","elsevierCitationCount":0},{"title":"Front-line ibrutinib therapy for chronic lymphocytic leukemia (CLL) in the real world: responses, toxicity, outcomes and subsequent therapies","googleId":"E2rHa1_j8l4J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3011/80746","googleCitationCount":10,"googleAuthor":"AR Mato","doi":"10.1182/blood.V130.Suppl_1.3011.3011","elsevierCitationCount":0},{"title":"A randomized, double-blind, placebo-controlled phase 1 study of the pharmacokinetics and pharmacodynamics of REGN3918, a human antibody against complement …","googleId":"274ZQq446eIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1039/262930","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-112262","elsevierCitationCount":0},{"title":"Durable responses observed with JAK inhibition in T-cell lymphomas","googleId":"UZjtDdiN3_MJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2922/263945","googleCitationCount":8,"googleAuthor":"JH Schatz","doi":"10.1182/blood-2018-99-112123","elsevierCitationCount":0},{"title":"Study of AUTO3, the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22, followed by anti-PD1 consolidation in patients with relapsed/refractory …","googleId":"sPlf185ZpDkJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1679/272906","googleCitationCount":7,"googleAuthor":"M Al-Hajj","doi":"10.1182/blood-2018-99-119197","elsevierCitationCount":0},{"title":"Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis","googleId":"o2J09wx4aSoJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/5/653/36139","googleCitationCount":14,"googleAuthor":"DL Tao","doi":"10.1182/blood-2016-10-747931","elsevierAuthor":"Tao D.","publicationName":"Blood","elsevierCoverDate":"2017-02-02","elsevierCoverDisplayDate":"2 February 2017","elsevierCitationCount":"11"},{"title":"Preference for emicizumab over prior factor treatments: results from the HAVEN 3 and HAVEN 4 studies","googleId":"MasJUbiiWuMJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1187/262613","googleCitationCount":6,"googleAuthor":"I Paz-Priel","doi":"10.1182/blood-2018-99-118132","elsevierCitationCount":0},{"title":"Disparities in survival by insurance status in follicular lymphoma","googleId":"LV-T6381k84J","googleLink":"https://ashpublications.org/blood/article-abstract/132/11/1159/39365","googleCitationCount":9,"googleAuthor":"X Han","doi":"10.1182/blood-2018-03-839035","elsevierAuthor":"Goldstein J.","publicationName":"Blood","elsevierCoverDate":"2018-09-13","elsevierCoverDisplayDate":"13 September 2018","elsevierCitationCount":"8"},{"title":"Impact of bortezomib-or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma …","googleId":"xNEC15tPatAJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/744/83672","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.744.744","elsevierCitationCount":0},{"title":"HLH: genomics illuminates pathophysiological diversity","googleId":"TTCWnf1fqM0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/1/5/39284","googleCitationCount":8,"googleAuthor":"B Tesi","doi":"10.1182/blood-2018-05-845818","elsevierAuthor":"Tesi B.","publicationName":"Blood","elsevierCoverDate":"2018-07-05","elsevierCoverDisplayDate":"5 July 2018","elsevierCitationCount":"4"},{"title":"Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) …","googleId":"9X98QjCTLe8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/2806/80358","googleCitationCount":9,"googleAuthor":"AJ Cowan","doi":"10.1182/blood.V130.Suppl_1.2806.2806","elsevierCitationCount":0},{"title":"Frequency of PAR4 Ala120Thr variant associated with platelet reactivity significantly varies across sub-Saharan African populations","googleId":"8fd-4b1p6y0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/19/2103/39471","googleCitationCount":6,"googleAuthor":"TL Lindahl","doi":"10.1182/blood-2018-05-852335","elsevierAuthor":"Heenkenda M.K.","publicationName":"Blood","elsevierCoverDate":"2018-11-08","elsevierCoverDisplayDate":"8 November 2018","elsevierCitationCount":"7"},{"title":"Daratumumab monotherapy for patients with relapsed or refractory (R/R) natural killer/T-cell lymphoma (NKTCL), nasal type: an open-label, single-arm, multicenter …","googleId":"Sbkom2KEnXYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1617/273215","googleCitationCount":7,"googleAuthor":"WS Kim","doi":"10.1182/blood-2018-99-111885","elsevierCitationCount":0},{"title":"Radiotherapy priming chimeric antigen receptor T cell therapy is a safe and promising approach in relapsed/refractory diffuse large B cell lymphoma patients with high …","googleId":"Uwal8ZcL48oJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2961/263859","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-113979","elsevierCitationCount":0},{"title":"Daratumumab efficiently targets NK/T cell lymphoma with high CD38 expression","googleId":"TpmJVz5PMrkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2814/80426","googleCitationCount":12,"googleAuthor":"N Mustafa","doi":"10.1182/blood.V130.Suppl_1.2814.2814","elsevierCitationCount":0},{"title":"FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid …","googleId":"QniLgfHhB_gJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2800/263578","googleCitationCount":6,"googleAuthor":"C Thiede","doi":"10.1182/blood-2018-99-112127","elsevierCitationCount":0},{"title":"Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells","googleId":"TuJdbbgCvd4J","googleLink":"https://ashpublications.org/blood/article-abstract/131/16/1833/36846","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2017-05-787226","elsevierAuthor":"Shima H.","publicationName":"Blood","elsevierCoverDate":"2018-04-19","elsevierCoverDisplayDate":"19 April 2018","elsevierCitationCount":"6"},{"title":"Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine","googleId":"CX287NdligEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/7/761/39436","googleCitationCount":9,"googleAuthor":"","doi":"10.1182/blood-2018-04-846493","elsevierAuthor":"Manwani R.","publicationName":"Blood","elsevierCoverDate":"2018-08-16","elsevierCoverDisplayDate":"16 August 2018","elsevierCitationCount":"7"},{"title":"Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t (11; 14) relapsed/refractory multiple myeloma","googleId":"nZ3xgk3rEBcJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3131/80767","googleCitationCount":10,"googleAuthor":"JL Kaufman","doi":"10.1182/blood.V130.Suppl_1.3131.3131","elsevierCitationCount":0},{"title":"Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: a pooled analysis","googleId":"k4HQajZ9X_IJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/151/79823","googleCitationCount":10,"googleAuthor":"M Dreyling","doi":"10.1182/blood.V130.Suppl_1.151.151","elsevierCitationCount":0},{"title":"Ibrutinib and fungus: an invasive concern","googleId":"ltz8st7pXK8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/17/1882/36762","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-02-832154","elsevierAuthor":"Rogers K.","publicationName":"Blood","elsevierCoverDate":"2018-04-26","elsevierCoverDisplayDate":"26 April 2018","elsevierCitationCount":"7"},{"title":"Mutation-enhanced international prognostic systems for essential thrombocythemia (MIPSS-ET) and polycythemia vera (MIPSS-PV)","googleId":"3vQRfNjEX2sJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/578/263344","googleCitationCount":7,"googleAuthor":"P Guglielmelli","doi":"10.1182/blood-2018-99-109715","elsevierCitationCount":0},{"title":"Long-term follow-up of SWOG S0816: Response-adapted therapy for stage III/IV Hodgkin Lymphoma demonstrates limitations of PET-adapted approach","googleId":"xXWsaoGtQAAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/929/266214","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-113034","elsevierCitationCount":0},{"title":"The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial","googleId":"HauUETMFZ5gJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/2/214/36717","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood-2017-01-759258","elsevierAuthor":"Kelly A.M.","publicationName":"Blood","elsevierCoverDate":"2017-07-13","elsevierCoverDisplayDate":"13 July 2017","elsevierCitationCount":"8"},{"title":"A single autologous stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) patients. Safety …","googleId":"HcUsG23K6DkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2153/261875","googleCitationCount":6,"googleAuthor":"K Nadiminti","doi":"10.1182/blood-2018-99-118443","elsevierCitationCount":0},{"title":"No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the …","googleId":"aPmnI7URzNUJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/783/266048","googleCitationCount":6,"googleAuthor":"DJ Culligan","doi":"10.1182/blood-2018-99-116845","elsevierCitationCount":0},{"title":"Venetoclax (Ven) with Azacitidine (Aza) for untreated elderly Acute Myeloid Leukemia (AML) Patients (Pts) unfit for induction chemotherapy: Single center clinical …","googleId":"bRmCuR4JFxcJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/181/79391","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.181.181","elsevierCitationCount":0},{"title":"Long term efficacy, safety and PK/PD profile of the anti-C1s antibody (BIVV009) in primary cold agglutinin disease patients","googleId":"LQPb2LZlCSkJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/703/83662","googleCitationCount":11,"googleAuthor":"U Jaeger","doi":"10.1182/blood.V130.Suppl_1.703.703","elsevierCitationCount":0},{"title":"Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or-refractory patients with relapsed/refractory multiple myeloma …","googleId":"1cYbZZ0NqqMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3288/264510","googleCitationCount":9,"googleAuthor":"SZ Usmani","doi":"10.1182/blood-2018-99-112669","elsevierCitationCount":0},{"title":"Spirit 2: final 5 year analysis of the UK national cancer research institute randomized study comparing imatinib with dasatinib in patients with newly diagnosed chronic …","googleId":"99KJ2TaCDakJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/457/275807","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-110128","elsevierAuthor":"Clark R.E.","publicationName":"British Journal of Haematology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0"},{"title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia (AML): results from the prospective randomized AMLSG 09-09 phase-iii study","googleId":"5JBhlT2CT5MJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/81/266344","googleCitationCount":6,"googleAuthor":"RF Schlenk","doi":"10.1182/blood-2018-99-113442","elsevierCitationCount":0},{"title":"Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial","googleId":"Ih52cHgR0-cJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3005/263897","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-110543","elsevierAuthor":"Copland M.","publicationName":"Current Hematologic Malignancy Reports","elsevierCoverDate":"2019-08-15","elsevierCoverDisplayDate":"15 August 2019","elsevierCitationCount":"4"},{"title":"Benefits and limitations of long-term eculizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH): Real-world data from large cohort study in Russia","googleId":"yBMN0evgOYsJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2589/264219","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-99-120139","elsevierAuthor":"Tarasova Y.V.","publicationName":"Gematologiya i Transfusiologiya","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"The SMART Anti-hC5 antibody (SKY59/RO7112689) shows good safety and efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","googleId":"BsSDoMlrBKQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/535/265551","googleCitationCount":6,"googleAuthor":"Z Nagy","doi":"10.1182/blood-2018-99-113274","elsevierCitationCount":0},{"title":"Enrollment of older adults in clinical trials evaluating patients with hematologic malignancies-the Food and Drug Administration (FDA) experience","googleId":"HiV743RpS2YJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/861/83583","googleCitationCount":11,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.861.861","elsevierCitationCount":0},{"title":"High Prevalence of BTK Mutations on ibrutinib therapy after 3 years of treatment in a real-life cohort of CLL patients: a study from the French Innovative Leukemia …","googleId":"26o8Jb3a8ZQJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/584/263038","googleCitationCount":8,"googleAuthor":"LM Fornecker","doi":"10.1182/blood-2018-99-114027","elsevierCitationCount":0},{"title":"Incidence of vascular thromboembolic events in patients receiving immunotherapy: A single institution experience","googleId":"f5wd1ZbHSiYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4864/72519","googleCitationCount":12,"googleAuthor":"M Machiorlatti","doi":"10.1182/blood.V130.Suppl_1.4864.4864","elsevierCitationCount":0},{"title":"Durability of responses on continuous therapy and following drug cessation in deep responders with venetoclax and rituximab","googleId":"e1zblRtM4c0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/183/273119","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-183","elsevierCitationCount":0},{"title":"Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function","googleId":"dKaVMfYKhRMJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/6/799/36331","googleCitationCount":14,"googleAuthor":"NA Bello","doi":"10.1182/blood-2016-08-705541","elsevierAuthor":"Bello N.A.","publicationName":"Blood","elsevierCoverDate":"2017-02-09","elsevierCoverDisplayDate":"9 February 2017","elsevierCitationCount":"9"},{"title":"Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL), diffuse large B-cell …","googleId":"4KokDyuEXBQJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1690/273046","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-113328","elsevierCitationCount":0},{"title":"Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL","googleId":"bWSeOnzCrqcJ","googleLink":"https://ashpublications.org/blood/article-abstract/129/2/188/36078","googleCitationCount":12,"googleAuthor":"LT Chen","doi":"10.1182/blood-2016-04-713719","elsevierAuthor":"Kuo S.H.","publicationName":"Blood","elsevierCoverDate":"2017-01-12","elsevierCoverDisplayDate":"12 January 2017","elsevierCitationCount":"11"},{"title":"A phase 1 dose escalation study of ARQ 531 in selected patients with relapsed or refractory hematologic malignancies","googleId":"42dLdmS7PcIJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/3136/263890","googleCitationCount":7,"googleAuthor":"FT Awan","doi":"10.1182/blood-2018-99-116338","elsevierCitationCount":0},{"title":"A phase 1/2 study of oral 5-azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T-cell …","googleId":"tP5gC-qKhfsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1515/79408","googleCitationCount":9,"googleAuthor":"L Falchi","doi":"10.1182/blood.V130.Suppl_1.1515.1515","elsevierCitationCount":0},{"title":"Sequential CD19-and CD22-CART cell therapies for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","googleId":"PAdc6C84TD8J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2126/261582","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-111856","elsevierCitationCount":0},{"title":"Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (rux) with best available therapy (BAT) in hydroxyurea (HU)-resistant …","googleId":"9cmEa1moZmYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1753/273242","googleCitationCount":7,"googleAuthor":"F Pane","doi":"10.1182/blood-2018-99-115129","elsevierAuthor":"Griesshammer M.","publicationName":"Annals of Hematology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"10"},{"title":"Results from the phase 3 DUOTM trial: a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or …","googleId":"1i-7bRp-fJQJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/493/80997","googleCitationCount":9,"googleAuthor":"P Hillmen","doi":"10.1182/blood.V130.Suppl_1.493.493","elsevierCitationCount":0},{"title":"Aspirin may be inadequate thromboprophylaxis in multiple myeloma","googleId":"S43pKKi_z7EJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3419/114607","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.3419.3419","elsevierCitationCount":0},{"title":"Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and …","googleId":"r57u0OxTWMEJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/927/266199","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-111279","elsevierCitationCount":0},{"title":"Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis","googleId":"lD1s2lZ8OJwJ","googleLink":"https://ashpublications.org/blood/article-abstract/131/3/365/38296","googleCitationCount":14,"googleAuthor":"D Giannarelli","doi":"10.1182/blood-2017-09-806034","elsevierAuthor":"Molica S.","publicationName":"Blood","elsevierCoverDate":"2018-01-18","elsevierCoverDisplayDate":"18 January 2018","elsevierCitationCount":"7"},{"title":"A novel point-of-care whole blood coagulation assay to monitor emicizumab therapy in patients with hemophilia","googleId":"FVeepYAuUm0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/2475/264456","googleCitationCount":6,"googleAuthor":"MA Suster","doi":"10.1182/blood-2018-99-113623","elsevierCitationCount":0},{"title":"Double blind randomized control trial of postoperative low molecular weight heparin bridging therapy for patients who are at high risk for arterial thromboembolism …","googleId":"4lvNyMp2cGEJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/424/275575","googleCitationCount":7,"googleAuthor":"M Rodger","doi":"10.1182/blood-2018-99-109964","elsevierCitationCount":0},{"title":"Phase II study of high dose cytarabine followed by pembrolizumab in relapsed/refractory acute myeloid leukemia (AML)","googleId":"YCdsxMKyoPwJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1349/116142","googleCitationCount":11,"googleAuthor":"JF Zeidner","doi":"10.1182/blood.V130.Suppl_1.1349.1349","elsevierCitationCount":0},{"title":"Phase 1 results of ZUMA-3: KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with relapsed/refractory acute lymphoblastic …","googleId":"tk0kjOs-h5EJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/888/83345","googleCitationCount":9,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.888.888","elsevierCitationCount":0},{"title":"Baseline suvmax did not predict histological transformation from follicular lymphoma to aggressive lymphoma in the phase III GALLIUM study","googleId":"oV24HwMwyyYJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4160/275688","googleCitationCount":9,"googleAuthor":"SF Barrington","doi":"10.1182/blood-2018-99-116686","elsevierCitationCount":0},{"title":"Hematopoietic stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections","googleId":"_bPIQ-_kgi8J","googleLink":"https://ashpublications.org/blood/article-abstract/131/5/533/104434","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood-2017-10-812859","elsevierAuthor":"Hetzel M.","publicationName":"Blood","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"6"},{"title":"Effect of ropeginterferon alfa-2b in prefibrotic primary myelofibrosis","googleId":"Ent2ZbVJmb8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3029/263666","googleCitationCount":6,"googleAuthor":"M Schalling","doi":"10.1182/blood-2018-99-119268","elsevierCitationCount":0},{"title":"GWAS of osmotic hemolysis in 12,352 healthy blood donors identifies red cell genetic variants associated with steady state hemolysis in patients with sickle cell …","googleId":"RJ6F2IQ6i-sJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1117/116387","googleCitationCount":8,"googleAuthor":"G Page","doi":"10.1182/blood.V130.Suppl_1.1117.1117","elsevierCitationCount":0},{"title":"Mass cytometry of Hodgkin lymphoma reveals a CD4 (+) exhausted T-effector and T-regulatory cell rich microenvironment","googleId":"Kw4xxlM5mpMJ","googleLink":"http://shipplab.dfci.harvard.edu/wp-content/uploads/2018/06/Blood-2018-04-843714-full.pdf","googleCitationCount":8,"googleAuthor":"X Hu"},{"title":"Anti-CD30 chimeric antigen receptor T cell therapy for CD30+ relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients","googleId":"eEDHX4Z4RYYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1660/273228","googleCitationCount":7,"googleAuthor":"L Huang","doi":"10.1182/blood-2018-99-116741","elsevierCitationCount":0},{"title":"Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy","googleId":"Y9cWbhftBuAJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/4022/265257","googleCitationCount":8,"googleAuthor":"R Gardner","doi":"10.1182/blood-2018-99-117493","elsevierCitationCount":0},{"title":"Management of joint replacement in hemophilia A with inhibitors during emicizumab prophylaxis","googleId":"qALaC3ojrskJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2360/80230","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2360.2360","elsevierCitationCount":0},{"title":"Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis","googleId":"bDsXM36jB7AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0006497120321583","googleCitationCount":6,"googleAuthor":"LS Kean","doi":"10.1182/blood-2018-02-785881","elsevierAuthor":"Kean L.S.","publicationName":"Blood","elsevierCoverDate":"2018-06-14","elsevierCoverDisplayDate":"14 June 2018","elsevierCitationCount":"3"},{"title":"Minimal residual disease status with venetoclax monotherapy is associated with progression-free survival in chronic lymphocytic Leukemia","googleId":"KByUWev1icMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3134/263873","googleCitationCount":7,"googleAuthor":"AW Roberts","doi":"10.1182/blood-2018-99-110183","elsevierAuthor":"Juárez-Salcedo L.","publicationName":"Drugs in Context","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"12"},{"title":"Double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)","googleId":"UBG9AVP2x7UJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1831/273138","googleCitationCount":7,"googleAuthor":"G Garcia-Manero","doi":"10.1182/blood-2018-99-118948","elsevierCitationCount":0},{"title":"Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A …","googleId":"W5FkSn3tEe8J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3087/80701","googleCitationCount":9,"googleAuthor":"E Terpos","doi":"10.1182/blood.V130.Suppl_1.3087.3087","elsevierCitationCount":0},{"title":"In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ, γ inhibitor, in combination with romidepsin or bortezomib in …","googleId":"qVgEIMrwexYJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/819/83537","googleCitationCount":13,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.819.819","elsevierCitationCount":0},{"title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","googleId":"oAbmF7RkNoUJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1433/262925","googleCitationCount":10,"googleAuthor":"AD Goldberg","doi":"10.1182/blood-2018-99-117772","elsevierCitationCount":0},{"title":"High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell …","googleId":"lW2YXz0sqSsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4533/72181","googleCitationCount":9,"googleAuthor":"R Vij","doi":"10.1182/blood.V130.Suppl_1.4533.4533","elsevierCitationCount":0},{"title":"Longer term follow-up on the first patients with severe Hemoglobinopathies treated with Lentiglobin gene therapy","googleId":"7obOCdcO2YsJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/4609/72554","googleCitationCount":10,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4609.4609","elsevierCitationCount":0},{"title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma","googleId":"2hWyln9gF38J","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/3134/80784","googleCitationCount":8,"googleAuthor":"CC Hofmeister","doi":"10.1182/blood.V130.Suppl_1.3134.3134","elsevierCitationCount":0},{"title":"Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic cell transplantation","googleId":"sZAcj2U8mnkJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3415/264928","googleCitationCount":6,"googleAuthor":"J Kline","doi":"10.1182/blood-2018-99-115108","elsevierCitationCount":0},{"title":"Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast-phase myeloproliferative neoplasms: results of a phase II study (MPN-RC 109 …","googleId":"ARTEhEtwY78J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/3027/263644","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-99-111935","elsevierCitationCount":0},{"title":"Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase II study","googleId":"FZFc_m2XvcEJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/154/79660","googleCitationCount":8,"googleAuthor":"L Cerchietti","doi":"10.1182/blood.V130.Suppl_1.154.154","elsevierCitationCount":0},{"title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the …","googleId":"e32KUFN9tPMJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1622/273276","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood-2018-99-112076","elsevierCitationCount":0},{"title":"Interim results of the Canadian tyrosine kinase inhibitor discontinuation trial for 2nd attempt of treatment free remission: treatment free remission accomplished by …","googleId":"d7DHA05y4_oJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/1622/79655","googleCitationCount":8,"googleAuthor":"D Kim","doi":"10.1182/blood.V130.Suppl_1.1622.1622","elsevierCitationCount":0},{"title":"AVID200, a potent trap for TGF-β ligands inhibits TGF-β1 signaling in human myelofibrosis","googleId":"uHOIiTqKEh4J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1791/273182","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood-2018-99-116474","elsevierCitationCount":0},{"title":"Phase I/IB study of azacitidine and hedgehog pathway inhibition with sonidegib (LDE225) in myeloid malignancies","googleId":"iAuEd6bSG5EJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/2629/79876","googleCitationCount":7,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.2629.2629","elsevierCitationCount":0},{"title":"Outcomes of ibrutinib therapy given after prior venetoclax therapy in ibrutinib-naïve patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)","googleId":"s-y9zHZapk0J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/5556/263295","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-99-116942","elsevierCitationCount":0},{"title":"Preclinical evaluation of Hdp-101, a novel anti-Bcma antibody-drug conjugate, in multiple myeloma","googleId":"EYM4O106mjQJ","googleLink":"https://heidelberg-pharma.com/files/ASH2018_HDP101.pdf","googleCitationCount":9,"googleAuthor":""},{"title":"Hepcidin suppression by momelotinib is associated with increased iron availability and erythropoiesis in transfusion-dependent myelofibrosis patients","googleId":"bQYBIbdelTYJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/4282/275580","googleCitationCount":6,"googleAuthor":"V Gupta","doi":"10.1182/blood-2018-99-111349","elsevierCitationCount":0},{"title":"Resistance to SL-401 in AML and BPDCN is associated with loss of the diphthamide synthesis pathway enzyme DPH1 and is reversible by azacitidine","googleId":"pHU5STBB3BYJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/797/83277","googleCitationCount":8,"googleAuthor":"K Togami","doi":"10.1182/blood.V130.Suppl_1.797.797","elsevierCitationCount":0},{"title":"Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in …","googleId":"Unr5WZfybr8J","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/187/71259","googleCitationCount":10,"googleAuthor":"M Hamadani","doi":"10.1182/blood.V130.Suppl_1.187.187","elsevierCitationCount":0},{"title":"Mechanisms of adaptation to ibrutinib in high risk chronic lymphocytic leukemia","googleId":"7heNOPR9CY0J","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/585/263142","googleCitationCount":7,"googleAuthor":"V Spina","doi":"10.1182/blood-2018-99-116739","elsevierAuthor":"Merli M.","publicationName":"American Journal of Hematology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"1"},{"title":"Assessment of emicizumab-driven clot stability in hemophilia A model","googleId":"9dayJvP4pa8J","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/2478/263997","googleCitationCount":6,"googleAuthor":"","doi":"10.1182/blood-2018-99-118379","elsevierCitationCount":0},{"title":"Phase 1 Study of MDR1 inhibitor plus brentuximab vedotin in relapsed/refractory Hodgkin lymphoma","googleId":"PgMIUUoBLCIJ","googleLink":"https://ashpublications.org/blood/article-abstract/132/Supplement%201/1636/272939","googleCitationCount":6,"googleAuthor":"AF Herrera","doi":"10.1182/blood-2018-99-110403","elsevierCitationCount":0},{"title":"Pharmacokinetics and pharmacodynamics of Ionis-FXIRx, an antisense inhibitor of factor XI, in patients with end-stage renal disease on hemodialysis","googleId":"qWbzA6gQauwJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/1116/116382","googleCitationCount":8,"googleAuthor":"M Walsh","doi":"10.1182/blood.V130.Suppl_1.1116.1116","elsevierCitationCount":0},{"title":"Targeting primary pre-B cell acute lymphoblastic leukemia and CD19-negative relapses using trivalent CAR T cells","googleId":"iy6PPV8JPAAJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4614/72130","googleCitationCount":9,"googleAuthor":"X An","doi":"10.1182/blood.V130.Suppl_1.4614.4614","elsevierCitationCount":0},{"title":"Clonal suppression of TP53 mutant MDS and oligoblastic AML with hypomethylating agent therapy improves overall survival","googleId":"OSCRVD2BtTUJ","googleLink":"https://ashpublications.org/blood/article/132/Supplement%201/1817/272984","googleCitationCount":5,"googleAuthor":"S Yun","doi":"10.1182/blood-2018-99-117297","elsevierAuthor":"Deng J.","publicationName":"European Journal of Haematology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"0"},{"title":"Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM-002A), a first-in-class inhibitor of phosphatidylinositol-3-phosphate 5-kinase …","googleId":"fWFSSmqdiFsJ","googleLink":"https://ashpublications.org/blood/article/130/Supplement%201/4119/72807","googleCitationCount":8,"googleAuthor":"","doi":"10.1182/blood.V130.Suppl_1.4119.4119","elsevierCitationCount":0},{"title":"A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","googleId":"jEKaBwG5PmoJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/Supplement%201/734/83557","googleCitationCount":10,"googleAuthor":"A Kumar","doi":"10.1182/blood.V130.Suppl_1.734.734","elsevierCitationCount":0},{"title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of …","googleId":"vPw42Z-XU0MJ","googleLink":"https://kups.ub.uni-koeln.de/16514/","googleCitationCount":37,"googleAuthor":"C Tam"},{"title":"Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients","googleId":"N0fcXcBfBCYJ","googleLink":"https://ashpublications.org/blood/article-abstract/130/13/1535/36530","googleCitationCount":30,"googleAuthor":"G Guenechea","doi":"10.1182/blood-2017-03-774174","elsevierAuthor":"Río P.","publicationName":"Blood","elsevierCoverDate":"2017-09-28","elsevierCoverDisplayDate":"28 September 2017","elsevierCitationCount":"21"},{"title":"Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP …","googleId":"3BwPDdcUjWQJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/final-analysis-of-the-front-line-phase-iii-randomized-act-1-trial","googleCitationCount":12,"googleAuthor":"","doi":"10.1182/blood-2018-99-110429","elsevierCitationCount":0}]